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ABSTRACT   
Alternative splicing of pre-mRNA is a ubiquitous and versatile mechanism 
controlling the expression of human genes. In humans, approximately 93% of multi-
exonic genes are alternatively spliced, producing functionally distinct proteins. 
Dysregulation of alternative splicing results in the overexpression of the oncogene 
splice factor SRSF1, which has been implicated in various types of tumours. Initial 
research has shown that the alternatively spliced isoforms of vascular endothelial 
growth factor (VEGF) (pro-angiogenic) promotes tumorigenesis. VEGF is regulated 
through serine-arginine (SR)-specific protein kinase SRPK1 and SRSF1. 
Additionally, the activity and intracellular localisation of the SRSF1 is regulated by 
the kinases SRPK1 and Clk1. Therefore, it is worthly to target SRPK1 and SRSF1 in 
chronic myelogenous leukaemia cell line (K562 cells).    
 
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder of stem cell 
origin. It arises from BCR-ABL1 fusion forming the Philadelphia chromosome. This 
fusion leads to a constitutively activated tyrosine kinase. Treatment of CML was 
revolutionised by tyrosine kinase inhibitors (TKIs). Despite the success of TKI in 
eliminating CML, drug resistance develops in patients over time. Allogenic bone 
marrow transplantation (BMT) is the only curative therapy, however the mortality 
rates increase due to infection.   
 
The precise role of SRPK1 and Clk1 in haematological malignancies is unclear. This 
study has sought to target SRPK1, Clk1, TK and SRSF1 through inhibition or 
knockdown to identify the effects of alternative splicing on the expression of 
CASPASE-9, RON and RUNX1 in K562 cells. Additionally, this study would 
  
xxii 
 
investigate the drug efficacy of imatinib (TK inhibitor) used in conjunction with 
either SPHINX (SRPK1 inhibitor) or TG003 (Clk1 inhibitor) in K562 cells. In this 
study, it may identify novel therapeutic targets that could be beneficial for patients 
with leukaemia. 
 
This study demonstrated that targeting SRPK1 and SRSF1 through inhibition or 
knockdown had little or no significant positive effect on the alternative splicing of 
CASPASE-9, RON and RUNX1 in K562 cells. Comparatively, targeting Clk1 with 
the selective inhibitor TG003, resulted in significantly positive effects on the 
alternative splicing for both CASPASE-9 and RON and RUNX1. This was confirmed 
by increased apoptosis of K562 cells. Knockdown studies of Clk1, showed a 
significant effect on RUNX1 only, eliciting the production of the Runx1 isoform. 
Finally, co-treatment of imatinib (TK inhibitor) and SPHINX elicited an effect on 
alternative splicing resulting in an overall shift to the pro-apoptotic isoforms using 
minimal doses of the drugs. Additionally, combinations of kinase inhibitors 
(imatinib and TG003) exhibited a more effective shift in RON splicing towards Ron 
isoforms. This suggests that co-therapy may offer a potential therapy for CML 
patients.  
 
The introduction of tyrosine kinase inhibitors has successfully improved the 
prognosis of CML. However, intrinsic and acquired resistance to imatinib is 
becoming an ever-increasing clinical problem. This study, for the first time, has 
demonstrated novel therapeutic target to Clk1 that affects the alternative splicing of 
CASPASE-9, RON and RUNX1 in K562 cells. Targeting of the genes is essential in 
the treatment of CML as cell differentiation, migration, invasion and apoptosis are 
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affected. This study not only shows that the Clk1 selective inhibitor TG003 is 
beneficial on alternative splicing of CASPASE-9 but conjucated inhibitors of 
imatinib and SPHINX induce a greater effect on the splicing of CASPASE-9 in K562 
cells. Compared to the use of imatinib alone, co-treatment using both drugs maybe 
more effective in the treatment of CML and therefore may circumvent acquired drug 
resistance seen in patients with leukaemia.     
CHAPTER 1 Introduction 
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CHAPTER 1.  INTRODUCTION 
 
1.1 Haematopoiesis and haemopoietic stem cells 
 
Haematopoiesis is a hierarchical process in bone marrow whereby all mature blood 
cells are generated from haematopoietic stem cells (HSCs) (Figure 1.1), which are 
multipotent cells that located in bone marrow. HSCs can self-renew to produce more 
HSCs and they can differente into many cell types through multipotent progenitors 
(MPPs) (Morrison, Uchida and Weissman, 1995). HSCs differentiate into common 
myeloid progenitors (CMPs) and common lymphoid progenitors (CLPs) terminating 
mature myeloid and lymphoid cells. The CMPs can differentiate into all myeloid 
lineages through megakaryocyte/erythrocyte progenitors (MEPs) and granulocytes 
and macrophages progenitors (GMPs). MEPs can differentiate further into mature 
red blood cells and platelets, while monocytes and granulocytes resulted from 
GMPs. In addition, CLPs can differentiate to lymphocytes (T- or B-cells) and natural 
killer cells (NKCs) (Morrison, Uchida and Weissman, 1995).  
 
The proliferation and differentiation of MPPs, along with GMPs and CLPs leads to 
the production of differentiated and functional haematopoietic cells, allowing the 
cells to react to haematopoietic crises, including blood loss or infection  (Shao et al., 
2013) HSCs are regulated by several growth factors (Zhang and Lodish, 2008), for 
example, the development of megakaryocytes and platelet formation are regulated by 
interleukins (IL-3, IL-6 and IL-11) along with thrombopoietin (TPO) (Buza-Vidas et 
al., 2006; Fortunel, Hatzfeld and Hatzfeld, 2000).  
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Figure 1.1. A diagram of normal haematopoietic system 
The development of blood cells from haematopoietic stem cells (HSCs) to mature 
blood cells through multipotent progenitors (MPPs). CMPs, common myeloid 
progenitors; CLPs, common lymphoid progenitors; GMP, macrophages progenitors; 
MEP, megakaryocyte/erythrocyte progenitors.  
1.1.1. Leukaemia 
Leukaemia or haematologic malignancy refers to an overproduction of immature 
leukocytes in the bone marrow leading an inhibition in the production of mature 
blood cells, causing anaemia, fatigue and other symptoms (Hoffbrand et al., 2011). 
The incidence of chronic myeloid leukaemia (CML) is estimated at approximately 
10 in 1,000,000 each year (Warmuth, Danhauser-Riedl and Hallek, 1999); in 2013 in 
the UK, approximately 710 individuals were diagnosed with CML (Cancer Research 
UK, 2016). The disorder can be diagnosed using several methods including blood 
tests, bone marrow (BM) aspiration, BM trephine biopsy, cytochemistry, histology, 
flow cytometeric immunophenotyping, immunohistochemistry, cytogenetic analysis, 
fluorescence in situ hypbridisation (FISH) and other molecular genetic analyses 
(Hoffbrand et al., 2011). The factors leading to an increase in the risk of developing 
leukaemia are listed in Table1.1.  
 
HSC
CMP
CLP
GMP MEP
Granulocyte
Monocyte
Megakaryocytes
RBCs 
Platelets
LymphocyteNK cell
MPP
B lymphocyteT lymphocyte
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Table 1.1. Genetic or environmental risk factors identified in leukaemia 
 
Congenital and inherited syndromes 
 
Inherited bone marrow hypoplasia syndromes 
Fanconi anaemia 
Schwachman–Diamond syndrome 
Dyskeratosis congenita 
DNA repair defects 
Bloom syndrome (DNA helicase mutations) 
Ataxia telangiectasia 
Inherited predisposition to haematological malignancies 
Chronic lymphocytic leukaemia 
Acute myeloid leukaemia 
Lymphoma 
Myeloma 
Polycythaemia vera 
Essential thrombocythaemia 
Down syndrome 
Environmental risk factors 
 
Exposure to genotoxic mutagens 
Atomic bombs 
Chemotherapy 
Radiotherapy 
Benzene 
Infections 
HTLV-1 
HIV 
Epstein-Barr virus 
Helicobacter pylori 
Immunosuppressive drugs 
 
According to the French-American-British (FAB) classification system, leukaemia 
can be classified as acute or chronic and is further classified depending on cell 
lineage as myeloid and lymphoid. This generates four major types of leukaemia: 1) 
acute myeloid leukaemia (AML), 2) acute lymphocytic leukaemia (ALL), 3) chronic 
myeloid leukaemia  (CML) and 4) chronic lymphocytic leukaemia (CLL) (Jones, 
2010). The World Health Organization (WHO) also classifies leukaemia into 
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myeloproliferative neoplasms (MPNs) and acute myeloid leukaemia (AML) (Arber 
et al., 2016), Table 1.2.  
 
Table 1.2. The WHO myeloid neoplasm and acute leukaemia classification 
system  
Myeloproliferative neoplasms (MPN) 
 
Chronic Myeloid Leukaemia (CML), BCR-ABL1
+  
Chronic Neutrophilic Leukaemia (CNL)  
Polycythemia Vera (PV)  
Primary MyeloFibrosis (PMF) 
PMF, prefibrotic/early stage 
PMF, overt fibrotic stage 
Essential Thrombocythemia (ET) 
Chronic Eosinophilic Leukaemia, Not Otherwise Specified (NOS) 
MPN, unclassifiable 
Mastocytosis 
Myeloid/lymphoid neoplasms with eosinophilia and rearrangement 
of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2  
Myeloid/Lymphoid Neoplasms with PDGFRA rearrangement  
Myeloid/Lymphoid Neoplasms with PDGFRB rearrangement  
Myeloid/Lymphoid Neoplasms with FGFR1 rearrangement 
Provisional entity: Myeloid/Lymphoid Neoplasms with PCM1-JAK2 
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) 
Chronic Myelomonocytic Leukaemia (CMML) 
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Atypical Chronic Myeloid Leukaemia (aCML), BCR-ABL1
-
  
Juvenile Myelomonocytic Leukaemia (JMML)  
MDS/MPN with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) 
MDS/MPN, unclassifiable 
Myelodysplastic syndromes (MDS) 
MDS with single lineage dysplasia 
MDS with Ring Sideroblasts (MDS-RS) 
MDS-RS and single lineage dysplasia 
MDS-RS and multilineage dysplasia 
MDS with multilineage dysplasia 
MDS with excess blasts 
MDS with isolated del(5q) 
MDS, unclassifiable 
Provisional entity: Refractory cytopenia of childhood 
Myeloid neoplasms with germ line predisposition 
Acute myeloid leukemia (AML) and related neoplasms 
AML with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1  
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11  
APL with PML-RARA  
AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A  
AML with t(6;9)(p23;q34.1);DEK-NUP214  
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM  
CHAPTER 1 Introduction 
29 
 
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1  
Provisional entity: AML with BCR-ABL1  
AML with mutated NPM1  
AML with biallelic mutations of CEBPA  
Provisional entity: AML with mutated RUNX1 
AML with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
AML, NOS 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic Leukemia 
Acute Monoblastic/Monocytic Leukemia 
Pure erythroid leukemia 
Acute Megakaryoblastic Leukemia 
Acute Basophilic Leukemia 
Acute Panmyelosis with Myelofibrosis 
Myeloid Sarcoma 
Myeloid proliferations related to Down syndrome 
Transient Abnormal Myelopoiesis (TAM) 
Myeloid Leukemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
Acute Leukemia’s of ambiguous lineage 
Acute undifferentiated Leukemia 
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Mixed phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-
ABL1  
MPAL with t(v;11q23.3); KMT2A rearranged  
MPAL, B/myeloid, NOS  
MPAL, T/myeloid, NOS 
B-lymphoblastic leukemia/lymphoma 
B-Lymphoblastic Leukaemia/Lymphoma, NOS 
B-Lymphoblastic Leukaemia/Lymphoma with recurrent genetic abnormalities 
B-Lymphoblastic Leukaemia/Lymphoma with t(9;22)(q34.1;q11.2);BCR-
ABL1  
B-Lymphoblastic Leukaemia/Lymphoma with t(v;11q23.3);KMT2A 
rearranged  
B-Lymphoblastic Leukaemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-
RUNX1  
B-Lymphoblastic Leukemia/Lymphoma with hyperdiploidy 
B-Lymphoblastic Leukemia/Lymphoma with hypodiploidy 
B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH  
B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1 
Provisional entity: B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1–like 
Provisional entity: B-Lymphoblastic Leukemia/Lymphoma with iAMP21 
T-Lymphoblastic Leukemia/Lymphoma 
Provisional entity: Early T-cell precursor Lymphoblastic Leukaemia 
Provisional entity: Natural killer (NK) cell Lymphoblastic 
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Leukaemia/Lymphoma 
 
1.2 Chronic Myeloid Leukaemia (CML) 
 
CML is a myeloproliferative disorder of haematopoietic stem cells (HSC) and arises 
from the fusion of the ABL1 gene (Abelson murine leukaemia viral oncogene 
homology) to BCR (breakpoint cluster region) resulting in the BCR–ABL1 oncogene 
(Kokate, Dalvi and Mandava, 2015). The fusion of BCR–ABL1 occurs from 
reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11), which is  
termed the Philadelphia chromosome (Ph+), Figure 1.2 (Zhu et al., 2015).  
 
In 1960, Peter Nowell discovered the Ph+ and named it after the US city (NOWELL 
and HUNGERFORD, 1960). It is common to find Ph+ in more than 95% of CML 
patients (Warmuth, Danhauser-Riedl and Hallek, 1999), however, the Ph+ can also 
be found in ALL (Koo, 2011). Although rare in ALL, (less than 5%), the presence of 
the Ph+ is considered a very high risk in paediatric patients (Koo, 2011). 
 
The fusion of BCR–ABL1 generates three distinct proteins (P190, P210 and P230) 
according to the breakpoints cluster region on BCR on chromosome 22. The 
breakpoint in ABL1 is usually in exon 2 (Li et al., 1999). The minor breakpoint 
cluster region (m-BCR) occurs between BCR exon e1 and ABL exon a2 resulting in 
e1a2 mRNA (Deininger, Goldman and Melo, 2000).    
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ABL1
Normal 
chromosome 9
Normal 
chromosome 22
BCR
Philadelphia 
chromosome
BCR– ABL1
t(9;22)(q34;q11)
Figure 1.2. The Philadelphia chromosome 
The reciprocal translocation between chromosome 9 and 22 fusing BCR to ABL1, 
generates the Philadelphia chromosome. 
 
The protein is translated as P190BCR-ABL and is commonly detected in ALL patients 
(Uchida et al., 2009). The major breakpoint cluster region (M-BCR) lies between 
BCR exons e13 (b2) or e14 (b3) and ABL exon a2 to produce b2a2 mRNA or b3a2 
mRNA and gives rise to the protein product; P210BCR-ABL (Bernt and Hunger, 2014; 
Deininger, Goldman and Melo, 2000). It has been reported that P210BCR-ABL is 
commonly detected in CML patients (Uchida et al., 2009). In rare cases of CML, the 
micro breakpoint cluster region (μ-BCR) lies between exons 19 and ABL exon a2 
producing e19a2 mRNA and the P230BCR-ABL protein product, Figure 1.3 (Deininger, 
Goldman and Melo, 2000; Uchida et al., 2009). These different fusion proteins 
express the same levels of c-ABL tyrosine kinase, however they differ in terms of 
BCR sequence (Sawyers et al., 2002). 
 
CML is characterised by increased the proliferation of immature granulocytic cells line.  
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Figure 1.3. The three forms of the BCR–ABL1 oncogene 
The arrows indicate the breakpoints in ABL1 and BCR producing the various breaks. 
The breakpoint in ABL1 is in exon a2 while BCR breaks at three distinct locations. 
The minor (m-BCR) occurs in fusions with BCR exon e1 resulting in e1a2 mRNA 
and translating as P190BCR-ABL, whereas the major (M-BCR) results from fusions with 
BCR exon e13 (b2) or e14 (b3) to produce b2a2 mRNA or b3a2 mRNA generating 
P210BCR-ABL. The rare form of CML is the micro (μ-BCR) cluster, which is results 
from fusion with BCR exon e19 producing e19a2 mRNA, translating as P230BCR-ABL 
protein.     
 
The disease progresses from a benign chronic phase (CP) to an accelerated phase (AP) and 
terminates in blast crisis (BC) (Giles et al., 2004). The progression from CP to BC occurs by 
continuous activation of BCR–ABL1 leading to increased cell proliferation, reactive oxygen 
species (ROS) generation, and activation of DNA damage with impairments in DNA repair, 
multiple mutations causing genomic instability, gene doubling, translocations and 
chromosomal breakage, Figure 1.4 (Hehlmann, 2012). 
 
Additional CML genetic abnormalities, other than the BCR–ABL1 fusion, include a double 
Ph+ chromosome, isochromosome i(17q), trisomy 8, trisomy 19, loss of chromosome 9, 
mutations in tumour-suppressor genes such as p53, INK4A/ARF and RB.  
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Figure 1.4. The role of BCR–ABL1 in CML progression to blast crisis (BC)  
The fusion of BCR–ABL1 stimulates cell proliferation in CML-CP accompanied by 
ROS activation, leading to DNA double breakages, genetic instability, chromosomal 
breakages, translocations and multiple mutations.    
 
It has been also identified that the RUNX1/MDS1/EVI1 fusion, generated from 
t(3;21)(q26;q22), and the NUP98/ HOXA9 fusion, generated from t(7;11)(p15;p15), 
develop CML to BC (Zhao et al., 2012). Previous studies have shown that mutations 
in RUNX1 associate with the BCR–ABL1 fusion promoting the acute myeloid 
leukaemia transformation of CML (Zhao et al., 2012).  
 
Common symptoms of CML include anaemia, diabetes, infection caused by syphilis 
and HIV retinopathy, however, vision loss is believed to form the initial diagnosis of 
CML (Huang and Sanjay, 2011). It is important to monitor disease progression by 
early diagnosis. Real-time polymerase chain reaction (PCR), flow cytometry, 
chromosome analysis and fluorescence in situ hybridization (FISH) are conventional 
methods used for clinical diagnosis. Due to the complexity of the techniques and 
high costs, Xu and co-workers have reported that chemiluminescence was the most 
effective clinical diagnosis method (Xu et al., 2016). Recent studies have 
demonstrated that cardiac tamponade is considered the first sign of CML-BC (Huang 
BCR–ABL1
BCR–ABL1 
with ROS
HSC
CML-CP
Rapid expansion 
of myeloid blasts 
CML-BC
DNA double and impaired 
of DNA repair, 
chromosomal breakage,
translocations,
multiple mutations.
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et al., 2016). According to WHO the diagnostic criteria for CML are listed in Table 
1.3 (Arber et al., 2016). 
 
1.3 CML treatment 
 
In recent decades, the main treatment for CML was cytoreductive chemotherapy 
such as Busulphan and Hydroxyurea, which controls white blood cell (WBC) counts. 
However, the disease did not show improvements in the accelerated and blast phase. 
The survival rate of the therapy ranges from 45 to 58 months (Fausel, 2007). 
Interferon (IFN) immunotherapy was used in the 1980s and proved as superior to 
cytoreductive therapy (Deininger et al., 2003) due to the production of a complete 
haematologic response (CHR) in more than 50% of patients. However, the IFN 
therapy generates nonspecific immunostimulatory mechanisms, is expensive, 
inconvenient in terms of IFN injections and it produces intolerant symptoms. The 
median survival rate was from 60 to 89 months (Fausel, 2007).  
 
Allogeneic bone marrow transplantation (BMT) is the only curative therapy for 
CML, however, mortality rates increases due to infection, bleeding and developing 
graft versus host disease (GvHD). Moreover, the difficulty of finding suitable donors 
limits the use of BMT as a therapy (Jain et al., 2013; Fausel, 2007). Tyrosine kinase 
inhibitors (TKIs) are the most common treatments for CML; they are highly 
efficacious, present minimal cytotoxicity and are specific in their targeting of gene 
mutations. Imatinib mesylate (IM) has become the first-line therapy for CML 
(Salizzato et al., 2016). IM (also called STI-571) acts as an inhibitor for tyrosine 
kinase (Brouard et al., 2001). Upon administration of IM, lekaemic cells stop 
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proliferating and undergo to a process of cell death (apoptosis) (Novak et al., 2015). 
The chemical structure of IM will be discussed later, (Chapter 2).  
 
The survival percentages for CML patients treated with IM ranges according to the 
stage of the disease. Patients in CP have an 80% chance of survival. However, in 
advanced disease stages such as AP and BC, the survival rates drop to 50% and 20%, 
respectively. Despite IM producing high remission rates and improvements in 
disease prognosis approximately 20-30% of patients develp resistance to IM over 
time (Salizzato et al., 2016).  
 
Imatinib resistance allows CML to progress and leads to failures in haematologic 
responses (CHR). This is due to the insufficient binding of tyrosine kinase inhibitors 
to the receptor, which is termed primary resistance mechanism. However, the most 
common resistance mechanism is secondary resistance to imatinib. It develops from 
point mutations within the BCR-ABL1 kinase domain, thereby reducing the affinity 
of binding sites (Wieczorek and Uharek, 2016; Bhamidipati et al., 2013). Second 
generation formulations of imatinib, e.g. dasatinib and nilotinib, decrease resistance 
and intolerance (Wieczorek and Uharek, 2016).  
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 Table 1.3. Heamatologic/cytogenetic criteria for CML  
CP CML 
 Cytogenetic evidence of Ph+ chromosome in peripheral blood or bone marrow 
 Morphology evaluation from bone marrow (BM) aspiration 
AP CML (diagnosed if any one or more of the following exist) 
 Persistent or increase while blood cells (>10 × 109/L) unresponsive to therapy 
 ≥10% of peripheral white blood cells or bone marrow cells are blasts 
 Peripheral blood basophils ≥20% 
 Persistent thrombocytopenia (>100 × 109/L) unrelated to therapy, or persistent 
thrombocytosis (>1000 × 109/L) unresponsive to therapy 
 Persistent or increase spleen size (splenomegaly) unresponsive to therapy 
 Additional genetic abnormalities other than the fusion of BCR–ABL1 gene 
BC CML (diagnosed if any one or more of the following exist) 
 ≥20% of peripheral blood or BM cells are blasts 
 Onset lymphoblast in the peripheral blood or BM cells 
 
Each drug is used according to disease stages. Dasatinib has an effective response in 
the CML chronic phase, accelerated phase and blast phase of the disease. Nilotinib is 
approved by the US Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) for chronic phase and accelerated phase therapy (Rogers 
et al., 2012). However, nilotinib causes problems in diabetic patients as it raises 
blood sugar (Rea et al., 2014). Bosutinib and ponatinib modify the disease in cases 
of relapse or intolerance (Caldemeyer et al., 2016). The main goal of these therapies 
is to maintain remission and prevent progression of the disease, with high efficacy 
and minimal toxicity. 
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Several clinical trials have shown that kinase inhibitor combinations exert an 
efficacy against most of the mutated forms of the BCR–ABL1 oncogene (Change et 
al., 2011). One study suggested that treatment can be advanced cytogenetically and 
molecularly when combining imatinib and interferon (Fava, Rege-Cambrin and 
Saglio, 2015). Recent study reported that targeting the CK2 and MEK protein 
kinases elicit better effects in eliminating CML cells with reducing viability of 
imatinib resistat CML cells (Salizzato et al., 2016). Another trial found that co-
treatment with amiloride and imatinib could be a potential treatment for CML 
(Chang et al., 2011). These studies suggest incorporating a combinatorial kinase 
treatment approach could overcome the imatinib resistance.  
 
1.4 Alternative splicing (AS) 
 
Splicing is a cell mechanism whereby introns (non-coding DNA regions) are excised 
and exons (coding regions) are joined together, Figure 1.5. Alternative splicing 
generates several mature mRNAs from a single gene, allowing for a diversity in 
terms of protein expression. In humans, 94% of genes undergo alternative splicing, 
resulting in the production of functional isoforms, therefore single genes can 
generate more than one variant mRNA, encoding different proteins (Pan et al., 2008; 
Wang et al., 2008).   
 
AS was first characterised in the 1970s in adenoviruses (Chow et al., 1977).  
 
Approximately a decade later, researchers discovered that more than one mRNA 
could be generated from a single immunoglobulin μ gene by alternative splicing 
(Early et al., 1980). There are several modes of alternative splicing. Approximately 
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75% of all human genes undergo cassette exon or exon skipping events. Therefore, 
exon skipping is the most common form of alternative splicing in eukaryotes 
(Weatheritt, Sterne-Weiler and Blencowe, 2016).   
 
The other types include: 1) alternative 3’ splice site selection (3’ SS selection), 2) 
alternative 5’ splice site selection (5’ SS selection) and 3) intron retention and 
mutually exclusive exons (Keren, Lev-Maor and Ast, 2010).  
 
Figure 1.5 shows the different AS mechanisms. Exon skipping or cassette exon 
occurs when exons are spliced out from the transcript with flanking introns. 
Alternative 3’ splice site and 5’ splice site selection happens when two or more 
splice sites are recognised by splice factors at the beginning or end of an exon, 
respectively. Intron retention occurs when an intron remains in the mRNA transcript 
while one of two exon remains in the mRNA after splicing, but not both is known as 
mutually exclusive exons (Cartegni, Chew and Krainer, 2002). 
 
A recent study from Martinez-Montiel and co-workers investigated natural products 
(actinomycetes, filamentous fungi, and medical plants) that inhibited gene splicing, 
(Martinez-Montiel et al., 2016). Another study demonstrated the importance of AS 
in histone methylation and demethylation in neurons (Fiszbein and Kornblihtt, 
2016). It has also been reported that suppressing some protein kinases, such as 
Serine/Arginine splicing factor kinase (SRPK1) affects splicing during angiogenesis 
(Amin et al., 2011). Therefore, controlling gene expression through protein kinase 
activity has allowed us to hypothesis that inhibiting SRPK1 and Clk1 could 
significantly reduce CML progression.  
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1.5 The regulation of alternative splicing  
 
1.5.1. pre-mRNA splicing 
 
Mature mRNA result from spliced precursor messenger RNAs (pre-mRNAs) at 
splice sites found at exon-intron junctions consisting of 5’ and 3’ splice site 
sequences. The sequence of the 3’ splice site has the 3’ splice site itself, a 
polypyrimidine tract and a branchpoint (BP) sequence. In humans, the 5’ splice site 
consensus sequence is CAG GURAGU while the 3’ splice site consensus sequence 
is YAG. 
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Simple splicing
1 31 3
Alternative splicing
1 2 3
Exon skipping or 
‘cassette’ exon
1 3
1 2 3
Alternative 3’ splice site
21 3
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pre-mRNA mRNA
2 2
Figure 1.5. The splicing and four basic modes of alternative splicing showing 
exon skipping, alternative 3’ and 5’ splice sites, intron retention and mutually 
exclusive exons    
Exons (grey and black rectangles) are connected by introns (black lines). The dotted 
black lines indicates the alternative splicing patterns and the dotted red lines indicate 
the splicing patterns. In each model, grey exons are constitutive and black exons are 
alternative. 
 
The branchpoint has a YNYURAC consensus sequence and a polypyrimidine tract 
usually has T residues, Figure 1.6. The process of splicing occurs through a major 
ribonucleoprotein complex called as spliceosome which contains five building 
Intron retention
31 2
21 3
21 3
1 3 4
21 4
Mutually exclusive exons
1 432
Alternative 5’ splice site
2 31
1 32
1 32
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blocks known as small nuclear RNAs (U1, U2, U4, U5 and U6 snRNAs), associated 
with five small nuclear ribonucleoproteins (U1, U2, U4, U5 and U6 snRNPs). 
 
Some snRNPs interact with pre-mRNA in early spliceosome assembly, while others 
interact with each other. The types of snRNPs and their interactions are listed in 
Table 1.4 (de Almeida and O'Keefe, 2015; O'Keefe and Newman, 1998). 
 
It has been shown that proteins, Prp8, Snu114 and Brr2 are associated with U5 
snRNA (Nancollis et al., 2013). Any mutation present in U5 snRNA influences the 
stability of Prp8, thus affecting splicing regulation (Kershaw et al., 2009). Therefore, 
the U5 snRNP is regarded as the centre of the spliceosome assembly (Nancollis et 
al., 2013). 
 
The spliceosome assembles on pre-mRNAs through multiple pathways. Firstly, U1 
snRNP recognises the 5’ splice site leading to an interaction of U2 snRNP with BP 
sequences. Next, the U4/U6U5 tri-snRNPs associates with bound snRNPs and pre-
mRNA. Following this, U5 snRNP interacts with the 5’ and 3’ splice site and 
destabilises the U1 snRNP association. The U5 snRNP binds to the 5’ splice site and 
U6 associates with U2 snRNPs resulting in the U2/U4/U6 complex. The complex 
releases U4 snRNP and forms a complex association of U2/U6 snRNP with U2 
snRNP at the BP. U6 snRNP interacts with the 5’ splice site, Table 1.4.  
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Figure 1.6. Introns start from the GU sequence at the 5’ splice site at the 
upstream exon  
The 3’ splice site has three parts: the branch site (highly conserved adenines), a 
polypyrimidine tract and a 3’ splice site (AG) sequence at the downstream exon.   
 
Table 1.4. Small nuclear ribonucleoproteins (snRNPs) and their interactions 
SnRNPs Interaction with pre-
mRNA 
Interaction to other snRNPs 
U1 5’ splice site  
U2  Branchpoint  U4/U5U6 
U6 snRNP (late stage of spliceosome 
assembly) 
U4   
U5 5’ and 3’ splice site  
U6  U2 snRNP 
 
Finally, the two exons are re-joined and the intron is removed as a lariat shape. The 
spliceosome disassembles, splicing components are recycled and the mRNA is 
exported. 
 
It has been reported that splice factor 1 (SF1), heterodimeric splice factor U2 
auxiliary factor (U2AF-35 and U2AF-65), and SR proteins are involved in the 
YYNYURAC YAGCAG
5’ splice site Branchpoint Polypyrimidine tract 3’ splice site
Exon ExonIntron
GURAGU
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assembly of the spliceosome to regulate alternative splicing (O'Keefe et al., 1994; 
Rudner et al., 1998). 
 
1.5.2. Serine/arginine-rich proteins as a family of alternative splicing regulators 
 
The serine/arginine-rich proteins (SR proteins) are a large superfamily of nuclear 
RNA binding proteins (Zhou and Fu, 2013). SR proteins were identified initially in 
Drosophila in the 1990s and later the proteins SRSF1 and SRSF2 were identified in 
humans (Manley and Krainer, 2010). The majority of SR proteins share two RNA-
binding domains (RNA-recognition motif (RRM) and RRM homologue (RRMH)) 
and RS domain. Some SR proteins has one RRM and RS domain, such as SC35, 
SRp20 and SRp54. However, 9G8 is the only SR protein that contains a zinc-
knuckle domain instead of an RRMH. The RS domain, however is composed of 
RS/SR residues that is divided into RS1 and RS2 subdomains. The RS1 subdomain 
consists of a docking motif and initiation box and its phosphorylated by SRPK1, 
however, the RS2 is phosphorylated by Clk1, Figure 1.7 (Shepard and Hertel, 2009; 
Zhou and Fu, 2013). The phosphorylation of SRSF1 by SRPK1 and Clk1 will be 
discussed in section 1.5.4.3. 
 
A new standardised nomenclature has been suggested for the SR protein family. In 
humans, nine genes (SRSF1-7, 9, and 11) encode SR proteins which act as splicing 
factors (Shepard and Hertel, 2009; Vu et al., 2013). In this thesis, the new 
nomenclature will be used, however for clarity, the previous and recent SR protein 
names and their domain topologies are shown in Figure 1.8.   
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Figure 1.7. The structure of the SR protein (SRSF1) 
The domain structure of SR proteins: two RNA-binding domains (RRM and RRMH) 
and RS domain. The RS domain consists of The RS/SR residues, which is divided 
into two subdomains (RS1 and RS2). A docking motif and an initiation box in the 
RS1 domain as shown in blue. RS1 segments are important for SRPK1 
phosphorylation. RS2 segments are important for Clk1 phosphorylation.  
 
 
Figure 1.8. The SR protein family 
The main domain characteristics of SR proteins structure. RRM (RNA recognition 
motif); RRMH (RNA recognition motif homology); RS (arginine/serine-rich 
domain); Zn (Zinc knuckle).  
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It has been observed that SR proteins interact with other proteins, the SR-related 
proteins, to regulate splicing. Despite their lack of RRM, SR-related proteins carry 
RS domains and RNA binding motifs (PWI), or zinc finger motifs (Zn) (Zhou and 
Fu, 2013). The interaction between SR proteins and SR-related proteins occurs 
through the RS domains of both proteins, thereby initiating splicing (Shepard and 
Hertel, 2009). Some examples of SR-related proteins include both subunits of the 
U2AF heterodimer (U2AF-35 and U2AF-65), U1-70K, and the splicing co-activators 
SRm 160/300  (Long and Caceres, 2009; Kim et al., 2011).  
 
It has been reported that other domains of SR-related proteins are responsible for 
enzymatic activities. Clk/Sty1 is an example of another RS domain containing 
proteins, it contains an RS and kinase domain. However, other RS domains may 
contain RS domains and motifs characteristic of RNA helicases (DEAH Box), such 
as hPRP5 (Long and Caceres, 2009). 
 
1.5.3. Functions of SR proteins 
 
1.5.3.1. The role of SR proteins in pre-mRNA splicing  
 
Splicing codes are specific codes by which enable spliceosomes to distinguish 
between exons and introns in pre-mRNA. The human splicing code depends on the 
interaction of splicing activators (SR proteins) or splicing repressors (heterogeneous 
nuclear ribonucleoprotein or hnRNPs) with snRNPs. The splicing activators are 
found within exons (exonic splicing enhancers, ESEs) or within introns (intronic 
splicing enhancers, ISEs). The splicing silencer sequences are located within exons 
(exonic splicing silencers, ESSs) or within introns (splicing silencers, ISSs) (Wu and 
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Hurst, 2016). There are more than twenty members of hnRNPs, including, hnRNP 
A1, A2, A3 and hnRNP B1 (Qu et al., 2015).  
 
The functions of SR proteins can be divided into two categories: exon-dependent and 
exon-independent functions. The exon-dependent functions of SR proteins form 
interactions between the RS domain of the SR proteins and ESE’s facilitating the 
recruitment of spliceosomal components. For example, interactions between U1-70 
snRNP to 5’ splice site from one side and interacting U2AF (U2AF-65 and U2AF-
35) to the 3’ splice site from another side (Shepard and Hertel, 2009). The SR 
proteins bound to ESE’s also promote incorporation of the tri-snRNA U4/U6U5 
into the spliceosome, Figure 1.9A (Shepard and Hertel, 2009). SR proteins also 
function without interaction with exons (exon-independent functions); the U2 snRNP 
bound to the branchpoint sequence (A) and SR proteins stimulate the interaction of 
U1 snRNP to 5’ splice site and U2AF to a 3’ splice site. SR proteins also recruit the 
U4/U6•U5 tri-snRNP into the spliecosome, Figure 1.9B (Shepard and Hertel, 2009). 
 
In addition to the structure of these domains, the activity of SR proteins is related to 
the RS domain. That was proved by previous study with RS domain lacking SRSF2 
(SC35) had no activator effect compared to the SR proteins with RS domain 
(Dreumont et al., 2010). 
 
It has been also suggested that splicing relies on the specificity of SR protein 
binding, the location of the interaction and the competitive binding of different SR 
proteins and competition with other RNA splicing regulators (Zhou and Fu, 2013). 
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Figure 1.9. Exon dependent and independent mechanisms of splicing activation  
A) The exon dependent functions of SR proteins. SR proteins bound to an exonic 
splicing enhancer (ESE) promote splicing by stabilising bound U1 snRNP to the 5’ 
splice site and the U2AF to the 3’ splice site. GU sequences are binding sites for the 
U1 snRNP, while polypryrimidine tracts (Py) and AG sequences are binding sites for 
the U2AF-65 (the large subunit of the splice factor) and U2AF-35, respectively. The 
SR proteins bound to ESEs stimulate the incorporation of the tri-snRNA U4/U6U5 
into the spliceosome. B) The exon independent functions of SR proteins. The U2 
snRNP bound to the branchpoint (A) and SR proteins promote splicing by activating 
the interaction of U1 snRNP and U2AF to splice site pairing. U2AF-65 stimulates 
the binding of U2 snRNP to the branch site. SR proteins are also associated with the 
recruitment of U4/U6•U5 tri-snRNPs.  
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1.5.3.2. The role of SR proteins beyond pre-mRNA splicing  
 
SR proteins are not only essential for splicing, but they have important roles in post-
transcriptional gene expression through promoting mRNA export. SRSF3 (SRp20) 
and SRSF7 (9G8) are important key export protein adapters; they enhance mRNA 
export through the recruitment of the “export receptor Nuclear RNA export factor 
1/Tip-associated protein (NXF1/TAP)” (Huang and Steitz, 2005). Both SR proteins 
also control the shuttling of mRNA into the cytoplasm. Previous studies have shown 
that SRSF1 interacts with polyribosomes and promoting the translation of luciferase 
reporters (Michlewski, Sanford and Caceres, 2008).  
 
SR proteins also have key roles in RNA stability, quality control (Zhang and 
Krainer, 2004) and chromatin interaction (SRSF1 (ASF/SF2) and SRSF3 (SRp20)). 
These interactions rearrange DNA and arrest the G2/M cell cycle (Loomis et al., 
2009). It has been shown that SR proteins can function before splicing; they interact 
with RNA polymerase II (RNAP II) transcripts, coupling transcription to splicing 
(Das et al., 2007; Yu and Reed, 2015). Despite the fact that SR proteins are stimulus 
proteins for splicing, are involved in mRNA export, stability and translation, they 
can also negatively influence splicing when overexpressed. They specifically target 
mRNAs by incorporating premature termination codons (PTCs) into sequences, 
thereby enhancing the nonsense-mediated mRNA decay (NMD) pathway. SR 
proteins have widespread roles in pre-mRNA mechanisms, therefore it is important 
to focus on SR protein regulation mechanims to understand their cellular activities in 
gene expression. 
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1.5.4. The regulation of SR proteins 
 
1.5.4.1. Post-translational modification of SR proteins 
 
SR proteins can be regulated by multiple enzymatic mechanisms known as post-
translational modifications (PTMs) that contribute to the formation of fully mature 
and functional proteins. Arginine methylation, acetylation and phosphorylation are 
some of the different types of post-translational modifications. Methylation 
specifically is important for SR protein and SR-related protein function (Zhou and 
Fu, 2013). 
 
SRPK1 mediates the phosphorylation of SR proteins leading to the import and 
accumulation of these proteins at nuclear speckles. Under appropriate 
phosphorylation states, SR proteins are targeted to nascent pre-mRNAs to activate 
splicing. For methylation, three methylated arginine residues (R93, R97 and R109) 
occur in the SR protein SRSF1. These arginines play key roles in controlling the 
localisation of SRSF1 (Wang, Peterson and Loring, 2014; Zhou and Fu, 2013). 
Cytoplasmic accumulation of SRSF1 resulting from methylation processing 
mutations reduces SRSF1 levels in the nucleus, inhibiting the alternative splicing of 
targeted genes promoting nonsense-mediated (NMD) mRNA decay  (Sinha et al., 
2010). Furthermore, it has been revealed that some SR proteins are regulated by 
lysine acetylation through the opposing functions of histone acetyltransferases 
(HATs) and histone deacetyleases (HDACs) (Edmond et al., 2011).  
 
1.5.4.2. SR specific kinases 
 
The activity of SR proteins is highly regulated by the reversible phosphorylation of 
serine residues in the RS domain. Several protein kinases have been identified that 
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phosphorylate SR proteins; the serine/arginine protein kinase family (SRPKs), 
cycline dependent like kinases (Cdc-like-kinase) or Clk/Sty (also known as Clk1), 
DNA topoisomerase I and phosphatidylinositol 3-kinase (AKT).  
 
SRPKs are protein kinases that are serine- and arginine-rich and constitute a 
subfamily of serine-threonine kinases that specifically phosphorylate serine/arginine-
rich domains (Daniilidou et al., 2011). SRPK and Clk/Sty family kinases coordinate 
their activities to regulate SR proteins through specifici interaction with the RS 
domain of SRSF1 proteins (Zhou and Fu, 2013). The SRPKs phosphorylate SR 
proteins with high efficiency and specificity. However, the Clk/Sty family are dual 
specific kinases that phosphorylate serine/threonine and tyrosine residues. Thus, 
SRPKs phosphorylate SR proteins with a greater efficiency and specificity than 
Clk/Sty. Despite this, Clk/Sty phosphorylates more residues than SRPKs in the RS 
domain of SRSF1. Numerous studies have revealed that members of SRPK are 
responsible for the nuclear import of phosphorylated SRSF1, while Clk/Sty members 
play key roles in interrupting phosphorylated SRSF1 (Ghosh and Adams, 2011).  
 
Generally, SRPKs are characterised by spacer domains that separating the kinase 
domains into two lobe forming docking grooves (covered in section 1.5.4.3). Spacer 
domains are only present in serine/threonine kinases and not in tyrosine kinases, thus 
Clk phosphorylate SR proteins differently (Zhou and Fu, 2013). Extensive research 
has revealed that deletion of the spacer domain increase translocation of SRPKs into 
the nucleus (Ding et al., 2006).  
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SRPK1, SRPK2, and SRPK3 are examples of alternatively spliced products 
generated by the SRPK family. SRPK1 is expressed predominantly (Zhou and Fu, 
2013) and functions as a tumour suppressor or an oncogene in different cell types 
(Wang et al., 2014). SRPK2 and SRPK3 are expressed in the nervous system and 
muscle cells, respectively (Zhou and Fu, 2013). Apart from SRPKs, it is known that 
Clk/Sty mediates the phosphorylation of SR proteins to activate splicing. Clk/Sty is a 
member of the LAMMER family of protein kinase. All members of the Clk family 
(Clk1-4) are localised to the nucleus, unlike SRPKs that are mainly cytoplasm based 
(Zhou and Fu, 2013). However, SRPKs can mobilise to the nucleus during the M 
phase of the cell cycle and stimulate aggregation of splice factors (Gaddy et al., 
2010).  
 
1.5.4.3. Phosphorylation of SRSF1 recycling for splicing  
 
SRPK1 phosphorylates SRSF1 through a dual-track mechanism combining 
processive phosphorylation (the kinase attaches to the substrate after each round of 
phosphorylation) and distributive phosphorylation (where the kinase and substrate 
dissociate after each round of phosphorylation), Figure 1.10; A and B (Ghosh and 
Adams, 2011; Shepard and Hertel, 2009). SRPK interacts with the initiation box 
(Ser221-Ser225) of the RS1 sequence to initiate phosphorylation using processive 
mechanisms allowing the docking groove of SRPK1 to recognise the docking motif 
peptide of SRSF1 (Ghosh and Adams, 2011). Some studies have found that the 
docking motif/docking groove interaction limitats the number of phosphorylated 
serines and increase the affinity between the SRSF1 and SRPK1  (Ngo et al., 2005).  
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Figure 1.10. The mechanisms of SRSF1 phosphorylation by SRPK1 
A. The processive mechanism for phosphorylation. SRPK1 docks at the docking 
motif of RS1 while the initiation box is activated. The SRPK1 attached to the SRSF1 
after each round of phosphorylation without dissociation. B. The distributive 
mechanism by which the SRPK1-SRSF1 dissociate after each round of 
phosphorylation. Green circles: phosphate groups.  
 
After SRPK1 interacts with SRSF1, phosphorylation of 5-8 of the 12 available 
serines in the RS1 occurs rapidly and efficiently towards the N-terminal. After 
phosphorylation, the high affinity between enzyme (SRPK1) and substrate 
(phosphorylated SRSF1) diminishes and distributive phosphorylation becomes 
activated (Ghosh and Adams, 2011). 
 
The remaining unphosphorylated serines in RS1 are modified by SRPK1 using a 
distributive phosphorylated reaction (Ngo et al., 2005). The phosphorylated RS 
domain translocates SRSF1 from the cytoplasm into the nucleus for storage in 
nuclear speckles (Naro and Sette, 2013). 
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Unlike SRPK1, Clk1 lacks a docking groove and phosphorylates the RS domain of 
SRSF1 randomly. However, Clk1 mediates phosphorylation through the distribution 
of acidic and basic charges in its shallow area. This charge dispersal causes the 
interaction of the hypophosphorylated RS domain to become more effective with 
Clk1 when compared to the unphosphorylated RS domain. Therefore, the pre-
phosphorylated RS domain SRPK1 may become the substrate of Clk1.  
 
The overexpression of Clk1 causes the phosphorylation of 7 serines in the SRSF1 
RS2 domain, leading to its redistribution from nuclear speckles to active splicing 
sites, thereby controlling gene expression (Zhou and Fu, 2013; Ghosh and Adams, 
2011; Ngo et al., 2005). SR proteins, such as SRSF1, are regulated through the 
interactions between two families of protein kinases; SRPK1 and Clk1. SRPK1 
initiates phosphorylation of SRSF1 to facilitate its nuclear import via protein import 
receptors known as transportin-SRs (TRN-SR). These phosphorylated SRSF1s are 
stored in the nuclear speckles for additional phosphorylation by Clk1. Once SRSF1s 
have been re-phosphorylated, they are released from the nuclear speckles to splice 
sites (Zhou and Fu, 2013; Ghosh and Adams, 2011). Hyper-phosphorylated SRSF1 
binds to pre-mRNA to initiate splicing, leading to the production of different mRNA 
isoforms from the same gene.  
 
Once splicing is completed, nuclear phosphatases such as protein phosphatase 1 
(PP1) and protein phosphatase 2A (PP2A) play important role in dephopsphorylated 
SRSF1 and export them to the cytoplasm for the next round of phosphorylation and 
splicing, Figure 1.11 (Ma et al., 2010). It has been reported that PP1 
dephosphorylates SRSF1 in a direction toward the C-terminal (Corkery et al., 2015). 
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Therefore, SRPK1 and Clk1 both play key roles in regulating the activities of SR 
proteins and gene expression (Zhou and Fu, 2013). 
 
1.5.5. SR proteins, SRPKs and Clk kinase families in cancer 
 
The SR protein SRSF1 is typically described as a proto-oncogene, as there is 
growing evidence that SRSF1 overexpression is associated with several types of 
cancer, mainly as a result of changes at the alternative splicing level. More than 50% 
of genetic mutations lead to the disruption of at least one of the SR proteins (SRSF1, 
SRSF2, SRSF5, and SRSF6). It has also been reported that SRSF1-3 overexpression 
was detected found in malignant ovarian tissue, whereas, other SR proteins were 
elevated in breast cancer. The overexpression of SRSF1 was detected in several solid 
tumours, such as lung, colon, kidney, liver, pancreas, and breast carcinomas. In 
addition, overexpression of SRSF1 leads to transformation fibroblasts into immortal 
rodent fibroblasts forming sacromas in mice unlike other SR proteins, e.g. SRSF2 
and SRSF6. That would suggest the important role of SRSF1 in the progression of 
malignancy (Long and Caceres, 2009). 
 
Specific mutations in SR genes are associated with leukaemia, e.g., mutations of 
SR3B1, SRSF2, U2AF1, U2AF-65, ZRSR2, SF2A1, SF1 and PRPF40B were found 
in a wide range of myeloid leukaemias. Specifically, these mutations were detected 
in ~85% of myelodysplastic syndromes associated with ring sideroblasts (MDS-RS), 
55% in chronic myelomonocytic leukaemia, 26% in AML and 7% in primary AML 
(Lasho et al., 2012; Zhou and Fu, 2013).  
  
The SRPK kinases are upregulated in tumourgenesis, e.g. SRPK1 and SRPK2 were  
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Figure 1.11. The role of SRPK1 and Clk1 kinases in phosphorylation and 
shuttling SRSF1  
SRPK1 phosphorylates SR proteins (SRSF1) and transported into the nucleus by 
protein import receptors, transportin-SR (TRN-SR). Phosphorylated SRSF1 will be 
stored in the nuclear speckles. Additional phosphorylation is mediated by Clk1 to 
induce the release of phosphorylated SRSF1 into the nucleoplasm to regulate 
splicing. Once splicing is completed, SRSF1s are dephosphorylated by protein 
phosphatase 1 (PP1) and protein phosphatase 2A (PP2A). Spliced mRNA will be 
exported for translation and dephosphorylated SRSF1s are recycled for the next 
round of phosphorylation. 
 
overexpressed in non-small lung cancer due to hyperphosphorylation of SRSF1 and 
SRSF2 (Zhou and Fu, 2013). 
 
Other studies have shown that elevated SRPK2 occurs in myeloid leukaemia (Jang et 
al., 2008). In contrast, downregulated SRPK1 was detected in cisplatin-resistant 
human tumours (Zhou and Fu, 2013). These studies suggest that over- or under 
regulation of SRPKs are linked to several human malignancies. Apart from SRPKs, 
it has been shown that all Clk kinase family members are elevated during 
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erythroleukaemia cell differentiation (Garcia-Sacristan et al., 2005). Indeed, Clk1 is 
overexpressed in ovarian, breast and prostate cancer (Liu et al., 2013). 
 
Angiogenesis is the formation new blood vessels during embryonic development and 
growth. The process is regulated by the vascular endothelial growth factor (VEGF), 
which is an essential angiogenic factor, alternatively spliced by SRSF1 to produce 
both pro- and anti-angiogenic isoforms (Zeng et al., 2016). The pivotal role of SR 
proteins in gene expression leads to elevated levels of SRSF1 which in turn increases 
the production of pro-angiogenic VEGFA isoforms. However, overexpression of 
SRSF2 and SRSF6 increases VEGFA, anti-angiogenic isoforms (Merdzhanova et 
al., 2010; Nowak et al., 2008). 
 
Upregulation of SRPK1 has been linked to hyperphosphorylation of SRSF1, leading 
to increases in the nuclear import of SRSF1 (Nowak et al., 2010). Previous study has 
observed a shift in splicing towards anti-angiogenic isoform following inhibition 
SRPK1, SRPIN340, which led to reduce tumour growth in nude mice (Amin et al., 
2011). Taken together, these observations suggest that SRPK1 and SRSF1 play 
important roles in splicing during angiogenesis (Oltean et al., 2012). These findings 
suggest that targeting the SR protein kinases and/or SR proteins may act as potential 
therapeutics in treating human cancers.  
 
1.5.6. Receptor Tyrosine Kinases (RTKs) and their roles in cancer 
 
Alternative splicing regulation is important as it increase the functional capacity of a 
gene. Aberrant splicing events cause alterations in cellular signalling pathways, 
including tyrosine kinase receptor signalling. As a result, abnormalities in protein 
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concentration, composition, localisation, activity and irregularity arise potentially 
leading to disease (Wang et al., 2015) of human receptors tyrosine kinases (RTKs) 
that comprise twenty subfamilies have been recorded (Lemmon and Schlessinger, 
2010). Some of RTKs are listed in Table 1.5. 
 
All RTKs have a similar molecular structures and activation mechanisms. The 
epidermal growth factor receptor (EGFR), Figure 1.12, is an example of an RTK and 
is composed of four domains: two extracellular ligand-binding domains (L1 and L2), 
two cysteine rich domains (CR1 and CR2) and a cytoplasmic region containing six 
of tyrosine (Y) residues. The mechanism of RTK activation is similar to all 58 
proteins. Generally, e.g. the EGFR becomes activated through the binding of its 
receptor, the epidermal growth factor (EGF). Receptor-mediated activation of EGFR 
phosphorylates tyrosine residues, which then activate various downstream 
intracellular signalling pathways, such as (Ras-MAPK and PI3K-mTOR) (Lemmon 
and Schlessinger, 2010).  
 
In the Ras-MAPK pathway, the phosphorylated tyrosine residues recruit the 
Sos/Grb2 complex, activating Ras (Dhillon et al., 2007) initiating the 
Raf/MEK/ERK phosphorylation cascade. Activated ERK translocates to the nucleus, 
undergroing regulation and further phosphorylation by transcription factors (Roberts 
and Der, 2007). As RTKs are common to most cell types, the Ras-MAPK pathway is 
involved in cell growth and proliferation, differentiation, migration, angiogenesis 
and the suppression of apoptosis (Dhillon et al., 2007).  
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The PI3K-mTOR pathway is involved in cell growth and survival and is initiated by 
phosphorylation of RTKs and Ras (Dienstmann et al., 2014).  
 
Table 1.5. The human receptor tyrosine kinases (RTKs)  
RTKs Description RTKs subfamilies 
EGFR Epidermal growth factor receptor ErbB 
FGFR Fibroblast growth factor receptor FGF 
InsR Insulin receptor Ins 
VEGFR VEGF receptors (vascular endothelial 
growth factor) 
VEGF 
HGF Hepatocyte growth factor receptor (HGF) Met 
MSP Macrophage-stimulating protein receptor Met 
 
 
Activated AKT promotes proliferation signals and apoptosis evasion through the 
activation of survival factors, such as NFKB. Additionally, AKT activation 
influences cell growth through increased mTOR activity and positively regulates the 
G/S cell cycle (Porta, Paglino and Mosca, 2014).  
 
Constitutive activation of AKT is also caused by overexpression of SRPK1 which 
cause a titration of pleckstrin homology (PH) domain leucine-rich repeat protein 
phosphatases (PHLPP) away from AKT leading to AKT activation. Consequently, 
activated SRPK1 induces SRSF1 phosphorylation leading to cellular transformation 
and tumorigenesis (Wang et al., 2014). 
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Frequent activation of EGFR can triggers cancer (breast, gastric and other tumour 
types) due to its involvement in pathways that promote proliferation, angiogenesis 
and inhibit apoptosis, therefore it is crucial to target these RTKs in the treatment of 
different solid and haematological tumours (Roberts and Der, 2007). 
1.12. A schematic representation of the Ras-MAPK and PI3K-mTOR pathways 
activation by RTKs (EGFR) 
The EGFR consists of four domains: two ligand-binding domains (L1 and L2) and 
two cysteine rich domains (CR1 and CR2) and six tyrosine residues (Y), three are 
shown for simplicity. The binding of EGF to EGFR activates RTK, which leads to 
phosphorylate tyrosine residues and trigger intracellular processes. The Ras-MAPK 
pathway is involved in proliferation, differentiation, angiogensis and suppression 
apoptosis depending on cell type. In this pathway the activated through Sos/Grb2 
complex leading to several phosphorylation towards ERK. The PI3K-mTOR 
pathway has a potential downstream to inhibit apoptosis and promote cell survival. 
AKT is phosphorylated through activated PI3K. The overexpression of SRPK1 leads 
to titrate PHLPP away, thus activation of AKT. Phosphorylated SRPK1 has also a 
role in phosphorylation SRSF1 downregulating cell proliferation, differentiation and 
inhibit apoptosis. Abbreviations: EGF, epidermal growth factor; EGFR, epidermal 
growth factor receptor; Sos, son of sevenless; Grb2, growth factor receptor-bound 
protein 2; Ras, rat sarcoma viral oncogene homolog; Raf, v-raf murine sarcoma viral 
oncogene homolog B1; MEK, MAP kinase kinase (MAPKK or MEK or MAPK2); 
ERK, extracellular signal-regulated kinase; PI3K, phosphatidylinositol 3-kinase; 
AKT, v-akt murine thymoma viral oncogene homology; mTOR, Mammalian target 
of rapamycin; NFKB, nuclear factor kappa-light-chain-enhancer of activated B cells; 
PHLPP, titrate pleckstrin homology (PH) domain leucine-rich repeat protein 
phosphatases. 
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EGFR, also known as HER1/erbB-1, is one of four transmembrane receptors of the 
EGFR family. Inhibiting EGFR by erlotinib in combination with gemcitabine has 
provided a successful treatment in patients with metastatic pancreatic cancer 
(Roberts and Der, 2007). 
 
Another important RTK is RON (Recepteur d’Origine Nantais) or the macrophage 
stimulating protein receptor (MST1R), which belongs to the Met proto-oncogene 
family. The receptor is involved in cell motility, cell dissociation, adhesion and 
invasion of extracellular matrices (Batth, Yun and Kumar, 2015a; Kang, Babicky 
and Lowy, 2014). RON consists of an extracellular domain, a single chain of 
transmembrane domains and an intracellular tyrosine kinase domain for engagement 
with c-Met (Leonis, Thobe and Waltz, 2007). Both RON and c-Met are closely 
related and are activated in response to their ligands: MSP for RON and HGF for c-
Met (Zhang et al., 2008a). Mature RON is a heterodimeric protein of disulfide-
linked α (35 kDa) and β (145 kDa) subunits, originating from the proteolytic 
cleavage of a single chain (proMSP) (Wang et al., 2013). The β- subunit is involved 
in downstream signalling pathways through phosphorylation of tyrosine kinase upon 
MSP, Figure 1.13. Following RON activation, phosphorylation of the intracellular 
signalling pathways (Ras-MAPK and PI3K-mTOR) is initiated (Yao et al., 2013).  
 
Under normal phoysiological conditions, RON is expressed at low levels, however, 
the ΔRON (exon 11 skipped) is highly overexpressed in malignancies, such as 
gastroesophageal adenocarcinoma (Wang et al., 2013). Generation of oncogenic 
variants of RON in cancer will be described later.  
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Figure 1.13. RON activation mechanisms and intracellular signalling pathways  
MSP activates RON dimerisation through the activation of tyrosine kinase. Upon 
activation, the tyrosine kinase phosphorylates through the activated β- subunit of 
RON resulting in Ras-MAPK and PI3K-mTOR stimulation. Cell growth, survival 
and invasiveness are mediated through the Ras-MAPK pathway. In addition, cell 
shape, motility, matrix invasion and gene transcription are regulated by the PI3K-
mTOR pathway. Abbreviations: Sos, son of sevenless; Grb2, growth factor receptor-
bound protein 2; Ras, rat sarcoma viral oncogene homolog; MEK, MAP kinase 
kinase (MAPKK or MEK or MAPK2); PI3K, phosphatidylinositol 3-kinase; mTOR, 
Mammalian target of rapamycin. 
 
1.5.7. Splicing activity of non-Receptor tyrosine kinases (BCR–ABL1) and their 
roles in CML 
 
Not only can RTKs able to stimulate the cellular signalling pathways through 
constitutive activation of tyrosine kinases, but non-receptor tyrosine kinases 
(nRTKs) also play essential roles in the activation of tyrosine kinases through the 
fusion of the Bcr-Abl oncoprotein (Naka et al., 2016). Bcr-Abl protein is 
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predominantly located in the cytoplasm of human haemopoietic lineages, such as 
myeloid, erythroid and lymphoid cells (Naka et al., 2016). The fusion of Bcr-Abl is 
associated with the activation of Ras-MAPK and PI3K-mTOR pathways leading to 
regulate gene transcription, cell proliferation and survival, differentiation and 
inhibition apoptosis (Gowda et al., 2014; Sheng, Wang and Green, 2009). Clinical 
trails have shown that proliferation of CML expressing BCR–ABL1 cells can be 
suppressed in after inhibition of the Ras-MAPK signalling pathway (Sheng, Wang 
and Green, 2009). In addition, the Bcr-Abl can activate the Janus kinase (JAK)-
signal transducers and downstream to STAT5 through HCK or JAK2, Figure 1.14. 
Activation of JAK-STAT leads to the suppression of apoptosis (Gowda et al., 2014). 
However, Bcr-Abl protein can directly activate STAT5 through the haemopoietic 
cell kinase (Hck) to upregulate the anti-apoptotic isoform Bcl-xL (Bibi et al., 2014; 
Chai, Nichols and Rothman, 1997; Pene-Dumitrescu et al., 2008). It has been shown 
that the constitutive activation of tyrosine kinases in BCR–ABL1 cells, increases the 
levels of anti-apoptotic signals, including B-cell lymphoma-2 (Bcl-2), B-cell 
lymphoma extra-large (Bcl-xL) and myeloid cell leukaemia-1 (Mcl-1) (Naka et al., 
2016). 
 
The fusion oncogene BCR–ABL1 resides on the Ph+ chromosome and initiates CML 
and was found to play an essential role in the haematopoietic transformation from 
CML-AP to CML-BC (Chu et al., 2007; O'Hare et al., 2011). Sensitivity to 
apoptosis inducing agents was also reduced in BCR–ABL1 associated HL-60. 
Therefore, the fusion of BCR–ABL1 in CML causes cells to be more resistant to 
cytotoxic agents (Amarante-Mendes et al., 1998; Roy et al., 2015). 
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Figure 1.14 The main BCR–ABL1 intracellular signalling pathways  
Constitutive activation of the tyrosine kinase in BCR–ABL1 in CML. Multiple 
pathways such as Ras-MAPK, PI3K-mTOR and JAK-STAT are stimulated resulting 
in suppression of apoptosis, cell survival and proliferation. The fusion of Bcr–Abl 
oncoprotein activates downstream of Ras-MAPK signalling, the JAK-STAT 
pathway through HCK or JAK2 and PI3K-mTOR signalling through adaptor 
proteins, such as CRKL, CRK and CBL. Abbreviations: Sos, son of sevenless; Grb2, 
growth factor receptor-bound protein 2; Ras, rat sarcoma viral oncogene homolog; 
MEK, MAP kinase kinase (MAPKK or MEK or MAPK2); JAK, Janus kinase; 
STAT, signal transducers and activators of transcription. 
 
1.6 Small molecule protein kinase inhibitors as therapeutic agents 
 
In recent years, researchers have been focused on the identification of small 
molecule inhibitors that target protein kinases in cancer. Of these, the SRPIN340 was 
found to inhibit SRPK1 leading to the production of the anti-angiogenic VEGF 
isoform, VEGF165b, thereby reducing tumour growth in nude mice (Amin et al., 
2011).  
 
The overexpression of SRPK1 or Clk1 has been linked to the increased the 
phosphorylation of SR factors (Siqueira et al., 2015), increasing protein expression 
and mediating tumour cell proliferation, Figure 1.15A. SRPIN340 (SR protein 
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inhibitor 340) and more recently SPHINX (SR protein inhibitor X) function as an 
ATP-competitive inhibitors that appear to specifically target SRPKs without 
inhibiting other protein kinases (Siqueira et al., 2015; Fukuhara et al., 2006). 
Following SR protein phosphorylation inhibition, SR-splicing factors become 
inhibited and trigger apoptosis in cancer cells, Figure 1.15B. Another strategy 
inhibits SR protein phosphorylation through a benzothiazol compound (TG003) 
directed against Clk1 kinase activity, suppressing Clk1-dependent alternative 
splicing, Figure 1.15B (Fukuhara et al., 2006). More detail on SRPK1 and Clk1 
inhibitors will be covered in Chapter 3 and Chapter 4, respectively. 
 
Similarly, the frequent activation of RTKs in cancer has stimulated intensive efforts 
by clinicians and the pharmaceutical industry to develop inhibitors targeted against 
tyrosine kinase (TKIs) for cancer treatment. These inhibitors include ATP-
competitive imatinib mesylate (IM) that controls the continuous proliferation of 
cancerous cells in leukaemia (Tamascar and Ramanarayanan, 2009). Imatinib acts as 
a competitive inhibitor to the adenosine triphosphate (ATP) site on the Bcr-Abl 
protein fusion. Under normal conditions, ATP binds to the kinase domain on Bcr-
Abl casuing phosphorylation and activation of tyrosine residues. However, in a 
disease state, STI571 or IM binds to the kinase domain blocking phosphorylation 
and activation of tyrosine residues (Tamascar and Ramanarayanan, 2009), Figure 
1.16.  
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1.6.1. ALTERNATIVE SPLICING IN LEUKAEMIA 
1.6.1.1. Alternative splicing of genes involved in apoptosis  
Cell death is a natural process whereby old, unwanted and compromised cells are 
killed. There are several forms of cell death including necrotic cell death and 
apoptotic cell death. The cell morphology and its molecular features are used to 
differentiate the type of cell death. Apoptosis or cell suicide is the principle 
mechanism of cell death (Edinger and Thompson, 2004). 
 
A complex cellular mechanism, apoptosis consists of protein cascades instingating 
changes in cell structures, resulting in cell shrinkage, nuclear fragmentation 
(karyorrhexis) and cell death. Apoptosis is more common in eukaryotic cells and is 
the primary cell death mechanism that can proceed to necrosis in the absent of 
phagocytosis (Krysko et al., 2008). Necrosis causes the swelling of organelles, 
leading to cell rupture and spillage of the cellular components causing localised 
tissue inflammation and immune system involvement (Ziegler and Groscurth, 2004). 
 
Two pathways initiate apoptosis: the intrinsic and extrinsic. The intrinsic pathway is 
activated in a response to intracellular stress, e.g. DNA damage, oxidative stress and 
others. The net impact is the release of p53, initiating apoptosis. The Bcl-2 family of 
proteins produce pro-apoptotic members (Bax, Bid, Bak) and anti-apoptotic 
members (Bcl-2, Bcl-xL). Under normal physiological conditions, the pro-apoptotic 
members translocate to the mitochondria and induce permeability of the outer 
mitochondrial membrane (OMM), and producing pro-apoptotic effectors such as 
Direct IAP-binding protein with low PI (DIABLO or SMAC), Cytochrome C, 
apoptosis-inducing factor (AIF) and others.  
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Figure 1.15. The inhibition of SRPK1 or Clk1 by protein kinase inhibitors 
A. The overexpression of SRPK1 in cancer increases phosphorylation of SRSF1 that 
can be stored in nuclear speckles. Further phosphorylation is required by Clk1 to 
release SRSF1 to splicing sites, increasing the production of mRNA isoform A, 
triggering increased cell proliferation and delayed apoptosis. B. Targeting SRPK1 
(SRPIN340 or SPHINX) or Clk1 (TG003) reduces activation of SRSF1 and 
ultimately switched in splicing, thus increase apoptosis through to up-regulation the 
expression of isoform B. 
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Figure 1.16. The inhibition of the tyrosine kinase receptor by imatinib (IM) 
The tyrosine kinase inhibitor (TKI) such as imatinib (IM) blocks activation of 
receptor tyrosine kinases (RTK) by competing with ATP binding at the kinase 
domain leading to the inhibition of downstream cellular signalling pathways. 
 
Cytochrome C binds to apoptotic caspase activating factor (APAF-1) forming 
apoptosomes. Caspase-9 is also activated thereby triggering the apoptosis pathway. 
Meanwhile, SMAC interacts with inhibitors of apoptosis proteins (IAPs) to inhibit 
their function and initiate apoptosis (Favaloro et al., 2012). 
 
The extrinsic pathway is mediated by the activation of the TNF receptor superfamily, 
also called death receptors. The binding of these receptors to their respective ligands 
leads to the formation of the Death Initiation Signalling Complex (DISC) which 
triggers a caspase cascade comprising caspase-8 and caspase-3 amongst others. 
Some cells have sufficient caspase-8 to activate caspase-3 and downstream caspase 
cascades. However, other cells have limited caspase-8, which would require 
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mitochondrial amplification (Favaloro et al., 2012). In malignancies, anti-apoptotic 
factors are overexpressed as a result of desregulation in SR/hnRNP protein 
expression. This could lead to inhibit apoptosis allowing cancerous cells to survive 
(Kedzierska and Piekielko-Witkowska, 2017; Placzek et al., 2010).  
 
Caspases are a group of cysteine-aspartic proteases, while caspase-9 is one of the 
most important intrinsic apoptotic pathway initiators. CASPASE-9 is located on 
chromosome 1p36 (Hadano et al., 1999) and is alternatively spliced, generating two 
protein isoforms (pro- and anti-apoptotic) of opposing function (Vu et al., 2013). 
These isoforms result from the inclusion or exclusion of a four-exon cassette (exon 
3-6), Figure 1.17. In leukaemia, the ratio of caspase-9a/9b isoforms is dys-regulated 
and occurs through the down-regulation of pro-apoptotic protein isoforms (caspase-
9a) and the up-regulation of anti-apoptotic protein isoforms (caspase-9b). Previous 
studies have suggested that phosphorylation of SR proteins affect CASPASE-9 
splicing. SRSF1 (SRp30a or ASF/SF2) is one of the most important SR proteins 
involved in the regulation of alternative splicing of CASPASE-9 (Vu et al., 2013; 
Shultz et al., 2011). 
 
1.6.1.2. Alternative splicing of other genes involved in leukaemia 
The proto-oncogene RON (macrophage-stimulating 1 receptor) is located on 
chromosome 3p21 and has two main splice variants; excluding or including 147 base 
pairs (bp) of exon 11 in the β-chain (Kang, Babicky and Lowy, 2014). This splicing 
produces two isoforms: Ron and ΔRon; including or skipping exon 11 respectively. 
Due to the deletion, ΔRon contains an uneven number of cysteine residues, 
therefore, these would oligomerise in a dysregulated manner leading to constitutive 
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activation of RTKs, Figure 1.18. Previous studies have demonstrated increased 
ΔRon expression in malignancies, such as gastric cancer (Kang, Babicky and Lowy, 
2014). Another study found that SRSF1 plays an important role in the alternative 
splicing of Ron, via the binding to an ESE and enhancing skipping exon 11 (Long 
and Caceres, 2009). Therefore, inhibiting protein kinases or their splicing factors, 
such as SRPK1 or SRSF1 may be a potential therapy against leukaemic cells.  
 
Runt-related transcription factor 1 (RUNX1), also known as acute myeloid leukaemia 
1 (AML1) is located on chromosome 21q22. It is a crucial haematopoietic 
transcription factor and regulates gene expression by binding to specific DNA 
sequences (Komeno et al., 2014). RUNX1 encodes α and β subunits of the 
heterodimeric core binding factor (CBF); the CBFα of which interacts with RUNX1 
while the CBFβ subunit is essential for haematopoietic development (Zhao et al., 
2012).  
 
RUNX1 is also known as AML1, PEBP2αB (polymavirus enhancer binding protein 
2αB) and CBFα2 (core-binding factor α2). It generates two isoforms by alternative 
splicing of exon 6: Runx1 (with exon 6) and ΔRunx1 (without exon 6), Figure 1.19. 
It has been shown that ΔRunx1 levels are increased in malignancies (Komeno et al., 
2014). 
 
AML typically arises from accumulated genetic mutations which are classified 
according to their role. Class-I-mutations stimulate cell proliferation while class-II-
mutations suppress blood cell differentiation. These classes are known as the ''two 
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hit theory'' or ''multi-hit hypothesis'' and was prosposed by Alfred Knudson in 1971 
(Knudson, 1971; Wu, Gomes and Sinclair, 2014).  
Acute leukaemias are generated from different chromosomal abnormalities, such as: 
1) t(8;21)(q22;q22) resulting in the fusion of RUNX1-ETO (Runt-related 
transcription factor 1- eight twenty-one) genes, 
2) t(12;21)(p12;q22) resulting in the fusion of TEL-RUNX1 genes, and 3) 
t(3;21)(q26;q22) resulting in the fusion of RUNX1/MDS1/EVI1 genes (Zhao et al., 
2012). 
 
However, it has been reported that rare cases of patients with Ph+ are detected in 
AML. However, common cases of Ph+ are found in CML and they are considered as 
blast phases due to rapid expansion of immature blood cells (blasts)  (Bacher et al., 
2011). Therefore, co-expression of RUNX1 with BCR–ABL1 induces the acute 
myeloid leukaemia (AML) transformation in CML patients (Zhao et al., 2012), 
suggesting the importance of evaluating the effect of combinations of ΔRunx1 
expression in CML cells. 
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Figure 1.17. The alternative splicing of CASPASE-9  
The alternative splicing of CASPASE-9 generates two isoforms: caspase-9a mRNA 
that includes exons 3, 4, 5 and 6 and caspase-9b mRNA excludes exons 3, 4, 5 and 6.  
 
 
Figure 1.18. The effect of alternative splicing on RON (MST1R)  
The alternative splicing of RON generates: Ron and ΔRon protein isoforms including 
or excluding exon 11, respectively. The expression of ΔRon is increased in 
malignancies due to the constitutively active tyrosine kinase. 
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 Figure 1.19. RUNX1 alternatively splicing isoforms 
Runx1 and ΔRunx1 isoforms are generated from RUNX1. The ΔRunx1 isoform 
blocks blood cell differentiation resulting in the massive accumulation of immature 
cells.   
 
1.7 The hypothesis, aim and objectives 
 
SRPK1 and Clk1 regulate the phosphorylation of SRSF1. While SRPK1 plays a 
direct role importing phosphorylated SRSF1 into the nucleus (Zhou and Fu, 2013), 
Clk1 has an indirect role whereby it controls the nuclear distribution of SRSF1 at the 
splicing site (Ghosh and Adams, 2011). As the role of SRPK1 and Clk1 in leukaemia 
is unclear, this study hypothesised that SRPK1 and Clk1 regulate alternative splicing 
via SRSF1 phosphorylation in CML. 
 
Targeting SRPK1, Clk1 and SRSF1 through 1) chemical inhibitors, 2) knock-downs 
using small interfering RNA (siRNA), or 3) establishing a stable knock-down using 
lentiviral transduction (short hairpin RNA- shRNA) may exert differential 
expression effects on the alternative splicing of CASPASE-9, RON, and RUNX1 in 
CML (K562) cells. Studies have shown that co-treatment of IM and amiloride 
improves CML therapy rather than one agent alone (Change et al., 2011). 
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Combining kinase inhibitors of TK and SRPK1 or Clk1 inhibitors may provide 
useful therapeutic options for leukaemia patients. 
 
The specific objectives of this thesis are: 
 
 To investigate how inhibiting or knocking down SRPK1 or SRSF1 switch 
splicing of CASPASE-9, RON or RUNX1 in K562 cells (Chapter 3). 
 To investigate how inhibiting or knocking down Clk1 switched splicing of 
CASPASE-9, RON or RUNX1 in K562 cells (Chapter 4). 
 To determine the effect of IM alone or in combination with SPHINX or 
TG003 on the alternative splicing of CASPASE-9, RON or RUNX1 in K562 
cells (Chapter 5). 
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CHAPTER 2.  MATERIALS AND METHODS 
2.1 Cell culture 
2.1.1. Cell line Maintenance 
 
All cell lines were purchased from the European Collection of Authenticated Cell 
Cultures (ECACC, UK). Leukaemic cell lines (Table 2.1) were cultured in 75 cm2 
flasks and grown in RPMI-1640 supplemented with L-glutamine and sodium 
bicarbonate, 10% (v/v) foetal bovine serum (FBS) and 1% (v/v) penicillin-
streptomycin solution P/S (Sigma-Aldrich, UK). All cells were incubated at 37°C in 
5% CO2 and were tested for mycoplasma contamination. 
 
Alternative splicing was analysed following protein kinase inhibition in several 
leukaemic cell lines (Table 2.1). Of these cell lines, alternative splicing could be 
demonstrated only in the chronic myeloid leukaemia K562 cell line. Therefore, K562 
cell line was chosen for subsequent experiments.  
 
The adherent cell line, PC-3, was u sed as a control in comparing K562 cells treated 
with si-SRPK1. PC-3 was cultured in Dolbecco’s Modified Eagle Medium (DMEM) 
supplemented with L-glutamine and sodium bicarbonate, 10% (v/v) foetal bovine 
serum (FBS) and 1% (v/v) penicillin-streptomycin solution P/S (Sigma-Aldrich, 
UK). When cells reaching confluency, they were also washed with 1 × PBS and 
incubated with 0.05% trypsin EDTA (Gibco-Invitrogen) to detach. Cells were 
incubated at 37°C for 5 minutes. Follownig detachment, cells were counted and used 
for further experiments.  
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Table 2.1. Cell line characteristics  
 
2.1.2. Routine passaging of cells 
When cell passaging, suspension cells were stained with trypan blue, counted on a 
haemocytometer and seeded according to the requirements of each experiment. All 
media was removed from cells by centrifugation of cells at ≥13,000 × g for 3 
minutes. Cells were washed twice with 1 × phosphate buffered saline (PBS).    
 
Adherent cells were also washed with 1 × PBS. Cells were incubated with 0.05% 
trypsin EDTA (Gibco-Invitrogen) to detach, and incubated at 37°C for 5 minutes. 
Follownig detachment, cells were counted and used for further experiments. 
Cell line Growth 
characteristic 
Molecular feature  
K562 Suspension  CML t(9;22) 
KARPAS-45  Suspension T-cell ALL  
MOLT-4 Suspension T-cell ALL 
RPMI-8226 Suspension Human myeloma  
U266 Suspension Human myeloma  
U937 Suspension Human Caucasian histiocytic lymohoma  
HL-60 Suspension Human Caucasian promyelocytic leukaemia  
SUPT-1  Suspension T-cell ALL   
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2.1.3. Thawing and freezing of cells 
2.1.3.1. Thawing procedure 
To defrost cells, cryovials were removed from liquid nitrogen and thawed at 37°C for 
1 minute; they were centrifuged at ≥13,000 × g for 3 minutes and cultured in 10 mL 
appropriate media.  
 
2.1.3.2. Freezing procedure 
Suspension cells were grown to > 1 × 106 cells/mL, re-suspend in freeze medium 
(75% RPMI-1640, 20% FBS and 5% dimethyl sulfoxide [DMSO]) and transferred to 
cryogenic vials. They were then stored at -80°C in a Mr Frosty (Nalgene®
 
Mr Frosty, 
Sigma-Aldrich, UK), a slow flreezing chamber with isopropanol, for 24 hours before 
being transferred to liquid nitrogen for long term storage. Adherent cell densities of 
> 2 × 106 cells/mL were re-suspended in 85% FBS and 15% DMSO and treated as 
above.  
2.2 Small molecule inhibitors 
K562 cells were treated with protein kinase inhibitors. All small molecules were 
dissolved in 100% DMSO for stocks and futhre diluted as appropriate in sterile 
water. K562 cells were treated with protein kinase inhibitors which were dissolved in 
100% DMSO (stocks) and further diluted as required required in sterile water. K562 
cells were treated with protein kinase inhibitors followed by EGF, to induce the 
SRPK1 or Clk1-dependent SR activation. As a control, K562 cells were also 
incubated with 0.02% DMSO to ensure that changes observed in gene expression 
following treatments were not due to DMSO. More detailed profiling small molecule 
inhibitors will be covered in later sections. 
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2.3 RNA extraction and assessment 
2.3.1. RNA extraction 
 
Total RNA was extracted from cells using RNeasy® Plus Mini Kit (Qiagen, UK). 
Initially, 10 μL of β-mercaptoethanol (β-ME) was added to 1 mL Buffer RLT Plus. 
Cells were washed twice in PBS and appropriate volume of Buffer RLT Plus 
supplemented with β-ME (Sigma-Aldrich, UK) was added. Harvested cells were 
mixed by vortexing for 30 seconds. To remove genomic DNA (gDNA), 
homogenized lysate was transferred to a gDNA spin column placed into a 2 mL 
collection tube. Genomic DNA removal with these columns is based on a chemical 
interaction between DNase and homogenized lysates. On-column digestion is more 
efficient in removing gDNA than in-solution methods. Centrifugation was carried 
out at ≥9000 × g for 30 seconds. The column was the discarded and the flow-through 
saved. The RNA was washed by adding one volume of 70% ethanol to the flow-
through and mixed by pipetting.  
 
Up to 700 μL from the sample was transferred into RNeasy spin column placed in a 
2 mL collection tube. Samples were centrifuged at ≥8000 × g for 15 seconds and the 
flow-through discarded. Then, 700 μL of Buffer RW1 was added to the RNeasy 
Mini spin column and centrifuged at ≥8000 × g for 15 seconds. The flow-through 
was discarded and 500 μL of Buffer RPE was added to the RNeasy spin column. 
After centrifugation at ≥8000 × g for 15 seconds, the flow-through was discarded. 
The previous step was repeated twice, and then the spin column was placed in a new 
1.5 mL eppendrof. The RNA was eluted twice by adding 30 μL RNase-free water 
directly to the membrane and stored at -80ºC. 
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2.3.2. Assessment of RNA yield and quality 
RNA purity and concentration was assessed using a Nanodrop 1000A UV 
spectrophotometer (Thermo Fisher Scientific, USA). Approximately 1 μL of RNA 
was used and purification determined by calculating the ratio of the sample 
absorbance at 260/280 nm (A260 /A280). The optimal ratio to for pure RNA was 1.8-
2.0.  
 
RNA integrity was determined by electrophoresing samples in 2% (w/v) agarose. 
Agarose (Bioline, UK) was dissolved in 1 × Tris-acetate (TAE) buffer (40 mM TRIS 
acetate, 10 mM EDTA, PH 8.3) by heating in a microwave. Ethidium bromide 
(EtBr) (10 mg/mL; Sigma-Aldrich, UK) was added to a final concentration of 3.43 
μg/mL. Molten agarose mixture was poured into a gel tray and left to solidify at 
room temperature for 15 minutes. RNA samples were mixed with DNA loading 
buffer (Bioline, UK) at a ratio of 4:1 and loaded onto the gel. Electrophoresis was 
carried out at 90 V for 40 minutes. Gels were visualised and ribosomal RNA (18S 
and 28S) was detected under UV light using Alpha Innotech instrumentation 
(FluorchemQ, USA). 
2.4 Reverse transcription polymerase chain reaction (RT-PCR) 
2.4.1. Primer design 
Primers for the genes of interest and reference gene (CASPASE-9, RON, RUNX1 and 
GAPDH) were designed using the web-based software Primer3Plus, Table 2.2- 2.3. 
The tool ensured specificity by avoiding cross homologies. Designed primers were 
blasted using NCBI Probe Database to ensure primer specificity and the absence of 
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primer-pair formations. Once ordered and delivered (Eurofins MWG Operon, 
Germany), the primers were tested and confirm specificity by melt-curve analysis 
using quantitative real-time PCR (qRT-PCR) and 2% agarose gel analysis. Primer 
specificity was represented as a single peak from the melt curve and a clear band on 
agarose.  
 
2.4.2. First standard synthesis of cDNA 
Approximately 13 μL from total RNA (0.5 - 1 μg) was added to nuclease-free water, 
mixed with 1 μL of random hexameric primers (0.5 mg/mL) and incubated at 70ºC 
for 5 minutes. Samples were immediately chilled on ice for 2-3 minutes to anneal the 
primer to targeted sequence. At this point, the samples were supplemented with:  
- 5 μL of M-MLV 5x reaction buffer,  
- 1.5 μL of dNTP mix,  
- 0.5 μL of RNasin Ribonuclease inhibitor,  
- 1.0 μL of M-MLV reverse transcriptase and  
- 2.0 μL of nuclease free water.  
First-strand of cDNA synthesis was performed by incubating the reaction mixture at 
37ºC for 60 minutes. Resulting cDNA was stored at -20ºC until required.   
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Table 2.2. List of RT-PCR oligonucleotide sequences 
Gene SRPK1 SRSF1        CLK1 
Gene name SRSF protein kinase 1  Serine and arginine rich splicing factor 1 CDC like kinase 1 
Accession no. NM_003137.4 NM_006924.4 NM_001162407.1 
Primer sequence F: GGCAATATCGTTCCTTGGAAGTT F: AACAGAGTGGTTGTCTCTGGACT  F: TGAATACTATCTTGGGTTTACCGTAT 
 R: CACAATGAGCTTGCGAGGCA  R: TTCCGTACAAACTCCACGACA  R: CGTTTCCTGGTTTTCTGTATCATAT 
Alignment F: base 1668 to 1744 F: base 570 to 588 F: base 1571 to 1601 
 R: base 1815 to 1870 R: base 589 to 703 R: base 1682 to 1687 
Amplicon 
sequence 
GGCAATATCGTTCCTTGGAAGTTCTAATC
GGATCTGGCTATAATACCCCTGCTGACAT
TTGGAGCACGGCATGCATGGCCTTTGAA
CTGGCCACAGGTGACTATTTGTTTGAACC
TCATTCAGGGGAAGAGTACACTCGAGAT
GAAGATCACATTGCATTGATCATAGAACT
TCTGGGGAAGGTGCCTCGCAAGCTCATT
GTG 
 
 
AACAGAGTGGTTGTCTCTGGACTGCCTC
CAAGTGGAAGTTGGCAGGATTTAAAGGAT
CACATGCGTGAAGCAGGTGATGTATGTTA
TGCTGATGTTTACCGAGATGGCACTGGT
GTCGTGGAGTTTGTACGGAA 
 
 
TGAATACTATCTTGGGTTTACCGTATTTCCAAC
ACACGATAGTAAGGAGCATTTAGCAATGATGG
AAAGGATTCTTGGACCTCTACCAAAACATATG
ATACAGAAAACCAGGAAACG 
Exon 13-15  2-3  10-12 
Splice variant Full transcript  Full transcript Full transcript 
Amplicon length 
(bp) 
203 134 117 
Organism Homo sapiens Homo sapiens Homo sapiens 
Source Primer3Plus Primer3Plus Primer3Plus 
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Table 2.2. List of RT-PCR oligonucleotide sequences (cont.) 
Gene  CASPASE-9 RON        RUNX1        
Gene name   Caspase-9 Macrophage Stimulating 1 Receptor (MST1R)  Runt-related transcription factor 1 
Accession no.  NM_001229.3 NM_002447.2 ENST00000431176 
Primer sequence F: GCTCTTCCTTTGTTCATC F: CCTGAATATGTGGTCCGAGACCCCCAG F: GCTTCACTCTGACCATCACTG 
 R: CATCTGGCTCGGGGTTACTGC R: CTAGCTGCTTCCTCCGCCACCAGTA R: GTCGCTGAACGCTGTCAGGTC 
Alignment F: base 450 to 633 F: base 2743 to 2913 F: 21: base 36231727 to 36231925 
 R: base 1114 to 1191 R: base 3061 to 3226 R: 21: base 36164068 to 36164326 
Amplicon 
sequence  
GCTCTTCCTTTGTTCATCTCCTGCTTAGAGGACACAGGCCAGGA
CATGCTGGCTTCGTTTCTGCGAACTAACAGGCAAGCAGCAAAGT
TGTCGAAGCCAACCCTAGAAAACCTTACCCCAGTGGTGCTCAGA
CCAGAGATTCGCAAACCAGAGGTTCTCAGACCGGAAACACCCAG
ACCAGTGGACATTGGTTCTGGAGGATTTGGTGATGTCGGTGCTC
TTGAGAGTTTGAGGGGAAATGCAGATTTGGCTTACATCCTGAGC
ATGGAGCCCTGTGGCCACTGCCTCATTATCAACAATGTGAACTT
CTGCCGTGAGTCCGGGCTCCGCACCCGCACTGGCTCCAACATCG
ACTGTGAGAAGTTGCGGCGTCGCTTCTCCTCGCTGCATTTCATG
GTGGAGGTGAAGGGCGACCTGACTGCCAAGAAAATGGTGCTGGC
TTTGCTGGAGCTGGCGCAGCAGGACCACGGTGCTCTGGACTGCT
GCGTGGTGGTCATTCTCTCTCACGGCTGTCAGGCCAGCCACCTG
CAGTTCCCAGGGGCTGTCTACGGCACAGATGGATGCCCTGTGTC
GGTCGAGAAGATTGTGAACATCTTCAATGGGACCAGCTGCCCCA
GCCTGGGAGGGAAGCCCAAGCTCTTTTTCATCCAGGCCTGTGGT
GGGGAGCAGAAAGACCATGGGTTTGAGGTGGCCTCCACTTCCCC
TGAAGACGAGTCCCCTGGCAGTAACCCCGAGCCAGATG 
CCTGAATATGTGGTCCGAGACCCCCAGGGATGGGTGGCAGG
GAATCTGAGTGCCCGAGGGGATGGAGCTGCTGGCTTTACAC
TGCCTGGCTTTCGCTTCCTACCCCCACCCCATCCACCCAGT
GCCAACCTAGTTCCACTGAAGCCTGAGGAGCATGCCATTAA
GTTTGAGTATATTGGGCTGGGCGCTGTGGCTGACTGTGTGG
GTATCAACGTGACCGTGGGTGGTGAGAGCTGCCAGCACGAG
TTCCGGGGGGACATGGTTGTCTGCCCCCTGCCCCCATCCCT
GCAGCTTGGCCAGGATGGTGCCCCATTGCAGGTCTGCGTAG
ATGGTGAATGTCATATCCTGGGTAGAGTGGTGCGGCCAGGG
CCAGATGGGGTCCCACAGAGCACGCTCCTTGGTATCCTGCT
GCCTTTGCTGCTGCTTGTGGCTGCACTGGCGACTGCACTGG
TCTTCAGCTACTGGTGGCGGAGGAAGCAGCTAG 
 
GCTTCACTCTGACCATCACTGTCTTCACAAACCC
ACCGCAAGTCGCCACCTACCACAGAGCCATCAAA
ATCACAGTGGATGGGCCCCGAGAACCTCGAAGAC
ATCGGCAGAAACTAGATGATCAGACCAAGCCCGG
GAGCTTGTCCTTTTCCGAGCGGCTCAGTGAACTG
GAGCAGCTGCGGCGCACAGCCATGAGGGTCAGCC
CACACCACCCAGCCCCCACGCCCAACCCTCGTGC
CTCCCTGAACCACTCCACTGCCTTTAACCCTCAG
CCTCAGAGTCAGATGCAGGATACAAGGCAGATCC
AACCATCCCCACCGTGGTCCTACGATCAGTCCTA
CCAATACCTGGGATCCATTGCCTCTCCTTCTGTG
CACCCAGCAACGCCCATTTCACCTGGACGTGCCA
GCGGCATGACAACCCTCTCTGCAGAACTTTCCAG
TCGACTCTCAACGGCACCCGACCTGACAGCGTTC
AGCGAC 
 
Exon 2-7 10-12 5-8 
Splice variant Caspase-9a: exons 2-7 (742 bp) 
Caspase-9b: exons 2 and 7 (292 bp) 
Ron: exons 10-12 (484 bp) 
ΔRon: exons 10 and 12 (337 bp) 
Runx1: exons 5-8 (482 bp) 
ΔRunx1: exons 5, 7 and 8 (290 bp) 
Amplicon length 
(bp) 
742 484 482 
Organism Homo sapiens Homo sapiens Homo sapiens 
Source Primer3Plus Primer3Plus Primer3Plus 
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Table 2.3. Reference genes primer information 
Gene GAPDH 
Gene name Glyceraldehyde-3-phosphate dehydrogenase 
Accession no. NM_002046 
Primer sequence F:  ACGGATTTGGTCGTATTGGGC 
R:  CTCCTGGAAGATGGTGATGG 
Alignment F: base 214 to 217 
R: base 425 to 425 
Amplicon sequence ACGGATTTGGTCGTATTGGGCGCCTGGTCACCAGGGCTGCTTTTAACTC
TGGTAAAGTGGATATTGTTGCCATCAATGACCCCTTCATTGACCTCAAC
TACATGGTTTACATGTTCCAATATGATTCCACCCATGGCAAATTCCATG
GCACCGTCAAGGCTGAGAACGGGAAGCTTGTCATCAATGGAAATCCCAT
CACCATCTTCCAGGAG 
Exon 2-5 
Amplicon length (bp) 212 
Splice variant Full transcript 
Organism Homo sapiens 
Source Primer3Plus 
 
2.4.3. Standard reverse transcription polymerase chain reaction (RT-PCR) 
PCR was performed using sequence specific primers. Each 23 μL PCR reaction 
contains;  
- 5 μL of 5 × Green GoTaq  
- 1.5 μL of 25 mM MgCl2  
- 0.6 μL of 10 mM dNTP mix  
- 0.1 μL of GoTaq Hot Start Polymerase (Promega, UK)  
- 10.3 μL of nuclease free water (Sigma-Aldrich, UK)  
- 5 μM oligonucleotide primers and, 
- 0.5 μL (500-1000 ng) cDNA template.  
For negative control amplifications, cDNA was replaced with 0.5 μL nuclease free 
water. Cycling was performed using a PTC200 DNA engine (MJ RESEARCH, 
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USA) using the following conditions, Table 2.4. RT-PCR products were store at -
20ºC until required. 
 
Table 2.4. Thermal cycles for standard PCR conditions 
 Conditions Temperature (ºC) Time (minutes) 
1 Initial Denaturation 94ºC 2:00 
2 Denaturation 94ºC 0:30 
3 Annealing 60ºC 0:30 
4 Extension 72ºC 0:30 
5 Repeat Step 2 33 cycles 
6 Final Extension 72ºC 5:00 
7 Forever  4ºC -  
 
2.5 Agarose gel electrophoresis 
Agarose gel electrophoresis separated RT-PCR products according to molecular 
weight. PCR product reactions were electrophoresed in 2% agarose gels with 
ethidium bromide (EtBr) (10 μg/mL) (Sigma-Aldrich, UK). DNA hyperladder: 
HyperLadder  (Bioline, UK) was electrophoresed simultaneously to estimate RT-
PCR product sizes. A gel was made and allowed set (as previously described) and an 
electrophoresis tank filled with 1 × TAE buffer to approximately 2 mm above the gel 
surface. PCR reaction volumes were loaded and electrophoresis carried out at 100 V 
for 40 minutes. After electrophoresis, the PCR products were visualised under UV 
light using Alpha Innotech technology (FluorchemQ, USA).  
 
2.5.1. Normalisation of RT-PCR  
To ensure gene expression are alternations were due to treatments alone, gels were 
analysed using ImageJ software that measured RT-PCR band densities; the data from 
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which was exported to Statistical Package for the Social Sciences (SPSS) software. 
The graphs depicted the splice variants from K562 cells, such as Casp9a/9b mRNA 
ratios. Data were presented as mean ± SE. Statistical differences between treatment 
groups were compared using one-way ANOVA. P values less than or equal to 0.05 
were significant (* P≤0.05).  
2.6 Gel extraction and purification of PCR products 
To sequence the PCR products, DNA purification following electrophoresis was 
required. The MiniElute® Gel Extraction kit (Qiagen, UK) was used to extract DNA 
from gels. Initially, PCR was performed in 23 μL reaction volumes (7 tubes) and 
pooled together. After electrophoresing the desired band was removed with a sterile 
scalpel.  
 
DNA Gel elution involved several steps. After weighing the gel, three volume of 
Buffer QG was added to 1 volume of gel (100 mg of gel ~100 μL). The gel solution 
was dissolved at 50ºC for 10 minutes with periodic vortexing. Once dissolved, one 
gel volume of isopropanol was added and mixed by inverting. The sample was 
placed in a MinElute spin column for centrifugation at ≥1000 × g for 1 minute. The 
flow through was discarded. Buffer PE (500 μL) was added to the MinElute column 
and incubated at room temperature for 5 minutes. The flow through was discarded 
after centrifugation at ≥1000 × g for 1 minute. At this point, MinElute columns were 
placed into clean 1.5 mL Eppendrof tubes. The elution was initiated by adding 
Buffer EB (30 μL) to the centre of the MinElute membrane, incubating at room 
temperature for 5 minutes and centrifuging for 2 minutes. The purified cDNA was 
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analysed on a 1.5% agarose gel and stored at -20°C until sequencing (Eurofins 
MWG Operon, Germany).  
2.7 Methods specific for Chapter 3 and 4 
2.7.1. Treatment of K562 cells with protein kinase inhibitors 
For inhibition studies, 10 μM of SRPIN340 (N-[2-(1-Piperidinyl)-5-(trifluoromethyl) 
phenyl] isonicotinamide), has shown to inhibit SRPK1, leading to the suppression of 
VEGFA in a mouse model (Dong et al., 2013). SRPIN340 is a specific 
serine/threonine protein kinase inhibitor that suppresses both SRPK1 and SRPK2 
expression (Dong et al., 2013). SRPIN349 exerts no inhibitory effects on SRPK1 
due to the lack of a lack of a triluorormethyl group, therefore it can be used as a 
negative control (Gammons et al., 2013).  
 
Alternative splicing was analysed in K562 cells treated with a range of SRPIN340 
concentrations. Two concentaions; 10 and 20 μM were used for futher experiments. 
After a 30 min pre-treatment with selective inhibitors for SRPK1, K562 cells were 
incubated with 100 ng/mL EGF for 24 hours. K562 cells were also treated with 
SRPK340/9 and 0.02% of DMSO prior to RNA extraction.  
 
In addition, SPHINX (5-methyl-N-[2-(morpholin-4-yl)-5-(tri-
fluoromethyl)phenyl]furan-2-carboxamide) was shown to have similar inhibitory 
properties to SRPIN340 in relation to SRPK1 suppression. However, SPHINX is a 
more selective inhibitor SRPK1 function (Gammons et al., 2013). K562 cells were 
treated with a range of SPHINX concentations (0 to 30 μM) followed by EGF, as 
previously descriped.  
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TG003, (Z)-1-(3-Ethyl-5-methoxy-2,3-dihydrobenzothiazol-2-ylidene)-2-propanone 
is a benzothiazole agent that suppresses Clk1. As a Cdc2-Like Kinase inhibitor, it 
acts as an ATP-competitive inhibitor for the Clk family. The agent increases 
skipping of mutated exon 31 of the dystrophin gene, suggesting an important role as 
a small molecule inhibitor in disease mechanisms (Sakuma, Iida and Hagiwara, 
2015).  
 
Another member of the family is TG009. This molecule elicits approximately 400 
times weaker inhibition than TG003, therefore it is used as a negative control 
(Muraki et al., 2004). K562 cells have demonstrated sensitivity to higher 
concentrations of TG003. Therefore, a range of TG003 concentrations (50 to 150 
μM) were chosen and followed by EGF or DMSO treatment, as previously 
descriped. All inhibitors and their chemical structures were drawn using 
ChemSketch software (Table 2.5). 
 
Both SRPIN340/349 and TG003/9 were kindly provided by Professor Masatoshi 
Hagiwara (University of Kyoto, Japan). They were dissolved in 100% DMSO to 
generate a 50 mM of stock. Further dilutions were prepared in sterile water (Table 
2.6).    
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Table 2.5. List of inhibitors and their chemical structures 
Compound Structure 
SRPIN340  
(SR protein inhibitor 340) 
 
SRPIN349 
(Negative SR protein inhibitor 349) 
 
SPHINX 
(SR protein inhibitor X) 
 
TG003  
(Cdc2-Like Kinase 1 inhibitor) 
 
TG009 
(Negative Cdc2-Like Kinase 1 inhibitor) 
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Table 2.6. List of inhibitors and their dilutions 
Compound Stock 
concentration 
Dilution Final concentration 
μM 
 SRPIN340- SRPIN349 50 mM 1:200 10 μM 
 
  1:100   20 μM 
 SPHINX 50 mM 1:400 5 μM 
  1:200 10 μM 
  1:100 20 μM 
  1:66.6 30 μM 
TG003 50 mM 1:40 50 μM 
  1:20 100 μM 
  1:13.3 150 μM 
 
2.7.2. RNA interference 
2.7.2.1. siRNA transfection 
Before transfection, K562 cells were cultured overnight with antibiotic free RPMI-
1640 media. On the day of transfection, cells were cultured for 2 hours in Opti-
MEM® I Reduced Serum Media (Life Technologies, UK), after which they were 
seeded in 6-well plates at a density of 0.5 × 106. Cells were then transfected with a 
siGENOME siRNA smartpool of SRPK1, SRSF1 and a siGENOME siRNA pool of 
Non-targeting (Thermoscientific, UK).  
 
According to the manufacturer’s guidelines, 2 mM of the siRNA transfection stock 
was prepared through dissolving in 1 × siRNA buffer (Thermoscientific, UK) and 
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further diluted to 100 nM. In two separate tubes, 100 nM siRNA and Dharmfect 2 
transfection reagent (increases cell membrane permeability) were diluted in Opti-
MEM® I Reduced Serum Media. Incubation of both was carried out at room 
temperature for 5 minutes followed by gentle pipetting to mix. After this, the 
transfection mix was prepared by adding the diluted siRNA to the transfection 
reagent and incubating at room temperature for 20 minutes.  
 
During incubation, Opti-MEM® I medium was removed from the cells and replaced 
with fresh medium.  The cells were transfected with the appropriate volume of 
transfection mix at a final concentration of 75 nM siRNA and 2 µM Dharmatect 2 
reagent per well for 48 - 72 hours. After 4 hours of incubation, the transfection 
reagent was removed and replaced with antibiotic free medium. All procedures were 
carried out in technical and biological triplicates. 
K562 cells were also seeded in 6-well plate at a density of 0.5 × 106 and transfected 
with three different CLK1 silencer siRNA and Non-targeting, Chapter 4 (Ambion, 
UK). The three siRNAs and the Non-targeting siRNA were dissolved as the 
candidate siRNA of SRPK1 and SRSF1.  
  
2.7.2.2. shRNA transduction 
 
Stable knockdown was of SRPK1 was achieved using SMART vector 2.0 lentiviral 
shRNA constructs in K562 cells. A puromycin selection cassette ensured the 
elimination all untransduced cells. To achieve this, the minimal puromycin 
concentration was determined. K562 cells were cultured in complete medium, in 6-
well plate, at 3 × 105 cells per well. The next day, the medium was replaced with 
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fresh medium supplemented with different puromycin concentrations (0.1 - 10 
μg/mL). The cells were incubated at 37°C in 5% CO2 for 3 to 4 days. Cell 
proliferation was assessed and medium supplemented with puromycin was replaced 
every two days. Cells were examined daily and the minimal puromycin 
concentration that efficiently eliminated all untransduced cells between 4 - 6 days 
was identified.  
 
For a successful transduction, it was necessary to use a ratio of SMART vector 2.0 
that would generate a particular multiplicity of infection (MOI). Different cell lines 
have different MOIs for establishing stable knockdown of the target genes. shRNA 
transduction was achieved according to the manufacture’s guidelines.  
2.7.3. Apoptosis quantification using acridine orange staining 
Acridine orange (AO) is a nucleic acid selective stain used in cell-cycle studies. AO 
is a cationic dye, is membrane permeable and intercalates with the nucleic acids of 
viable cells to distinguish between apoptosis and necrosis. Apoptosis quantification 
was carried out using a fluorescence microscope (Nikon Eclipse 80i). K562 cells 
were plated at a concentration of 20 × 103 cells/mL in 6-well plate, treated with 
kinase inhibitors and incubated at 37°C in 5% CO2 for 24 hours. Cells were pelleted 
at ≥40 × g for 5 minutes and supernatants discarded. The pellet was washed twice 
with PBS and finally resuspended with 150 μL PBS. Cells were adjusted in the 
cytofunnel (Fisher Scientific, UK) and centrifuged at ≥20,000 × g for 10 minutes 
using Cyospin 4 (Thermo Scientific, UK). Slides were removed from cytocentrifuge, 
air-dried and were fixed with absolute methanol for 10 minutes air dried again.  
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For staining, slides were immersed in fresh phosphate buffer [0.66% (w/v) potassium 
phosphate mono- basic + 0.32% (w/v) sodium phosphate dibasic, pH 6.4-6.5)], then 
stained in AO solution (0.12 mg/mL in phosphate buffer) for 45 seconds. Slides were 
placed in phosphate buffer for 10 minutes, followed by a further 15 minutes wash in 
fresh buffer.  
 
After staining and drying, slides were protected from light. For morphology 
analyses, slides were observed using a fluorescent microscope for up to 30 minutes 
before fluorescence faded. Nuclei morphology was analysed using a BG-12 
excitation filter and 0-530 barrier filter under × 40 objective lens. The criteria for 
identifying cells were nuclei and micronuclei (DNA) were stained yellow/green and 
the cytoplasm was stained red. Various stages of apoptotic and necrotic cell dealth 
were identified in cells treated with SRPIN340 or SPHINX when compared to EGF 
control. Percentages of viable, apoptotic and necrotic cells were determined in at 
least 1,000 cells per treatment. All experiments were repeated three times.    
2.7.4. APC Annexin V assay 
Annexin V:FITC staining detects apoptotic cells in a flow cytometry (BD 
Biosciences, USA). Annexins binding to phospholipids and Annexin V-FITC 
binding to phosphatidylserine (PS) is a calcium mediated process. In living cells, PS 
is located inside the lipid layer, however during apoptosis, phospholipids are 
exposed extracellularly due to e.g. cell assault. This causes PS stimulation and 
exposure at the cell surface, Therefore PS and Annexin binding are valuable 
apoptotic markers.  
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Before flow cytometric analysis, 1 × 106 of cells were washed twice with cold 1 × 
PBS and resuspended in 1 × binding buffer. Cells incubated with 5 μL of Annexin V 
and 5 μL propidium iodide for 15 minutes at room temperature, in the dark. After 
incubation, 400 μL of 1 × binding buffer was added prior to flow cytometry. Viable 
cells show no staining, they are APC Annexin V− or Propidium Iodide− while 
poptotic cells are APC Annexin V+ but Propidium Iodide−. Cells undergoing late 
apoptosis or already dead from necrosis are APC Annexin V+ and Propidium 
Iodide+, Figure 2.1. 
2.7.5. Protein analysis 
2.7.5.1. Cells harvesting and protein extraction 
Proteins were extracted from cells using Radioimmunoprecipitation assay (RIPA) 
lysis buffer (Sigma-Aldrich, UK). Harvested cells were washed twice with ice-cold   
CHAPTER 2 Materials and Methods 
94 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Apoptosis by flow cytometry using Annexin V and Propidium Iodide 
staining       
 
1 × PBS and centrifuged at 3000 × g for 3 minutes to pellet the cells, after which the 
1 × PBS was drained and ice-cold lysis buffer (0.5 mL per 5 × 106 cells) added. The 
RIPA buffer was supplemented with fresh protease and phosphatase inhibitor 
cocktail (1:1000) (Sigma-Aldrich, UK). Samples were further centrifuged at 4°C for 
10 minutes at ~20,000 × g and placed on ice, after which the supernatant (protein) 
was transferred to a fresh Eppendrof tube and stored at -80° C until use. 
 
2.7.5.2. The pierceTM BCA assay for protein quantification 
For protein estimation, dilutions of known concentrations were prepared to generate 
a standard curve. The protein standard, bovine serum albumin (BSA) (Sigma-
Aldrich, UK), was diluted in sterile water to prepare a set of BSA standards, Table 
2.7. For each standard, 25 µL was added in triplicates of 96-well plate.  
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Table 2.7. Preparation of BSA standards  
 Volume of diluent 
(µL) 
Volume of BSA 
(µL) 
Final BSA concentration  
(µg/mL) 
A 700 100 of Stock 250 
B 400 400 of vial A dilution 125 
C 450 300 of vial B dilution 50 
D 400 400 of vial C dilution 25 
E 400  100 of vial D dilution 5 
F 400 0 Blank 
 
Chilled samples were prepared by mixing 1 part of sample with seven parts of RIPA 
buffer (1:7, sample: RIPA buffer). For each diluted samples, 25 µL was added to 
triplicate 96-well plate. Protein quantification was carried out by preparing a 
working reagent (WR); 50 parts of BCA Reagent A to 1 part BCA reagent B (50:1, 
A:B). Whole protein content was quantified in triplicate at λ 595/490 nm using 
Revelation Quicklink software (Opsys Microplate Reader by Dynex Technologies, 
UK).  
 
2.7.5.3. SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to separate proteins according to size in an electric field (electrophoresis). Samples 
were thawed and 75 µg protein lysates were mixed with 1 × NuPAGE LDS sample 
buffer (Bio-rad, UK) supplemented with β-mercaptoethanol (1:20) (Sigma-Aldrich, 
UK) and make up to 20 µL. The mixture was heated to 95°C for 5 minutes prior to 
loading onto 4-15% Tris-Glycine eXtended (TGX) pre-cast gradient gel. In order to 
assess molecular weight, pre-stained protein standard markers (Bioline, UK) were 
loaded into the first lane. The gel was electrophoresed 1 × running buffer (10 × 
Running Buffer diluted in dH2O) at 150V for 1 hour. All chemicals are listed in 
Table 2.8.  
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Table 2.8. Buffer composition 
 
2.7.5.4. Western blot analysis 
Following gel electrophoresis, gel separated proteins were transferred to 
polyvinylidene fluoride (PVDF) membrane (GE Healthcare, UK). Membranes were 
activated by immersing in absolute methanol for 1 minute, and immersing in 1 × 
transfer buffer (10 × transfer buffer diluted in dH2O supplemented with 10% 
methanol) for 10 minutes. A sandwich of sponges, filter papers, gel and PVDF 
membrane were prepared in a cassette, Figure 2.2. The assembled cassette was 
placed in 1 × transfer buffer in a transfer tank and protein were transferred at 250V 
for 1 hour. 
 
After transfer, the unit was dissembled and the PVDF membrane blocked in 5% 
BSA and 1 × TBST (10 × TBST diluted in dH2O) at room temperature for 1 hour 
with constant agitation. Blocking the membrane prevents unspecific binding of 
antibodies to membranes. Antibodies were diluted in 5% BSA in 1 × TBST, Table 
2.9.  
No Buffers Composition 
 
1 10 × Running buffer 144 g Glycine, 30.3 g Tris base, 10 g SDS, 825 mL 
dH2O. 
 
2 
 
1 × Running buffer 
 
10% Running buffer (10×), 90% dH2O.  
 
3 
 
10 × Transfer buffer 
 
144 g Glycine, 30.3 Tris base 825 mL dH2O. 
 
4 
 
1 × Transfer buffer 
 
10% Transfer buffer (10×), 10% Methanol, 80% 
dH2O.  
 
5 
 
10 × TBST 
 
24.23 g Tris base, 80.06 g NaCl, 900 mL dH2O 
 
6 
 
1 × TBST 
 
100 mL TBST (10×), 10 mL Tween 20, 890 mL 
dH2O.  
Adjust pH to 7.5 
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Figure 2.2. Sandwich assembly for protein transfer to PVDF membrane 
 
After blocking, primary antibody was added and incubated overnight at 4°C with 
gentle agitation. The next day, membranes were washed 3 times with Tween (0.1%) 
and 1 × TBST for 5 minutes intervals and incubated with a secondary antibody 
diluted in blocking solution, at room temperature for 30 minutes with constant 
agitation. The secondary antibody was either anti-rabbit or anti-mouse IgG 
peroxidase (acts as an antibody-enzyme conjugate), Table 2.9. The membrane was 
washed 3 times with Tween (0.1%) and 1 × TBST for 5 minutes intervals. Finally, 
the membrane was incubated with equal amounts of luminol/enhancer and peroxide 
solutions for 1-4 minutes (Bio-rad, UK). The bound antibody was detected by an 
Amersham Imager 600 machine.  
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Table 2.9. Antibodies for Western blotting 
Primary antibodies 
Antibody Species Concentration/
Dilution 
Manufacturer 
 
SRPK1 
 
Mouse 
 
1 µg/mL 
 
Abcam, UK 
 
SRSF1 
 
Rabbit  
 
1 µg/mL 
 
Abcam, UK 
 
CLK1 
 
 
Rabbit 
 
900 µg/mL 
 
Aviva systems biology, 
USA  
 
Tubulin – α 
 
Mouse 
 
1:10 000 
 
Sigma-Aldrich, UK 
Secondary antibodies 
Polyclonal anti – Rabbit 
(peroxidase conjugated) 
Goat 1:10 000 Sigma-Aldrich, UK 
 
Polyclonal anti – Mouse 
(Horse radish peroxidase 
conjugated) 
Goat 1:10 000 Santa Cruz Biotechnology, 
UK 
 
2.7.5.5. Western blot normalisation 
ImageJ software was used to quantitatively analyse Western blots. Density values 
were exported to SPSS to calculate the average and standard error for each sample. 
The results were normalised against α-tubulin expression and the statistical 
differences compared with scrambled shRNA (sh-CTRL) or with the si-CTRL cells 
using one-way ANOVA. P values less than or equal to 0.05 were considered 
significant (* P≤0.05).  
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2.8 Methods specific for Chapter 5 
2.8.1. Treatment of K562 cells with protein kinase inhibitors 
Imatinib Mesylate (IM or STI571) is a tyrosine and serine/threonine protein kinase 
inhibitor (Selleckchem, UK) which was dissolved in DMSO and stored in 10 mM 
stocks at  -20°C.  
 
Imatinib mesylate (IM) or STI571 (4-[(4-methyl-1-piperazinyl) methyl]-N-[4-
methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino] phenyl] benzamide 
methanesulfonate (imatinib, Gleevec®; Novartis, Basel, Switzerland), is a tyrosine 
kinase inhibitor (TKI) of Bcr-Abl in CML (Tamascar and Ramanarayanan, 2009). 
As a powder (Selleckchem, UK), it was dissolved in DMSO and stored as 10 mM 
stocks at -20°C. The chemical structure of IM was drawn using ChemSketch 
software, Table 2.10.  
 
IM has been used as a front-line treatment for multiple cancers, most notably 
Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML). The 
formation of Ph+ is due to the fusion of Bcr-Abl proteins, resulting in constitutive 
tyrosine kinase activation. Despite the effectiveness of IM treatments, it induces 
approximately 98% of gene expression changes when used for one week  (Philips et 
al., 2014).   
 
Other studies have shown that other mutations may occur within the Bcr-Abl kinase 
domain, causing a reduced affinity for IM binding  (Wieczorek and Uharek, 2016; 
Bhamidipati et al., 2013). It has been suggested that combining protein kinase 
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inhibitors may provide successful cancer treatments (Dienstmann et al., 2014). For 
example, a shift in APAF-1, CRK, and SURVIVIN splicing was observed in K562 
cells treated with IM and amiloride (Chang et al., 2011). In this regard, the co-
administration of IM with other protein kinase inhibitors is required to re-sensitise 
CML patients to IM. 
 
The International Randomised Study (Yoon et al., 2013; Yeung et al., 2015)  
recommended IM range of 400 mg/day to 800 mg/day to treat Ph+ CML patients, 
depending on the disease stage (Yoon et al., 2013; Yeung et al., 2015). The 
European Treatment Outcome Study suggested the equivalent concentrations for 
CML (EUTOS) from mg/day to μg/mL (Table 2.11) (Egorin, Molimard and Mahon 
2007). Three different concentrations of IM alone were initially used; 1.0, 1.4 and 
2.9 μg/mL. A final dose of 1.0 μg/mL was chosen for subsequent experiments. Cells 
were treated with 1.0 μg/mL in combinations with SPHINX doses (5 – 20 μM) and 
TG003 doses (25 – 100 μM).  
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Table 2.10. The chemical structure of Imatinib 
Compound Structure 
Imatinib mesylate- IM or STI571 
(Tyrosine kinase inhibitor, TKI) 
 
 
Table 2.11. Imatinib ranges recommended for CML patients  
Compound Concentrations 
mg/day 
Concentrations  
μg/mL 
Imatinib mesylate- IM or STI571 
(Tyrosine kinase inhibitor, TKI) 
 
400 mg/day   
 
1.0 μg/mL 
 
 
 600 mg/day   1.4 μg/mL 
 800 mg/day   2.9 μg/mL 
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CHAPTER 3. TARGETING SERINE ARGININE-RICH SPLICING 
FACTOR 1 (SRSF1) AND SERINE ARGININE PROTEIN KINASE-
1 (SRPK1) IN A CHRONIC MYELOID LEUKAEMIA CELL LINE 
3.1 Introduction 
 
The serine/arginine-rich splicing factor 1 (SRSF1) is a proto-oncogene and is a 
member of the SR protein family. SRSF1, alternatively known as ASF/SF2 or 
SF2/ASF, is essential for alternative splicing regulation (Moulton, Gillooly and 
Tsokos, 2014). SRSF1 is also involved in several functions beyond mRNA splicing, 
including mRNA stability regulation, translation (Moulton, Gillooly and Tsokos, 
2014), nuclear export and nonsense-mediated mRNA decay (Goncalves and Jordan, 
2015). Several studies suggested that SRSF1 overexpression in some cancers is 
down to the dysregulation of alternative splicing in several genes, for example, 
SRSF1 overexpression was detected in paediatric acute lymphoblastic leukaemia 
(ALL) (Zou et al., 2012), similarly, it has been suggested that human lung cancer is 
linked to SRSF1 overexpression by increasing the anti-apoptotic isoforms of 3 
genes: BIN1, BIM and MCL1 (Das and Krainer, 2014).  
 
Angiogenesis (new blood vessel formation) is regulated by vascular endothelial 
growth factor A (VEGFA). It has been shown that upregulation of SRSF1 increases 
the production of a splice variant of VEGFA, called the pro-angiogenic (VEGF165) 
isoform in a mouse model of retinal neovascularization (Nowak et al., 2010). 
Another study indicated that SRSF1 overexpression led to the constitutive 
production of the ΔRon isoform, causing increased cell motility in breast and colon 
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carcinomas (Long and Caceres, 2009). SRSF1 overexpression also drives 
transformation of immortal lung cancer cells through increases in the caspase-9b 
(anti-apoptotic) isoform (Shultz et al., 2011).   
 
SRSF1 phosphorylation is controlled by serine-arginine protein kinase 1 (SRPK1) in 
order to regulate alternative splicing. Phosphorylated SRSF1 accumulates in the 
nucleus and is stored in the nuclear speckles (Aubol and Adams, 2011; Czubaty and 
Piekielko-Witkowska, 2017). It has been speculated that SRPK overexpression is 
linked to increased regulation of human immunodeficiency virus (HIV) and hepatitis 
C virus (HCV) (Karakama et al., 2010). Overexpression of SRPK1 has been reported 
in several malignancies, such as prostate cancer, breast cancer, lung cancer and 
glioma (Bullock and Oltean, 2017).   
 
Evidence shows that SRPK1 knockdown, or inhibition of its catalytic activity 
reduces SRSF1 phosphorylation levels, causing shifts in the alternative splicing of 
several genes, thereby limiting tumour growth (Goncalves et al., 2014; Mavrou and 
Oltean, 2016; Nowak et al., 2010). Despite these important observations, the precise 
roles of SRSF1 and SRPK1 in leukaemia remains unclear, therefore targeting SRSF1 
and/or SRPK1 and analysing the alternative splicing of e.g. CASPASE-9, RON, and 
RUNX1 in chronic myeloid leukaemia cells could be enlightening in uncovering 
disease molecular mechanisms. 
 
Moreover, SRPK1 knockdown limits tumour growth in colon cancer. It also shifts 
VEGFA alternative splicing, increasing the expression of the anti-angiogenic isoform 
in prostate cancer cells (Mavrou and Oltean, 2016). As SRPK1 regulates alternative 
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splicing and thus gene expression, it is critical to identify the precise roles SRPK1 or 
SRSF1 in K562 cells. 
3.2 Hypothesis  
 
The inhibition of SRPK1 or its splice factor (SRSF1), either pharmacologically or 
knockdown affects CASPASE-9, RON and RUNX1 alternative splicing in K562 cells. 
SRPK1 or SRSF1 knockdown was achieved through K562 cell transfection with 
siRNA or generate stable knockdown using lentiviral transduction (short hairpin 
RNA–shRNAs).  
3.3 Objectives 
 
All experiments were performed in the K562 cell line unless otherwise stated;  
 To assess proliferation of cells treated with SRPK1 small molecule inhibitors 
(Chapter 2, Materials and methods (Table 2.5)), prior to epidermal growth 
factor (EGF) addition. 
 To detect the effect of SRPK1 inhibitors on CASPASE-9, RON and RUNX1 
alternative splicing in K562 cells followed by EGF or dimethyl sulfoxide 
(DMSO) (Chapter 2: Materials and methods, section 2.7.1).  
 To investigate the effects of SRPK1 inhibitors on cell survival and cell death 
(apoptosis and necrosis) by acridine orange staining followed by EGF 
treatment. 
 To assess the cellular responses to SRPK1 inhibitors using an Annexin V/PI 
followed by EGF treatment. 
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 To generate SRPK1 stable knockdowns with shRNA lentiviral particles and 
to verify SRPK1 by Western blotting. 
 To introduce siRNA against SRPK1 or SRSF1 and confirm knockdown of 
SRPK1 or SRSF1 expression.  
 To confirm SRPK1 siRNA knockdown efficiency in PC-3 cells.  
 To detect siRNA SRSF1 effects on CASPASE-9, RON, and RUNX1 
alternative splicing.  
3.4 Results 
3.4.1. SRPK1 and SRSF1 expression in K562 cells 
 
 
The expression of SRPK1 and SRSF1 (mRNA and protein) in K562 cells was 
assessed using RT-PCR and Western blotting. Total mRNA was extracted from cells 
and reverse transcribed to cDNA. Primers, Chapter 2: Materials and methods (Table 
2.2), for SRPK1, SRSF1 and GAPDH were used to perform RT-PCR, generating 
products of 203 bp and 134 bp for SRPK1 and SRSF1, respectively. A GAPDH 
loading control was also used (212 bp),  
Figure 3.1A.  
 
Antibodies that listed in Chapter 2: Materials and methods (Table 2.9) were used for 
Western blott to assess the protein expression of SRPK1 and SRSF1 producing a 92 
kDa band for SRPK1 and a 32 kDa band for SRSF1. A loading control, α-tubulin at 
(55 kDa) was also used,  
Figure 3.1B.  
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Figure 3.1. SRPK1 and SRSF1 expression in K562 cells  
A. RT-PCR producted bands of 203 bp and 134 bp for SRPK1 and SRSF1, 
respectively. GAPDH yielded a product size of 212 bp and was used as a loading 
control. B. Western blotting generated a protein band of 92 kDa for SRPK1, 32 kDa 
for SRSF1 and 55 kDa for α-tubulin. 
  
3.4.2. The effects of SRPK1 small molecule inhibitors in K562 cells 
3.4.2.1. Proliferation of K562 cells following SRPK1 inhibition 
 
Approximately 1 × 106 K562 cells were used to assess cell proliferation upon 
SRPK1 inhibition with SRPIN340 or SPHINX. Cells were counted by trypan blue at 
24 hours following inhibition and compared to the no treatment 1 × 106 cell control 
(n = 3, ± SEM). 
 
The proliferation of cells treated with EGF only (100 ng/mL) was 1.5 × 106. K562 
cells were treated with 10 μM SRPIN340 reached 1.6 × 106 (p = 0.52) and K562 
cells treated with 20 μM SRPIN340 accounted for 1.98 × 106 (p = 0.11), one-way 
ANOVA, Figure 3.2.  
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K562 cells were also treated with different SPHINX concentrations (Figure 3.3). 
Cell numbers treated with only EGF (100 ng/mL) were approximately 1.5 × 106, 
while cell numbers were significantly increased to (2.2 × 106, p = 0.02) in those cells 
treated with 5 μM SPHINX, when compared to 1 × 106 cell control, one-way 
ANOVA. K562 cells treated with 10 and 30 μM SPHINX were 1.2 × 106 (p = 0.97) 
and 1.3 × 106 (p = 0.92) respectively, (one-way ANOVA). However, cell numbers 
for the 20 μM SPHINX treatment were 1.5 × 106 (one-way ANOVA, p = 0.74). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. K562 proliferation after 24 hour treatment with SRPIN340   
Quantitative analysis of K562 cells treated with only 100 ng/mL EGF (0 μM) and 10 
and 20 μM SRPIN340 followed by 100 ng/mL EGF. Cells were counted after 24 
hours and compared to a 1 × 106 cell control. The bars indicate standard errors (one-
way ANOVA). The data represents three independent experiments (n = 3). 
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Figure 3.3. K562 proliferation after 24 hour treatment SPHINX  
Quantitative analysis of K562 cells treated with only 100 ng/mL EGF (0 μM) and 
several SPHINX concentrations (5–30 μM) followed by 100 ng/mL EGF. After 24 
hours, cells were counted, a 1 × 106 untreated control compared proliferation of 
SPHINX treated cells. Cell proliferation was significantly increased in those cells 
treated with 5 μM SPHINX when compared to a 1 × 106 cell control. The bars 
indicate standard error, * P≤0.05 (one-way ANOVA). The data represents three 
independent experiments (n = 3). 
 
3.4.2.2. CASPASE-9 splicing in K562 cells following SRPK1 inhibition  
 
The effects of SRPK1 inhibition on CASPASE-9 splicing was investigated in K562 
cells and compared with cells treated with 0.02% DMSO (DMSO control) or cells 
treated with 100 ng/mL EGF (EGF control). The caspase-9a/9b expression ratio was 
quantified using densitometry and ImageJ software.  
 
The expression of the caspase-9b isoform was increased in cells treated with both 10 
μM SRPIN340 and 20 μM SRPIN340/9, when compared to the DMSO control 
CHAPTER 3 SRSF1 & SRPK1 in CML 
109 
 
(Figure 3.4B). In Figure 3.4C, the expression ratio of the caspase-9a/b isoform 
compared to the DMSO control was 1.34, while the expression ratio in cells treated 
with 10 μM SRPIN340 was 1.15 (p = 0.87, one-way ANOVA). Cells treated with 10 
μM SRPIN349 reached the expression ratio of caspase-9a/b isoform to 1.18 (p = 
0.93, one-way ANOVA). Furthermore, the caspase-9a/9b expression ratio in cells 
treated with 20 μM SRPIN340 and 20 μM SRPIN349 were significantly decreased to 
0.74 (p = 0.03) and 0.68 (p = 0.02) respectively, when compared to DMSO control 
(one-way ANOVA), Figure 3.4C. This significant effect, however, is not specific 
when cells treated with 20 μM SRPIN340 compared to 20 μM SRPIN349 (p = 0.99, 
one-way ANOVA). 
 
There was no change in splice variant caspase-9a and caspase-9b mRNA expression 
after SRPIN340 treatment, Figure 3.5B. The expression ratio of caspase-9a/9b 
isoform in the EGF control was 0.71 while in cells treated with 10 μM SRPIN340, 
the expression ratio was 0.54 (p = 0.91, one-way ANOVA), Figure 3.5C. However, 
the ratio of caspase-9a/9b was 0.59 (p = 0.96) in cells treated with 20 μM SRPIN340 
(one-way ANOVA), Figure 3.5C.  
 
Cells treated with SPHINX (5–30 μM) showed no obvious changes in splice variant 
caspase-9a and caspase-9b expression when compared to EGF control, Figure 3.6B. 
The expression ratio of caspase-9a/9b ratio in cells treated with EGF only (100 
ng/mL) was 1.16 while the expression ratio in cells treated with 5 μM SPHINX was 
1.24 (p = 0.99, one-way ANOVA). The expression ratio of caspase-9a/9b in cells 
treated with 10 μM and 20 μM SPHINX were 1.41 (p = 0.81) and 0.98 (p = 0.93), 
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Figure 3.6C. However, the expression ratio of caspase-9a/9b in cells treated with 30 
μM SPHINX was 0.71 (p = 0.26), Figure 3.6C.  
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Figure 3.4. SRPK1 inhibition (SRPIN340 and SRPIN349) on CASPASE-9 
alternative splicing  
A. CASPASE-9 showing the two splice variants resulting from inclusion or exclusion 
of exons 3–6 (caspase-9a and caspase-9b, respectively). Arrows indicate the position 
of forward and reverse CASPASE-9 primers. B. K562 cells were treated with 0.02% 
DMSO (DMSO control) and two concentrations of SRPIN340/9 were used at 10 and 
20 μM followed by (0.02%) DMSO. RT-PCR was performed and bands at 742 bp 
(casp-9a) and 292 bp (casp-9b) were detected. Intermediate bands at ~ 500 bp 
represent skipped exons. GAPDH was used as a loading control (212 bp). Each rung 
of the hyperLadder II represents 100 bp. C. Densitometric analysis of caspase-9a/9b 
isoforms representing the intensity ratio of caspase-9a against caspase-9b. K562 cells 
treated with SRPIN340 or SRPIN349 were compared with the DMSO control. The 
caspase-9a/9b ratio was significantly decreased for 20 μM SRPIN340 and SRPIN349 
treatments when compared to the DMSO control. However, this significant effect is 
not specific when cells treated with 20 μM SRPIN340 compared to 20 μM 
SRPIN349. The bars indicate standard error, * P≤0.05 (one-way ANOVA). The data 
represents three independent experiments (n = 3).  
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Figure 3.5. SRPK1 inhibition (SRPIN340) on CASPASE-9 alternative splicing  
A. CASPASE-9 showing the two splice variants resulting from inclusion or exclusion 
of exons 3–6 (caspase-9a and caspase-9b, respectively). Arrows indicate the 
positions of forward and reverse CASPASE-9 primers. B. K562 cells were treated 
with only 100 ng/mL EGF (0 μM SRPIN340) and two concentrations of SRPIN340 
were used at 10 and 20 μM followed by 100 ng/mL EGF. RT-PCR was performed 
and bands 742 bp (casp-9a) and 292 bp (casp-9b) were detected and GAPDH was 
used as a loading control. Intermediate bands at ~ 500 bp represent skipped exons. 
Each rung of the hyperLadder II represents 100 bp. C. Densitometric analysis of 
caspase-9a/9b isoforms. K562 cells treated with 10 μM and 20 μM SRPIN340 were 
compared with the EGF control (0 μM SRPIN340). The graph represents the 
intensity ratio of caspase-9a against caspase-9b. The bars indicate standard error 
(one-way ANOVA). The data represents three independent experiments (n = 3).  
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Figure 3.6. SRPK1 inhibition (SPHINX) on CASPASE-9 alternative splicing  
A. CASPASE-9 showing the two splice variants resulting from inclusion or exclusion 
of exons 3–6 (caspase-9a and caspase-9b, respectively). Arrows indicate the 
positions of forward and reverse CASPASE-9 primers. B. K562 cells were treated 
with only 100 ng/mL EGF (0 μM SPHINX) and range concentrations of SPHINX 
were used (5–30 μM) followed by 100 ng/mL EGF. RT-PCR was performed and 
bands at 742 bp (caspase-9a) and 292 bp (caspase-9b) were detected. Intermediate 
bands at ~ 500 bp represent skipped exons. GAPDH was used as a loading control. 
Each rung of the hyperLadder II represents 100 bp. C. Densitometric analysis of 
caspase-9a/9b isoforms. K562 cells treated with 5–30 μM SPHINX were compared 
with the EGF control (0 μM SPHINX). The graph represents the intensity ratio of 
caspase-9a against caspase-9b. The bars indicate standard error (one-way ANOVA). 
The data represent three independent experiments (n = 3).  
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3.4.2.2.1 The CASPASE-9 cDNA amplicon sequence 
 
Four CASPASE-9 isoforms are produced; however, only two were studied in these 
studies. CASPASE-9 mRNA PCR products were isolated from agarose gels and 
sequenced (Chapter 2). The sequenced CASPASE-9 was based on the reference 
sequence at NCBI GenBank (accession number: NM_001229.4). Figure 3.7 and 3.8 
show the caspase-9a sequence, including exons 2 - 7 and the caspase-9b sequence, 
including exons 2 - 7. 
5’…CGGGCAGGCTCTGGATCTCGGCGGGATCAGGCCAGGCAGCTGATCATAGATCTGGAGA
CTCGAGGGAGTCAGGCTCTTCCTTTGTTCATCTCCTGCTTAGAGGACACAGGCCAGGAC 
GCAGTAACCCCGAGCCAGATGCCACCCCGTTCCAGGAAGGTTTGAGGACCTTCGACCAGC
TGGACGCCATATCTAGTTTGCCCACACCCAGTGACATCTTTGTGTCCTACTCTACTTTCCCA
G…’3 
Figure 3.7. The sequence of caspase-9a showing exons 2–7 
Sequence analysis of the top band amplified using primers caspase-9F + caspase-9R, 
showing exon 2, exon 3, exon 4, exon 5, exon 6 and exon 7. In red: forward and 
reverse primers. Sequence in box is the actual cDNA sequence generated from the 
caspase-9a PCR product. 
 
 
 
 
 
 
 
ATGCTGGCTTCGTTTCTGCGAACTAACAGGCAAGCAGCAAAGTTGTCGAAGCCAACCCT
AGAAAACCTTACCCCAGTGGTGCTCAGACCAGAGATTCGCAAACCAGAGGTTCTCAGA
CCGGAAACACCCAGACCAGTGGACATTGGTTCTGGAGGATTTGGTGATGTCGGTGCTC
TTGAGAGTTTGAGGGGAAATGCAGATTTGGCTTACATCCTGAGCATGGAGCCCTGTGG
CCACTGCCTCATTATCAACAATGTGAACTTCTGCCGTGAGTCCGGGCTCCGCACCCGC
ACTGGCTCCAACATCGACTGTGAGAAGTTGCGGCGTCGCTTCTCCTCGCTGCATTTCAT
GGTGGAGGTGAAGGGCGACCTGACTGCCAAGAAAATGGTGCTGGCTTTGCTGGAGCT
GGCGCAGCAGGACCACGGTGCTCTGGACTGCTGCGTGGTGGTCATTCTCTCTCACGG
CTGTCAGGCCAGCCACCTGCAGTTCCCAGGGGCTGTCTACGGCACAGATGGATGCCCT
GTGTCGGTCGAGAAGATTGTGAACATCTTCAATGGGACCAGCTGCCCCAGCCTGGGAG
GGAAGC AA CT TTTTTCAT CAGG C GTGGT GG AGCAGAAAGA CATGGGTT
T G TGGCCTCCACTTCCCCTGAAGACGAGTCCC G 
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5’…CGGGCAGGCTCTGGATCTCGGCGGGATCAGGCCAGGCAGCTGATCATAGATCTGGAGA
CTCGAGGGAGTCAGGCTCTTCCTTTGTTCATCTCCTGCTTAGAGGACACAGGC 
GTGCTCTTGAGAGTTTGAGGGGAAATGCAGATTTGGCTTACATCCTGAGCATGGAGCCCTG
TGGCCACTGCCTCATTATCAACAATGTGAACTTCTGCCGTGAGTCCGGGCTCCGCACCCGC
ACTGGCTCCAACATCGACTGTGAGAAGTTGCGGCGTCGCTTCTCCTCGCTGCATTTCATGGT
GGAGGTGAAGGGCGACCTGACTGCCAAGAAAATGGTGCTGGCTTTGCTGGAGCTGGCGCA
GCAGGACCACGGTGCTCTGGACTGCTGCGTGGTGGTCATTCTCTCTCACGGCTGTCAGGCC
AGCCACCTGCAGTTCCCAGGGGCTGTCTACGGCACAGATGGATGCCCTGTGTCGGTCGAG
AAGATTGTGAACATCTTCAATGGGACCAGCTGCCCCAGCCTGGGAGGGAAGCCCAAGCTCT
TTTTCATCCAGGCCTGTGGTGGGG 
GCAGTAACCCCGAGCCAGATGCCACCCCGTTCCAGGAAGGTTTGAGGACCTTCGACCAGC
TGGACGCCATATCTAGTTTGCCCACACCCAGTGACATCTTTGTGTCCTACTCTACTTTCCCA
G…’3 
 
Figure 3.8. The sequence of caspase-9b showing exons 2–7 
Sequence analysis of the top band amplified using primers caspase-9F + caspase-9R, 
showing exon 2, exon 3, exon 4, exon 5, exon 6 and exon 7. In red: forward and 
reverse primers. Sequence in box is the actual cDNA sequence generated from the 
caspase-9b PCR product. 
 
3.4.2.3. RON splicing in K562 cells following SRPK1 inhibition  
 
SRPK1 inhibition on RON splice isoforms was assessed by RT-PCR and the 
expression ratio of Ron/ΔRon quantified using ImageJ software. Figure 3.9B, no 
changes were observed in Ron and ΔRon splice variants in cells treated with 
SRPIN340 or SRPIN349. In Figure 3.9C, the expression ratio of the Ron/ΔRon 
isoform in the DMSO control was 0.71, while in K562 cells treated with 10 μM 
SRPIN340 and 10 μM SRPIN349, the expression ratios were 0.79 (p = 0.64) and 
0.76 (p = 0.91), one-way ANOVA. In addition, 20 μM SRPIN340 led to a significant 
increase in the Ron/ΔRon expression ratio (0.91, p = 0.03), when compared to 
DMSO control (one-way ANOVA), Figure 3.9C. This elevation, however is not 
specific when compared to the expression ratio of Ron/ΔRon in cells treated with 20 
μM SRPIN349 (0.84, p = 0.23), one-way ANOVA. 
 
CAGGACATGCTGGCTTCGTTTCTGCGAACTAACAGGCAAGCAGCAAAGTTGTCGAAGC
CAACCCTAGAAAACCTTACCCCAGTGGTGCTCAGACCAGAGATTCGCAAACCAGAGGT
TCTCAGACCGGAAACACCCAGACCAGTGGACATTGGTTCTGGAGGATTTGGTGATGTC
G 
 
AGCAGAAAGACCATGGGTTTGAGGTGGCCTCCACTTCCCCTGAAGACGAGTCCCCTG 
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Furthermore, there were no statistical changes in Ron and ΔRon splice variant 
expression in cells treated with 10 and 20 μM SRPIN340, Figure 3.10B. The 
expression ratio of Ron/ΔRon was 0.73 in K562 cells treated with 100 ng/mL EGF 
only (0 μM SRPIN340). The expression ratio of Ron/ΔRon in cells treated with 10 
μM SRPIN340 and 20 μM SRPIN340 was (0.58, p = 0.64) and (0.81, p = 0.89), one-
way ANOVA), Figure 3.10C. 
 
K562 cells were treated with SPHINX (0 – 30 μM) and RON alternative splicing 
compared to the EGF control, Figure 3.11. RT-PCR showed no changes in RON 
splice variant mRNA expression after SPHINX treatment, Figure 3.11B. The 
expression ratio of Ron/ΔRon was 0.98 in K562 cells treated with EGF only (100 
ng/mL), Figure 3.11C. The expression ratios of Ron/ΔRon in K562 cells treated with 
5 and 10 μM SPHINX were (0.85, p = 0.94) and (0.86, p = 0.97), one-way ANOVA.  
Additionally, the Ron/ΔRon expression ratios in K562 cells treated with 20 and 30 
μM SPHINX were (1.07, p = 0.98) and (1.30, p = 0.32), one-way ANOVA. 
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Figure 3.9. SRPK1 inhibition (SRPIN340 and SRPIN349) on RON alternative 
splicing  
A. The RON gene showing the two splice variants resulting from the inclusion or 
exclusion of exon 11 (Ron and ΔRon variants, respectively). Arrows indicate the 
positions of forward and reverse Ron primers. B. K562 cells were treated with 
0.02% DMSO (DMSO control) and two concentrations of SRPIN340/9 were used at 
10 and 20 μM followed by (0.02%) DMSO. RT-PCR was performed and bands at 
484 bp (Ron) and 337 bp (ΔRon) were detected. GAPDH was used as a loading 
control (212 bp). Each rung of the hyperLadder II represents 100 bp. C. 
Densitometric analysis of Ron/ΔRon isoforms. K562 cells treated with SRPIN340 or 
SRPIN349 were compared with the DMSO control. The expression ratio of 
Ron/ΔRon significantly increased for the 20 μM SRPIN340 treatment. However, this 
significant effect is not specific when the expression ratio of cells treated with 20 μM 
SRPIN340 compared to 20 μM SRPIN349. The bars indicate standard error, * 
P≤0.05 (one-way ANOVA). The data represents three independent experiments (n = 
3).  
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Figure 3.10. SRPK1 inhibition (SRPIN340) on RON alternative splicing  
A. The RON gene showing the two splice variants resulting from inclusion or 
exclusion of exon 11 (Ron and ΔRon, respectively). Arrows indicate the positions of 
forward and reverse Ron primers. B. K562 cells were treated with only 100 ng/mL 
EGF (0 μM SRPIN340) and two concentrations of SRPIN340 were used at 10 and 
20 μM followed by 100 ng/mL EGF. RT-PCR was performed and bands at 484 bp 
(Ron) and 337 bp (ΔRon) were detected. GAPDH was used as a loading control. 
Each rung of the hyperLadder II represents 100 bp. C. Densitometric analysis of 
Ron/ΔRon isoforms. K562 cells treated with 10 and 20 μM SRPIN340 were 
compared with the EGF control (0 μM SRPIN340). The graph represents the 
intensity ratio of Ron against ΔRon. The bars indicate standard error (one-way 
ANOVA). The data represents three independent experiments (n = 3).  
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Figure 3.11. SRPK1 inhibition (SPHINX) on RON alternative splicing 
A. The RON gene showing the two splice variants resulting from inclusion or 
exclusion of exon 11 (Ron and ΔRon, respectively). Arrows indicate the positions of 
forward and reverse Ron primers. B. K562 cells were treated with only 100 ng/mL 
EGF (0 μM SPHINX) and range concentrations of SPHINX were used (5–30 μM) 
followed by 100 ng/mL EGF. RT-PCR was performed and bands at 484 bp (Ron) 
and 337 bp (ΔRon) were detected. GAPDH was used as a loading control. Each rung 
of the hyperLadder II represents 100 bp. C. Densitometric analysis of Ron/ΔRon 
isoforms. K562 cells treated with 5–30 μM SPHINX were compared with control 
cells treated with EGF only (0 μM SPHINX). The graph represents the intensity ratio 
of Ron against ΔRon. The bars indicate standard error (one-way ANOVA). The data 
represents three independent experiments (n = 3).  
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3.4.2.3.1 The RON cDNA amplicon sequence 
 
Ron RT-PCR products were sequenced as described previously. The sequenced Ron 
was based on the NBCI GenBank reference transcription ID_MST1R-001: 
(ENST00000296474). The Ron isoform sequence includes exons 10–12, Figure 
3.12. The ΔRon isoform sequence also includes exons 10 and 12, Figure 3.13.   
 
5’…TGTGAGAGGCAGCTTCCAGAGCAGCAGCTGTGCCGCCTTCCTGAATATGTGGTCCGAG
ACCCCCAGGGATGGGTGGCAGGGAATCTGAGTGCCCGA  
TACTGGTGGCGGAGGAAGCAGCTAG…’3 
Figure 3.12. Sequence analysis of the Ron isoform showing exons 10–12  
Sequence analysis of the top band amplified using primers Ron-F + Ron-R, showing 
exon 10, exon 11 and exon 12. In red: forward and reverse primers. Sequence in box 
is the actual cDNA sequence generated from the Ron PCR product.  
 
 
5’…TGTGAGAGGCAGCTTCCAGAGCAGCAGCTGTGCCGCCTTCCTGAATATGTGGTCCGAG
ACCCCCAGGGATGGGTGGCAGGGAATCTGAGTGC 
AGTATATTGGGCTGGGCGCTGTGGCTGACTGTGTGGGTATCAACGTGACCGTGGGTGGTGA
GAGCTGCCAGCACGAGTTCCGGGGGGACATGGTTGTCTGCCCCCTGCCCCCATCCCTGCA
GCTTGGCCAGGATGGTGCCCCATTGC 
TACTGGTGGCGGAGGAAGCAGCTAG…’3 
 
Figure 3.13. Sequence analysis of the ΔRon isoform showing exons 10–12  
Sequence analysis of the top band amplified using primers Ron-F + Ron-R, showing 
exon 10, exon 11 and exon 12. In red: forward and reverse primers. Sequence in box 
is the actual cDNA sequence generated from the ΔRon PCR product.  
 
 
GGGGATGGAGCTGCTGGCTTTACACTGCCTGGCTTTCGCTTCCTACCCCCACCCCATC
CACCCAGTGCCAACCTAGTTCCACTGAAGCCTGAGGAGCATGCCATTAAGTTTGAGTAT
ATTGGGCTGGGCGCTGTGGCTGACTGTGTGGGTATCAACGTGACCGTGGGTGGTGAG
AGCTGCCAGCACGAGTTCCGGGGGGACATGGTTGTCTGCCCCCTGCCCCCATCCCTG
CAGCTTGGCCAGGATGGTGCCCCATTGCAGGTCTGCGTAGATGGTGAATGTCATATCC
TGGGTAGAGTGGTGCGGCCAGGGCCAGATGGGGTCCCACAGAGCACGCTCCTTGGTA
T CT CT CTTT CTGCTGCT GTGGCTGCACTGGCGACTGCACTGGTCTTCAGC 
CCGAGGGGATGGAGCTGCTGGCTTTACACTGCCTGGCTTTCGCTTCCTACCCCCACCC
CATCCACCCAGTGCCAACCTAGTTCCACTGAAGCCTGAGGAGCATGCCATTAAGTTTG 
AGGTCTGCGTAGATGGTGAATGTCATATCCTGGGTAGAGTGGTGCGGCCAGGGCCAGA
TGGGGTCCCACAGAGCACGCTCCTTGGTATCCTGCTGCCTTTGCTGCTGCTTGTGGCT
GCACTGGCGACTGCACTGGTCTTCAGC 
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3.4.2.4. RUNX1 splicing in K562 cells following SRPK1 inhibition  
 
RUNX1 splicing was assessed by RT-PCR and Runx1/ΔRunx1 expression ratios 
quantified by ImageJ software. There were no change in Runx1 and ΔRunx1 mRNA 
expression after SRPIN340 or SRPIN349 treatment, Figure 3.14B. The expression 
ratio of Runx1/ΔRunx1 (Figure 3.14C) was 0.96 in K562 cells treated with 0.02% 
DMSO (DMSO control). The expression ratios in K562 cells treated with 10 μM 
SRPIN340 and 10 μM SRPIN349 were (0.90, p = 1.00) and (0.78, p = 0.93), one-
way ANOVA). Additionally, K562 cells treated with 20 μM SRPIN340 caused 0.57 
(p = 0.32) in the expression ratio of Runx1/ΔRunx1, while the 20 μM SRPIN349 
treatment caused 0.67 (p = 0.64), one-way ANOVA. 
 
There was no statistical change in RUNX1 alternative splicing after treatments 
with 10 and 20 μM SRPIN340, when compared to the EGF control, Figure 
3.15B. The expression ratio in cells treated with EGF only (100 ng/mL) was 
0.73, while the expression ratio in cells treated with 10 μM SRPIN340 was 0.64 
(p = 0.85), one-way ANOVA, Figure 3.15C. Additionally, the expression ratio of 
Runx1/ΔRunx1 in cells treated with 20 μM SRPIN340 was 0.86 (p = 0.66), one-
way ANOVA. Additionally, there were no changes in Runx1/ΔRunx1 splice 
variant expression in K562 cells treated with SPHINX,  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16B. The expression ratio of Runx1/ΔRunx1 treated with EGF only (100 
ng/mL) was 0.67, Figure 3.16C. The expression ratios of Runx1/ΔRunx1 in cells 
treated with 5–30 μM SPHINX were (0.58, p = 0.98), (0.57, p = 0.97), (0.84, p = 
0.75) and (0.81, p = 0.85), one-way ANOVA.   
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Figure 3.14. SRPK1 inhibition (SRPIN340 and SRPIN349) on RUNX1 
alternative splicing 
A. RUNX1 showing the two splice variants resulting from inclusion or exclusion of 
exon 6 (Runx1 and ΔRunx1 variants, respectively). Arrows indicate the positions of 
forward and reverse Runx1 primers. B. K562 cells were treated with 0.02% DMSO 
(DMSO control) and two concentrations of SRPIN340/9 were used at 10 and 20 μM 
followed by (0.02%) DMSO. RT-PCR was performed and bands at 482 bp (Runx1) 
and 290 bp (ΔRunx1) were detected. GAPDH was used as a loading control. Each 
rung of the hyperLadder II represents 100 bp. C. Densitometric analysis of 
Runx1/ΔRunx1 isoforms. K562 cells treated with SRPIN340 or SRPIN349 were 
compared with the DSMO control. The bars indicate standard error (one-way 
ANOVA). The data represents three independent experiments (n = 3).   
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Figure 3.15. SRPK1 inhibition (SRPIN340) on RUNX1 alternative splicing 
A. RUNX1 showing the two splice variants resulting from inclusion or exclusion of 
exon 6 (Runx1 and ΔRunx1, respectively). Arrows indicate the positions of forward 
and reverse Runx1 primers. B. K562 cells were treated with only 100 ng/mL EGF (0 
μM SRPIN340) and two concentrations of SRPIN340 were used at 10 and 20 μM 
followed by 100 ng/mL EGF. RT-PCR was performed and bands at 482 bp (Runx1) 
and 290 bp (ΔRunx1) were detected. GAPDH was used as a loading control. Each 
rung of the hyperLadder II represents 100 bp. C. Densitometric analysis of 
Runx1/ΔRunx1 isoforms. K562 cells treated with 10 and 20 μM SRPIN340 were 
compared with the EGF control (0 μM SRPIN340). The graph represents the 
intensity ratio of Runx1 against ΔRunx1. The bars indicate standard error (one-way 
ANOVA). The data represent three independent experiments (n = 3).  
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Figure 3.16. SRPK1 inhibition (SPHINX) on RUNX1 alternative splicing  
A. RUNX1 showing the two splice variants resulting from inclusion or exclusion of 
exon 11 (Runx1 and ΔRunx1, respectively). Arrows indicate the positions of 
forward and reverse Ron primers. B. K562 cells were treated with only 100 ng/mL 
EGF (0 μM SPHINX) and range concentrations of SPHINX were used (5–30 μM) 
followed by 100 ng/mL EGF. RT-PCR was performed and bands at 482 bp (Runx1) 
and 290 bp (ΔRunx1) were detected. GAPDH was used as a loading control. Each 
rung of the hyperLadder II represents 100 bp. C. Densitometric analysis of 
Runx1/ΔRunx1 isoforms. K562 cells treated with 5–30 μM SPHINX were compared 
with the EGF control (0 μM SPHINX). The graph represents the intensity ratio of 
Runx1 against ΔRunx1. The bars indicate standard error (one-way ANOVA). The 
data represents three independent experiments (n = 3).  
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3.4.2.4.1 The Runx1 cDNA amplicon sequences 
Runx1 mRNA sequence was confirmed using NCBI GenBank with Refseq® 
database: (NG_011402.2). Figure 3.17 shows the Runx1 sequence, including exons 
5–7 and part of exon 8. 
5’…GGAAAAGCTTCACTCTGACCATCACTGTCTTCACAAACCCACCGCAAGTCGCCACCTACCACAGAGCC
ATCAAAATCACAGT 
GACATCGGCAGAAACTAGATGATCAGACCAAGAGCTTGTCCTTTTCCGAGCGGCTCAGTGAACTGGAGCAG
CTGCGGCGCACAGCCATGAGGGTCAGCCCACACCACCCAGCCCCCACGCCCAACCCTCGTGCCTCCCTGAA
CCACTCCACTGCCTTTAACCCTCAGCCTCAGAGTCAGATGCAGG 
CCGCGCCAGTTCCCCGCGCTGCCCTCCATCTCCGACCCCCGCATGCACTATCCAGGCGCCTTCACCTACTC
CCCGACGCCGGTCACCTCGGGCATCGGCATCGGCATGTCGGCCATGGGCTCGGCCACGCGCTACCACACCT
ACCTGCCGCCGCCCTACCCCGGCTCGTCGCAAGCGCAGGGAGGCCCGTTCCAAGCCAGCTCGCCCTCCTAC
CACCTGTACTACGGCGCCTCGGCCGGCTCCTACCAGTTCTCCATGGTGGGCGGCGAGCGCTCGCCGCCGCG
CATCCTGCCGCCCTGCACCAACGCCTCCACCGGCTCCGCGCTGCTCAACCCCAGCCTCCCGAACCAGAGCG
ACGTGGTGGAGGCCGAGGGCAGCCACAGCAACTCCCCCACCAACATGGCGCCCTCCGCGCGCCTGGAGGAG
GCCGTGTGGAGGCCCTACTGA…’3  
 
Figure 3.18 shows the ΔRunx1 sequence and includes exons 5, 7 and part of exon 8.  
 
5’…GGAAAAGCTTCACTCTGACCATCACTGTCTTCACAAACCCACCGCAAG  
CGCGCCAGTTCCCCGCGCTGCCCTCCATCTCCGACCCCCGCATGCACTATCCAGGCGCCTTCACCTACTCC
CCGACGCCGGTCACCTCGGGCATCGGCATCGGCATGTCGGCCATGGGCTCGGCCACGCGCTACCACACCTA
CCTGCCGCCGCCCTACCCCGGCTCGTCGCAAGCGCAGGGAGGCCCGTTCCAAGCCAGCTCGCCCTCCTACC
ACCTGTACTACGGCGCCTCGGCCGGCTCCTACCAGTTCTCCATGGTGGGCGGCGAGCGCTCGCCGCCGCGC
ATCCTGCCGCCCTGCACCAACGCCTCCACCGGCTCCGCGCTGCTCAACCCCAGCCTCCCGAACCAGAGCGA
CGTGGTGGAGGCCGAGGGCAGCCACAGCAACTCCCCCACCAACATGGCGCCCTCCGCGCGCCTGGAGGAGG
CCGTGTGGAGGCCCTACTGA…’3          
Figure 3.17. Sequence analysis of Runx1 showing exons 5–8 
Sequence analysis of the top band amplified using primers Runx1-F + Runx1-R, 
showing exon 5, exon 6, exon 7 and exon 8. In red: forward and reverse primers. 
Sequence in box is the actual cDNA sequence generated from the Runx1 PCR 
product.   
TCGCCACCTACCACAGAGCCATCAAAATCACAGTGGATGGGCCCCGAGAACCTCGAAGACATCGGCAG
AAACTAGATGATCAGACCAAGAGCTTGTCCTTTTCCGAGCGGCTCAGTGAACTGGAGCAGCTGCGGCG
CACAGCCATGAGGGTCAGCCCACACCACCCAGCCCCCACGCCCAACCCTCGTGCCTCCCTGAACCACT
CCACTGCCTTTAACCCTCAGCCTCAGAGTCAGATGCAGGATACAAGGCAGATCCAACCATCCCCACCG
TGGTCCTACGATCAGTCCTACCAATACCTGGGATCCATTGCCTCTCCTTCTGTGCACCCAGCAACGCC
CATTTCACCTGGACGTGCCAGCGGCATGACAAGCCCGGCCCTCTCTGCAGAACTTTCCAGTCGACTCT
CAACGGCACCCGACCTGACAGCGTTCAGCGACC 
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5’…GGAAAAGCTTCACTCTGACCATCACTGTCTTCACAAACCCACCGCAAGTCGCCACCTACCACAGAGCC
ATCAAAATCACAGT 
GACATCGGCAGAAACTAGATGATCAGACCAAGAGCTTGTCCTTTTCCGAGCGGCTCAGTGAACTGGAGCAG
CTGCGGCGCACAGCCATGAGGGTCAGCCCACACCACCCAGCCCCCACGCCCAACCCTCGTGCCTCCCTGAA
CCACTCCACTGCCTTTAACCCTCAGCCTCAGAGTCAGATGCAGG 
CCGCGCCAGTTCCCCGCGCTGCCCTCCATCTCCGACCCCCGCATGCACTATCCAGGCGCCTTCACCTACTC
CCCGACGCCGGTCACCTCGGGCATCGGCATCGGCATGTCGGCCATGGGCTCGGCCACGCGCTACCACACCT
ACCTGCCGCCGCCCTACCCCGGCTCGTCGCAAGCGCAGGGAGGCCCGTTCCAAGCCAGCTCGCCCTCCTAC
CACCTGTACTACGGCGCCTCGGCCGGCTCCTACCAGTTCTCCATGGTGGGCGGCGAGCGCTCGCCGCCGCG
CATCCTGCCGCCCTGCACCAACGCCTCCACCGGCTCCGCGCTGCTCAACCCCAGCCTCCCGAACCAGAGCG
ACGTGGTGGAGGCCGAGGGCAGCCACAGCAACTCCCCCACCAACATGGCGCCCTCCGCGCGCCTGGAGGAG
GCCGTGTGGAGGCCCTACTGA…’3  
 
Figure 3.18. Sequence analysis of ΔRunx1 showing exons 5–8 
Sequence analysis of the top band amplified using primers Runx1-F + Runx1-R, 
showing exon 5, exon 6, exon 7 and exon 8. In red: forward and reverse primers. 
Sequence in box is the actual cDNA sequence generated from the ΔRunx1 PCR 
product.  
 
3.4.2.5. Apoptosis in K562 cells following treatment with SRPK1 inhibitors  
3.4.2.5.1 Apoptosis detection using acridine orange 
 
To establish whether SRPK1 inhibition induced apoptosis in K562 cells, acridine 
orange (AO) was used to distinguish cell survival from cell death (apoptosis or 
necrosis) according to cell morphological changes.  
 
Cells were treated with doses of SRPIN340 or SPHINX and compared to control 
cells treated with EGF (100 ng/mL) only, Figure 3.19. Viable cells (VC) with intact 
plasma membranes and rounded nuclei were present in untreated K562 cells when 
compared with the EGF control, Figure 3.19A. Apoptosis (Apo) was present in the 
EGF control and was represented by cell shrinkage, condensation of nuclear 
chromatin and membrane bound apoptotic bodies, Figure 3.19B. Additionally, 
GGATGGGCCCCGAGAACCTCGAA 
 
ATACAAGGCAGATCCAACCATCCCCACCGTGGTCCTACGATCAGTCCTACCAATACCTGGGATCCATT
GCCTCTCCTTCTGTGCACCCAGCAACGCCCATTTCACCTGGACGTGCCAGCGGCATGACAAGCCCGGC
CCTCTCTGCAGAACTTTCCAGTCGACTCTCAACGGCACCCGACCTGACAGCGTTCAGCGAC 
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apoptosis was noticed following exposure to 10 μM and 20 μM SRPIN340, Figures 
3.19C and D. Fragmentation of nuclear chromatin and apoptotic bodies were 
observed in cells treated with 5 μM and 30 μM SPHINX, Figures 3.20C and F. 
Necrosis (NC) denoted by ruptured cell membranes was observed in those cells 
treated with 10 μM and 20 μM SPHINX, Figures 3.20D and E. 
 
The total number of cells after treatment was not identified, however, at least 1000 
cells per treatment were quantified. The percentages of viable, apoptotic and necrotic 
cells were calculated and compared to the EGF control, Figure 3.21. It was observed 
that cells treated with 10 μM SRPIN340, for 24 hours, showed reduced apoptosis of 
15.3% (p = 0.68) and necrosis of 2% (p = 0.74) when compared with the EGF 
control (one-way ANOVA), Figure 3.21. Treatment with 20 μM SRPIN340 
increased apoptosis to 24.3% (p = 0.74) but decreased necrosis to 3.6% (p = 1.00) 
when compared to EGF controls (one-way ANOVA). Cell exposures to SPHINX 
doses (5–30 μM) for 24 hours showed that 5 μM and 30 μM induced apoptosis to 
22.3% (p = 0.95) and to 21.3% (p = 0.99) respectively when compared to the EGF 
control (one-way ANOVA). However, necrosis was reduced in cells treated with 5 
μM SPHINX to 1% (p = 0.50), whereas cells treated with 30 μM SPHINX, increased 
necrosis to 7.6% (p = 0.26) when compared with the EGF control (one-way 
ANOVA).     
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Figure 3.19. Apoptosis and necrosis in kinase inhibited K562 cells 
A. Untreated K562 cells were viable (viable cells: VC). B. Apoptosis was induced in 
the EGF control; arrows indicate apoptotic cells with condensed nuclear chromatin 
and bilobed or fragmented nuclei. C–D. Cells treated with 10 μM and 20 μM 
SRPIN340 increased apoptosis, which was characterised by condensed nuclear 
chromatin appearing as crescents on the nuclear membrane peripheries, chromatin 
fragmentation and cytoplasmic condensation. C. Arrows show apoptotic cells with 
fragmented nuclear chromatin and cytoplasmic condensation with cytoplasmic 
vacuole forming. D. Arrows show apoptotic cells with multi-lobed nuclei.  
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Figure 3.20.Apoptosis and necrosis in kinase inhibited K562 cells 
A. Untreated K562 cells were viable (viable cells: VC). B. Apoptosis was induced in 
the EGF control; arrows indicate apoptotic cells with condensed nuclear chromatin 
and bilobed or fragmented nuclei. C. and F. Treating K562 cells with 5 μM and 30 
μM SPHINX increased apoptosis; arrows indicate apoptotic cells with fragmented 
chromatin and condensed nuclei. D. and E. In contrast, cells treated with 10 μM and 
20 μM SPHINX induced necrosis with swelling and rupture of the plasma 
membrane, resulting in the relocation of cytoplasmic contents to the extracellular 
space. At least 1000 cells per treatment were quantified and assessed. 
 
Cells treated with 10 μM and 20 μM SPHINX revealed significant decreases in 
apoptosis of up to 3.6% (p = 0.00) and 3% (p = 0.00) when compared with the EGF 
control (one-way ANOVA). In contrast, cells treated with 10 μM and 20 μM 
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SPHINX showed significant increases in necrosis of up to 54.6% (p = 0.00) and 69% 
(p = 0.00) when compared with the EGF control (one-way ANOVA). 
 
Figure 3.21. Inhibitor treatment of K562 cells showing apoptosis and necrosis  
K562 cells were stained with acridine orange following treatments with SRPIN340 
(10 μM and 20 μM) or SPHINX (5–30 μM). At least 1,000 cells were assessed. The 
graph represents the percentage of viable cells (white), apoptotic cells (grey) and 
necrotic cells (dashed) per treatment. Treatment with 10 μM and 20 μM SPHINX 
significantly decreased apoptosis and increased necrosis when compared to the EGF 
control. The bars indicate standard error, **** P≤0.0001 (one-way ANOVA). The 
data represents three independent experiments (n = 3). 
 
3.4.2.5.2 Annexin V-FITC/Propidium Iodide apoptosis detection  
Annexin V-FITC/PI binding and flow cytometry was performed to investigate early 
apoptosis stages after treatment with SRPIN340 or SPHINX. In flow cytometric 
analysis, cells that were Annexin V-FITC positive and PI negative were apoptotic, 
while cells that were Annexin V-FITC and PI positive were necrotic, Figure 3.22. 
These results were compared with control cells treated with 100 ng/mL EGF (EGF 
control) only. Apoptosis within the EGF control population was 0.91% while 
necrosis was 3.4%, Figure 3.22A.  
 
Apoptotic cells comprised 0.61% under 10 μM SRPIN340 conditions and 0.56% 
under 20 μM SRPIN340 condition when compared to the EGF control, Figure 3.22B 
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and C. In contrast, necrotic cells were 4.4% under 10 μM SRPIN340 condition and 
5.9% under 20 μM SRPIN340 condition when compared to EGF control. Apoptotic 
cells treated with 5 μM SPHINX reached to to 0.79%, whereas necrotic cells to 5% 
in these cells, when compared to the EGF control, Figure 3.22D. Cells treated with 
10 μM, 20 μM and 30 μM SPHINX resulted in apoptosis of 0.68%, 0.51% and 
0.57% respectively, when compared to the EGF control, Figure 3.22E and G. 
However, for these conditions; 10 μM, 20 μM and 30 μM SPHINX, necrosis was 
similar to EGF control (3.0%, 3.7% and 3.2%, respectively). 
 
3.4.3. SRPK1 or SRSF1 knockdown in K562 cells 
3.4.3.1. Generating stable SRPK1 knockdown using shRNA in K562 cells  
 
To identify the effects of SRPK1 knockdown on CASPASE-9, RON or RUNX1 
splicing, the generation of a stable SRPK1 knockdown was required. To achieve this, 
K562 cells were transduced with lentivirus containing shRNA SRPK1 or scramble 
shRNA. The SMARTvector 2.0 lentiviral shRNA plasmid expressing a puromycin 
resistance cassette was used to select transduced cells. 
 
For successful transduction, the minimal puromycin concentration required to 
eliminate all untransduced cells within seven days, had to be determined, Figure 
3.23. Approximately 1 × 106 K562 cells were treated with increased doses (0.66–9 
μg/mL) of puromycin. Cells were examined daily. The number of cells in each 
treatment was calculated and compared with the original 1 × 106 cells. 
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Cells treated with 0.66 μg/mL puromycin reduced cell numbers to 6.5 × 105 
cells/well while 3 μg/mL puromycin reduced cell numbers to 1.8 × 104 cells/well. 
Subjecting cells to 5, 7 and 9 μg/mL puromycin reduced cell numbers to 1.5 × 104 
cells/well. Graphing this data (Figure 3.23) revealed that the 0.66 μg/mL 
concentration had the minimal visual toxicity, whereas 3 μg/mL had the strongest 
toxicological effect. Therefore, it was proposed that 1.5 μg/mL puromycin would be 
the minimal antibiotic concentration to kill all untransduced cells. 
 
Figure 3.24 shows SRPK1 and SRSF1 stable knockdown of SRPK1. K562 cells 
were transduced with lentivirus targeting SRPK1 or scrambled shRNA (sh-CTRL); 
1.5 μg/mL puromycin was added for seven days and protein extracted for Western 
blotting. Normalisation of SRPK1 and SRSF1 was carried out using the loading 
control, α-tubulin (75 μg of whole cell lysates).  
 
Figure 3.24A shows SRPK1 expression in stable SRPK1 knockdown cells similar to 
the sh-CTRL cells. The expression of SRPK1 in cells expressing stable SRPK1-KD 
was 0.09 (p = 0.94, one-way ANOVA), Figure 3.24B. In contrast, there was a 
reduction in SRSF1 expression in stable SRPK1-KD cells when compared with sh-
CTRL cells, Figure 3.24C. The expression of normalised SRSF1 was 0.87 (p = 0.08) 
in stabilised SRPK1-KD (one-way ANOVA), Figure 3.24D.  
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Figure 3.22. Apoptosis and necrosis in treated cells using Annexin V-FITC and 
Flow Cytometry 
Scatterplots of cell death (apoptosis; Annexin V-FITC and necrosis; Annexin V-
FITC with propidium iodide) in K562 cells treated with SRPIN340 (10 μM and 20 
μM) and SPHINX (5 – 30 μM). A. Control K562 cells treated with 100 ng/mL EGF 
only (EGF control). B–C. Cells treated with 10 and 20 μM SRPIN340. D–G. Cells 
treated with 5 – 30 μM. SPHINX. One representative experiment of three is shown. 
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Figure 3.23. The optimal concentration of puromycin to kill untransduced K562 
cells  
K562 cells (1 × 106 cells/well) were treated with different puromycin concentrations 
(0.66 – 9 μg/mL) and incubated for seven days. Following this, cell numbers 
decreased slowly for the 0.66 μg/mL treatment, whereas treatment with 3 μg/mL 
puromycin dramatically decreased cell numbers when compared to the starting 1 × 
106 cells. The results are displayed as mean ± SEM (n = 3).   
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Figure 3.24. The stable knockdown of SRPK1 in K562 cells 
A. SRPK1 expression in K562 cells treated with sh-scramble (sh-CTRL) or sh-
SRPK1 followed by Western blot analysis using antibodies against SRPK1 and α-
tubulin (loading control). SRPK1 was 92 kDa and α-tubulin 55 kDa. B. The 
quantification from replicates with normalisation to α-tubulin (equal loading). C. 
SRSF1 Western blot showing a 28 kDa protein product. D. Quantification from 
replication with normalisation to α-tubulin (equal loading). The transduction of K562 
cells with sh-SRPK1 slightly increased SRPK1 expression, whereas it decreased 
SRSF1 expression. The bars indicate standard error (one-way ANOVA). The data 
represent three independent experiments (n = 3). 
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3.4.3.2. The effect of siRNA SRPK1 and SRSF1 knockdown on alternative splicing 
in K562 cells 
 
Alterations in CASPASE-9, RON or RUNX1 splice patterns through SRPK1 or 
SRSF1 knockdown in K562 cells was assessed. The expression of SRPK1 and 
SRSF1 was demonstrated using control siRNA (si-CTRL), SRPK1 SMARTpool 
siGENOME siRNA (si-SRPK1) or SRSF1 SMARTpool siGENOME siRNA (si-
SRSF1) in K562 cells, Figures 3.25 and 3.27.  
 
K562 cells were transfected with si-CTRL (75 nM), si-SRPK1 (75 nM) or si-SRSF1 
(75 nM) for 48 and 72 hours. Following transfection, Western blotting was carried 
out, and normalisation of SRPK1 and SRSF1 to α-tubulin (equal loading) was 
performed (75 μg whole cell lysates). Figures 3.25A and B show SPRK1 expression 
in cells transfected with si-CTRL (75 nM), si-SRPK1 (75 nM) or si-SRSF1 (75 nM) 
for 48 hours. There was no difference in SPRK1 expression between si-SRPK1 cells 
and si-CTRL cells or si-SRSF1 cells and si-CTRL cells, Figure 3.25A. The 
expression ratio of normalised SRPK1 following si-SRPK1 was 0.64 (p = 0.97) and 
following si-SRSF1 was 0.70 (p = 0.99, one-way ANOVA), Figure 3.25B.  
 
Furthermore, there was a slight decrease in SPRK1 expression following transfection 
with si-CTRL (75 nM) or si-SRPK1 (75 nM) after 72 hours, Figure 3.25C. In 
addition, the SPRK1 expression was observed following transfection with si-SRSF1 
(75 nM) after 72 hours. The expression ratio of normalised SRPK1 following si-
SRPK1 was 3.39 (p = 0.43) compared with si-CTRL cells. Additionally, cells 
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transfected with si-SRSF1 was normalised SRPK1 to 3.11 (p = 0.31), one-way 
ANOVA. 
 
To establish whether higher SRPK1 expression was observed in K562 cells when 
compared to the prostate cancer cell line (PC-3), PC-3 cells were transfected with si-
CTRL (75 nM) or si-SRPK1 (75 nM) for 72 hours. It was observed that SPRK1 
expression was reduced in these cells when compared with the si-CTRL control, 
Figure 3.26A. Similarly, there was a significant reduction in the protein expression 
ratio of normalised SRPK1 to 0.34 (p = 0.01) when compared to si-CTRL cells (one-
way ANOVA), Figure 3.26B. 
 
SRSF1 expression levels, following si-SRPK1 or si-SRSF1 treatment for 48 hours, 
was observed and compared to si-CTRL cells, Figure 3.27A. The normalised 
expression ratio of SRSF1 was 1.07 (p = 0.96, one-way ANOVA), Figure 3.27B. At 
72 hours post-transfection, there was a decrease in SRSF1 levels in si-SRPK1 cells, 
and a greater reduction of SRSF1 in si-SRSF1 cells when compared to si-CTRL 
cells, Figure 3.27C. The protein expression of normalised SRSF1 was 1.14 (p = 
0.99) when compared to si-CTRL cells (one-way ANOVA), Figure 3.27D. Down-
regulation of SRSF1 at 72 hours’ incubation detects a significant reduction in the 
normalised protein of SRSF1 to 0.42 (p = 0.001) compared with the si-CTRL cells 
(one-way ANOVA), Figure 3.27D. 
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Figure 3.25. siRNA knockdown of SRPK1 and SRSF1 in K562 cells 
K562 cells were transfected with si-CTRL (75 nM), si-SRPK1 (75 nM) or si-SRSF1 
(75 nM) for 48 and 72 hours’ incubation. A. SPRK1 expression in transfected cells 
after 48 hours’ incubation. B. Expression quantification from three replicates 
normalised to α-tubulin. C. SPRK1 expression in transfected cells after 72 hours. D. 
The normalisation of SRPK1 to α-tubulin. The bars indicate standard error (one-way 
ANOVA). The data represent three independent experiments (n = 3). 
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Figure 3.26. siRNA knockdown of SRPK1 in PC-3 cells 
PC-3 cells were transfected with si-CTRL (75 nM) or si-SRPK1 (75 nM) for 72 
hours. A. SRPK1 expression in transfected PC-3 cells after 72 hours. B. 
Quantification ratio of three repeats with normalisation to α-tubulin. SRPK1 levels 
significantly decreased in si-SRPK1 transfected PC-3 cells (75 nM) for 72 hours. 
The bars indicate standard error, ** P≤0.01 (one-way ANOVA). The data represents 
three independent experiments (n = 3). 
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Figure 3.27. siRNA knockdown of SRPK1 and SRSF1 in K562 cells 
K562 cells were transfected with si-CTRL (75 nM), si-SRPK1 (75 nM) or si-SRSF1 
(75 nM) for 48 and 72 hours. A. SRSF1 from transfected cells at 48 hours. B. 
Expression quantification from three replicates normalised to α-tubulin. C. SRSF1 
expression in transfected cells at 72 hours. D. The normalisation of SRPK1 to α-
tubulin. SRSF1 was significantly decreased in transfected cells after si-SRSF1 (75 
nM) treatment for 72 hours. The bars indicate standard error (one-way ANOVA). 
The data represent three independent experiments (n = 3).  
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3.4.3.3. siRNA SRSF1 knockdown and its effect on alternative splicing in K562 
cells 
SRSF1 knockdown demonstrated how CASPASE-9, RON and RUNX1 alternative 
splicing in K562 cells was affected. Cells were transfected with si-CTRL (75 nM) or 
si-SRSF1 (75 nM) for 72 hours. For each gene, the expression ratio of splice variants 
in si-SRSF1 cells was compared to si-CTRL cells and quantified by densitometric 
analysis using ImageJ software.  
 
3.4.3.3.1 CASPASE-9 splicing in K562 cells following SRSF1 knockdown 
 
K562 cells transfected with siRNA SRSF1 increased the pro-apoptotic splicing 
isoform caspase-9a, Figure 3.28B. The effect of si-SRSF1 on CASPASE-9 mRNA 
was quantified (Figure 3.28C), showing a slight down- regulation in the expression 
ratio of caspase-9a/9b to 2.11 (p = 0.001) when compared with si-CTRL cells (0.64), 
one-way ANOVA. This significant effect is not specific when si-SRSF1 cells are 
compared to untreated K562 cells, Figure 3.28B.  
 
3.4.3.3.1 RON splicing in K562 cells following SRSF1 knockdown 
The effect of siRNA-SRSF1 on RON alternative splicing was examined, Figure 
3.29B. Knockdown of SRSF1 resulted in the expression ratio of 0.76 (p = 0.17) for 
Ron/ΔRon when compared to si-CTRL cells (0.40, one-way ANOVA), Figure 
3.29C.  
 
3.4.3.3.1 RUNX1 splicing in K562 cells following SRSF1 knockdown 
A down-regulation of expression was noted for Runx1 and ΔRunx1 variants after 
transfection with si-SRSF1, when compared to si-CTRL cells, Figure 3.30B. The 
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expression ratio of Runx1/ΔRunx1 in si-SRSF1 cells was 4.71 (p = 0.50), when 
compared to si-CTRL cells (3.35, one-way ANOVA), Figure 3.30C.  
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Figure 3.28. siRNA SRSF1 knockdown effects on CASPASE-9 alternative 
splicing  
A. CASPASE-9 showing the two splice variants resulting from inclusion or exclusion 
of exons 3-6 (caspase-9a and caspase-9b, respectively). Arrows indicate the positions 
of forward and reverse CASPASE-9 primers. B. K562 cells transfected with si-CTRL 
(75 nM), si-SRPK1 (75nM) or si-SRSF1 (75 nM) for 72 hours followed by caspase-
9a and caspase-9b RT-PCR.  RT-PCR bands at 742 bp (casp-9a) and 292 bp (casp-
9b) were detected. GAPDH was used as a loading control (212 bp). Each rung of the 
hyperLadder II represents 100 bp. Caspase-9a isoform increased in si-SRSF1 cells 
when compared to si-CTRL cells. This increase is not specific when si-SRSF1 cells 
compared to untreated K562 cells. C. Densitometric analysis of caspase-9a/9b 
isoforms. K562 cells transfected with si-SRSF1 (75 nM) were compared to si-CTRL 
(75 nM) cells. The graph represents the intensity ratio of caspase-9a against caspase-
9b. The expression ratio of caspase-9a/9b increased in cells transfected with si-
SRSF1 (75 nM) after 72 hours. The bars indicate standard error, *** P≤0.001 (one-
way ANOVA). The data represent three independent experiments (n = 3).  
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Figure 3.29. siRNA SRSF1 knockdown effects on RON alternative splicing  
A. The RON gene showing the two splice variants resulting from including or 
excluding exon 11 (Ron and ΔRon variants, respectively). Arrows indicate the 
positions of forward and reverse Ron primers. B. The RT-PCR gel of K562 cells 
transfected with si-CTRL (75 nM) or si-SRSF1 (75 nM) at 72 hours; 484 bp (Ron) 
and 337 bp (ΔRon). GAPDH was used as a loading control (212 bp). Each rung of 
the hyperLadder II represents 100 bp. C. Densitometric analysis of Ron/ΔRon 
isoforms. K562 cells transfected with si-SRSF1 (75 nM) were compared with si-
CTRL (75 nM). The graph represents the intensity ratio of Ron against ΔRon. The 
bars indicate standard error (one-way ANOVA). The data represent three 
independent experiments (n = 3).  
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Figure 3.30. siRNA SRSF1 knockdown effects on RUNX1 alternative splicing 
A. RUNX1 showing the two splice variants resulting from including or excluding 
exon 6 (Runx1 and ΔRunx1 variants, respectively). Arrows indicate the positions of 
forward and reverse Runx1 primers. B. RT-PCR gel of K562 cells transfected with 
si-CTRL (75 nM), si-SRPK1 (75nM) or si-SRSF1 (75 nM) at 72 hours; 482 bp 
(Runx1) and 290 bp (ΔRunx1). GAPDH was used as a loading control (212 bp). 
Each rung of the hyperLadder II represents 100 bp. C. Densitometric analysis of 
Runx1/ΔRunx1 isoforms. K562 cells transfected with si-SRPK1 (75nM) or si-
SRSF1 (75 nM) were compared to si-CTRL (75 nM). The graph represents the 
intensity ratio of Runx1 against ΔRunx1. The bars indicate standard error (one-way 
ANOVA). The data represent three independent experiments (n = 3). 
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3.5 Discussion 
In cancer, SRSF1 dysregulation due to SRPK1 overexpression, affects pre-mRNA 
alternative splicing, affects gene expression, increases proliferation, invasiveness and 
inhibition of apoptosis. Therefore targeting SRPK1 using the small molecule 
inhibitors SRPIN340 or SPHINX is considered a potential therapy against 
malignancies (Siqueira et al., 2015). 
 
A previous study found that SRPIN340 suppressed viral replication, such as the 
Sindbis virus, HIV and cytomegalovirus, suggesting that SRPIN340 is an antiviral 
agent (Karakama et al., 2010). Therefore, it was important to evaluate SRPK1 
inhibitors on cancer cell proliferation. A recent study has shown that cell viability 
was reduced in myeloid and lymphoid leukaemia by SRPIN340 treatment (Siqueira 
et al., 2015). However, in this study, K562 proliferation was increased following 
SRPIN340 or SPHINX treatment, suggesting that SRPK1 small molecule inhibitors 
did not affect K562 cell survival.  
 
SPRK1 overexpression has been reported in several solid tumours, such as colon, 
breast carcinoma and other types of malignancy (Mavrou et al., 2015). It has been 
shown that SRPIN340 switched splicing from VEGF165 to VEGF165b in human 
podocytes, resulting in reduced angiogenesis in a mouse model of retinal 
neovascularisation (Nowak et al., 2010). A recent study indicated that SPHINX 
effected VEGF splicing and inhibited tumour growth in a mouse model of orthotopic 
prostate cancer in PC-3 cells (Mavrou et al., 2015).  
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Studies from several laboratories have investigated the effects of protein kinase 
inhibition on genes associated with human cancer, as potential targets for therapy. 
One trial identified that phosphatidylinositol 3-kinase (Akt) inhibition, increased 
caspase-9a/9b splice isoform ratios in non-small cell lung cancers (Shulz et al., 
2011). Another trial suggested that thiol-mediated intermolecular disulphide bonding 
inhibition, resulted in the down-regulation of ΔRon isoforms in human gastric cancer 
cells (KATO-III) (Collesi et al., 1996). Additionally, treatment with the proteasome 
inhibitor MG13, was shown to reduce ΔRunx1 splice isoforms in human embryonic 
kidney cells (293T) (Komeno et al., 2014). A recent study it has shown that a novel 
“compound 30” reduced the activity of SRPK through phosphorylation inhibition of 
SR proteins. It was also found that compound 30 can inhibited the expression of 
MAP2K1, MAP2K2, VEGF and RON oncogenic isoforms (Siqueira et al., 2017).   
 
To expand on these findings and investigate the effects of protein kinase inhibitors 
on alternative splicing, this study investigated the splicing patterns of CASPASE-9, 
RON and RUNX1 in K562 cells where SRPK1 was inhibited. No specific effects 
were observed on the CASPASE-9 splice isoform, upon treatment with SRPIN340 
and SRPIN349 when compared to DMSO control. Additionally, there were no shifts 
in CASPASE-9 splicing in K562 cells treated with SRPIN340 or SPHINX, upon EGF 
induction of cell signalling.  
 
From cell morphological characteristics, a reduction in apoptosis was observed in the 
SRPIN340 or SPHINX treatment of K562 cells. Similarly, Annexin V-FITC staining 
revealed that SRPK1 inhibition reduced apoptosis in K562 cells. These data were in 
agreement with SRPIN340 reduced effectiveness on myeloid cells as opposed to 
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lymphoid leukaemia cell lines due to high expression of SRPK1 in myeloid 
leukaemia (Siqueira et al., 2015). However, a recent study demonstrated the effect of 
1-(3,4,5-trihydroxyphenyl)-dodecylbenzoate on apoptosis using both acridine orange 
and Annexin V staining (Maioral et al., 2016). Although the exact mechanism of 
action is not clear, p53 and AIF expression were increased in K562 cells treated with 
this compound. It was also observed that 1-(3,4,5-trihydroxyphenyl)-
dodecylbenzoate increased expression of pro-apoptotic Bax in Jurkat cells. These 
data suggest that 1-(3,4,5-trihydroxyphenyl)-dodecylbenzoate triggers apoptosis in 
K562 and Jurkat cells, thus reinforcing the compound as an anti-proliferative and 
cytotoxic inhibitor (Maioral et al., 2016). It was also observed that Jurkat cells are 
more sensitive to SRPIN340 treatment than K562 cells, due to the higher SRPK1 
levels in K562 cells, suggesting that SRPIN340 triggers apoptosis in these cells 
(Siqueira et al., 2015). 
 
The expression of the Ron isoform was significantly increased in K562 cells when 
treated with high concentrations of SRPIN340, when compared to DMSO control. 
This significant effect, however, is not specific when the expression of Ron in K562 
cells treated with SRPIN340 is compared to cells treated with SRPIN349. In 
addition, no shift in RON splicing was observed in K562 cells, during SRPK1 
inhibition (SRPIN340 or SPHINX followed by EGF addition). Furthermore, there 
was no switch in RUNX1 expression towards the Runx1 splice isoform in SRPIN340 
treated K562 cells. In contrast, there was a non-significant increase in Runx1 splice 
isoform expression in SPHINX treated K562 cells.  
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Overall, no switch in CASPASE-9, RON or RUNX1 splicing was observed in cells 
treated with SRPIN340 or SPHINX. This suggests that selective SRPK1 inhibitors 
could act differentially on CASPASE-9, RON or RUNX1 splicing in K562 cells. 
These weak effects on alternative splicing in SPRK1 inhibited K562 cells, could 
predict activation of other key protein kinases or reflect high SRPK1 levels in K562 
cells.  
 
SRPK1 inhibition did not induce apoptosis, nor generate strong effects on 
CASPASE-9, RON or RUNX1 splicing in K562 cells, therefore a SRPK1-knockdown 
(KD) was investigated to see if it would induce a splicing switch in K562 cells. 
Recently, a computational strategy was adopted to transduce cells with shRNAs 
generating stable knockdowns of specific genes. It was observed that generating 
SRPK1 stable knockdowns, switched the splicing of VEGF towards the VEGF165b 
isoform in PC-3 cells, resulting in decreased tumour growth in orthotopic prostate 
cancer mouse models (Mavrou et al., 2015). It has been also found that chimeric 
antibody target SRPK1 (ChanSRPK1) affects on the level of SRPK1 in lung cancer 
(Wu et al., 2017). However, in this study, generating stable SRPK1-KDs did not 
reduce SRPK1, whereas SRSF1 was reduced in K562 cells, confirming an increase 
of SRPK1 in K562 cells.    
 
Another computational study reported that VEGF alternative splicing was generated 
by the transfection of SRSF1-KD into podocytes (Amin et al., 2011). A reduction in 
MNK2b isoform expression was also observed in cells transfected with si-SRSF1 
(Karni et al., 2007). Based on these observations, this study investigated whether 
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SRPK1-KD or SRSF1-KD would affect CASPASE-9, RON and RUNX1 alternative 
splicing in K562 cells.  
 
SRPK1 was not significantly decreased in K562 cells transfected with si-SRPK1 or 
si-SRSF1 when compared to si-CTRL cells. Despite this, SRPK1 levels were 
strongly down-regulated in si-SRPK1 transfected PC-3 cells, when compared to si-
CTRL cells. This suggests that SRPK1 levels are higher in K562 cells when 
compared to PC-3 cells. SRSF1 levels were significantly reduced in si-SRSF1 
treated K562 cells after 72 hours.  
 
At the mRNA level, there was no clear switch in caspase-9b expression towards the 
pro-apoptotic splice isoform, caspase-9a, ΔRon towards Ron or in ΔRunx1 
expression towards Runx1 in si-SRSF1 treated K562 cells. These data suggest that 
SRPK1 and SRSF1 are not the regulators the splicing isoforms of these genes.  
 
Taken together, SRPK1 inhibitor treatments appear to react differentially towards the 
caspase-9, Ron and Runx1 isoforms in K562 cells, suggesting SRPK1 is not the 
main regulator of CASPASE-9, RON or RUNX1 splicing in these cells. The inhibition 
of SRPK1 may trigger activation of other key protein kinases in these cells. 
Furthermore, there was no significant reduction of SRPK1 protein in transduced or 
transfected K562 cells, unlike PC-3 cells, confirming SRPK1 levels are higher in 
K562 cells. Finally, there was no significant effect on CASPASE-9 or RUNX1 
splicing in SRSF1-KD treated K562 cells, whereas SRSF1-KD caused a shift in 
RON splicing towards the Ron isoform, suggesting SRPK1 is not the main regulatory 
kinase in CASPASE-9 or RUNX1 splicing in K562 cells.    
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3.5.1. Conclusion and future directions 
This study proposes that SRPK1 inhibition by small molecule inhibitors or 
shRNA/siRNA knockdown is more effective on splicing in PC-3 cells, but not K562 
cells. This suggests one of two scenarios; either SRPK1 levels are higher in some 
malignancies or it is more resistant in K562 cells.  
 
This study proposes the following research strategies to delineate the precise roles of 
these regulatory kinases in disease;  
 
1. The evaluation of SRPK1 protein and mRNA levels in other cancer cell lines 
could provide comparative insights into the action of SRPK1 in K562 cells.  
2. Future studies on novel SRPK1 inhibitor development could focus on 
haematological malignancies.  
3. The investigation of the main regulatory protein kinase and its splice factors 
in K562 cells could provide further insights into therapies with apoptotic 
activity against leukaemic cells.  
4. Additional studies could address the action of the negative control inhibitor 
(SRPIN349) on SRPK1 in K562 cells.  
5. Finally, the generation of stable SRSF1 knockdowns using shRNA 
technology and lentiviral plasmids could bring about new options in the 
development of effective drugs for leukaemia. 
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CHAPTER 4. TARGETING THE SPLICE FACTOR KINASE CLK1 
IN A CHRONIC MYELOID LEUKAEMIA CELL LINE 
4.1 Introduction 
SRSF1 is phosphorylated by SRPK1 and causes nuclear import of SRSF1 into 
nuclear speckles. Additional phosphorylation, mediated by Cdc2-like kinase 1 
(Clk1), induces SRSF1 release from nuclear speckles to regulate pre-mRNA 
splicing. The discovery of SRPK1 and Clk1 as critical mediators in SRSF1 
phosphorylation allowed us to speculate that suppression of these kinases could 
generate effects on alternative splicing in some malignancies. Clk1 is a dual 
specificity protein kinase that phosphorylates serine/threonine and tyrosine residues, 
therefore, Clk1 has an important role in disturbing phosphorylated SRSF1 at splice 
sites (Ghosh and Adams, 2011).  
 
Increased evidence links Clk1 overexpression to kidney cancer (Dominguez et al., 
2016). Other studies have suggested that blocking endogenous Clk1 activity by the 
selective Clk1 inhibitor (TG003) or shRNA knockdown, suppresses the proliferation 
of HeLa cells (Dominguez et al., 2016).  
 
As both SRPK1 and Clk1 phosphorylate SRSF1, we strategised that splicing could 
be altered following suppression of Clk1 in K562 cells. This approach could prove 
useful as a therapeutic option for leukaemic patients. 
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4.2 Hypothesis  
The inhibition of Clk1 pharmacologically or through siRNA could affect CASPASE-
9, RON and RUNX1 alternative splicing in K562 cells.   
 
4.3 Objectives 
 To assess proliferation of K562 cells treated with small molecule inhibitors 
of Clk1 (Chapter 2: Materials and methods (Table 2.5)), prior to epidermal 
growth factor (EGF) addition.  
 To detect the effects of inhibiting Clk1 on CASPASE-9, RON and RUNX1 
alternative splicing in K562 cells followed by EGF or dimethyl sulfoxide 
(DMSO) treatment (Chapter 2: Materials and methods, section 2.7.1). 
 To investigate the effects of inhibiting Clk1 on cell survival and cell death 
(apoptosis and necrosis) in K562 cells by acridine orange staining followed 
by EGF treatment. 
 To assess the cellular responses to the Clk1 inhibitor (TG003) using an 
Annexin V/PI assay followed by EGF treatment. 
 To introduce small interfering RNAs (siRNA) into K562 cells, targeting Clk1 
and to confirm knockdown of Clk1 expression.  
 To detect the effects of Clk1 siRNA mediated knockdown on CASPASE-9, 
RON and RUNX1 alternative splicing in K562 cells.   
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4.4 Results 
4.4.1. Clk1 expression in K562 cells 
Clk1 mRNA and protein expression was assessed in K562 cells using RT-PCR and 
Western blotting.
  
Figure 4.1A shows Clk1 mRNA from K562 cells, whereas Figure 4.1B shows Clk1 
protein expression in K562 cells.   
 
  
Figure 4.1. Clk1 expression in K562 cells 
A. RT-PCR of Clk1 mRNA expression (117 bp) and GAPDH (212 bp). B. Western 
blot showing the expression of Clk1 and α-tubulin. Clk1 is expressed at 57 kDa and 
α-tubulin at 55 kDa.   
 
4.4.2. The effects of small molecule inhibitors on Clk1 in K562 cells  
4.4.2.1. The proliferation of K562 cells following Clk1 inhibition 
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To investigate the effects of Clk1 inhibition on K562 proliferation, 1 × 106 cells were 
subjected to TG003 treatment at concentrations of 50, 100 and 150 μM. Equal 
concentration of EGF (100 ng/mL) was added to all wells. After 24 hours, cells were 
stained with trypan blue and counted using a haemocytometer. The number of cells 
was compared with the original 1 × 106 cells and results represented as mean ± SEM 
(n = 3). 
In those cells treated with EGF alone (100 ng/mL), cell proliferation was 1.54 × 106. 
K562 cells were treated with 50 μM TG003 was 1.09 × 106 (p = 1.00) when 
compared to the 1 × 106 cells originally plated (one-way ANOVA), Figure 4.2. Cells 
treated with 100 μM TG003 yielded 7.35 × 105 (p = 0.973), whereas cell 
proliferation was 5.05 × 105 (p = 0.728) in cells treated with 150 μM TG003, when 
compared to the 1 × 106 cells originally plated (one-way ANOVA). Therefore, it was 
decided to use 150 μM TG003 concentration to analyse alternative splicing effects in 
K562 cells.  
 
 
 
 
 
 
 
 
 
Figure 4.2. K562 cell numbers after TG003 treatment (24 hours)  
Quantitative analysis of K562 cells treated with 100 ng/mL EGF (0 μM) only and a 
range of TG003 concentrations (50 to 150 μM) followed by 100 ng/mL EGF. Cells 
were counted after 24 hours and compared to a 1× 106 cell control. The bars indicate 
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standard error (one-way ANOVA). The data represent three independent 
experiments (n = 3).  
 
4.4.2.2. CASPASE-9 splicing in K562 cells following Clk1 inhibition 
 
The effects of Clk1 inhibition on CASPASE-9 alternative splicing was examined in 
K562 cells and compared to cells treated with 0.02% DMSO only (DMSO control) 
or 100 ng/mL EGF (EGF control). The expression ratio of caspase-9a/9b was 
quantified by densitometric analysis using ImageJ software.  
 
A shift in splicing towards caspase-9a was observed in cells treated with 150 μM 
TG003 or the negative control inhibitor TG009, when compared to DMSO control, 
Figure 4.3B. The expression ratio of caspase-9a/9b in DMSO control was 0.63 while 
cells treated with 150 μM TG003 was 1.21 (p = 0.00). Additionally, the expression 
ratio of caspase-9a/9b in cells treated with 150 μM TG009 was 1.25 (p = 0.00) when 
compared to DMSO control (one-way ANOVA), Figure 4.3C. The significant effect 
in the expression ratio of caspase-9a/b in cells treated 150 μM TG003 is not specific 
due to the effect is not significant when it’s compared to the negatice control 
inhibitor TG009 (p = 0.98, one-way ANOVA).  
 
Additionally, CASPASE-9 alternative splicing was analysed in K562 cells treated 
with different concentrations of TG003 (50, 100 and 150 μM) followed by EGF 
treatment (100 ng/mL). Treatment of cells with TG003 was compared to cells treated 
with 100 ng/mL EGF only (control). Figure 4.4B shows the expressions of caspase-9 
were reduced in cells treated with higher concentration of TG003 (100 and 150 μM 
TG003). Figure 4.4C shows the expression ratio of caspase-9a/9b in EGF control 
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was 1.40 while in cells treated with 50 μM TG003, it was 2.03 (p = 0.13, one-way 
ANOVA). Interestingly, cells treated with 100 μM TG003 significantly increased the 
expression ratio of caspase-9a/9b to 2.44 (p = 0.01) when compared to the EGF 
control (one-way ANOVA). The expression ratio of caspase-9a/9b was 1.90 (p = 
0.29) in cells treated with 150 μM TG003 (one-way ANOVA). Caspase-9a and 
caspase-9b cDNA amplicons were analysed in Chapter 3 (Section 3.4.2.2.1).   
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Figure 4.3. Clk1 inhibition on CASPASE-9 alternative splicing 
A. CASPASE-9 showing the two splice variants resulting from inclusion or exclusion 
of exons 3–6 (caspase-9a and caspase-9b, respectively). Arrows indicate the 
positions of forward and reverse caspase-9 primers. B. K562 cells were treated with 
0.02% DMSO (DMSO control) and 150 μM TG003/9 followed by 0.02% DMSO. 
After 24 hours incubation, RT-PCR was performed and bands at 742 bp (casp-9a) 
and 292 bp (casp-9b) were detected. Intermediate bands at ~ 500 bp represent 
skipped exons. GAPDH was used as a loading control (212 bp). Each rung of the 
hyperLadder II represents 100 bp. C. Densitometric analysis of caspase-9a/9b 
isoforms representing the intensity ratio of caspase-9 against caspase-9b. K562 cells 
treated with TG003 or TG009 were compared with DMSO control. The ratio of 
caspase-9a/9b significantly increased for 150 μM TG003 and TG009 treatments 
when compared to DMSO control. However, this significant effect is not specific 
when cells treated with 150 μM TG003 compared to cells treated with negative 
control inhibitor (150 μM TG009). The bars indicate standard error, ** P≤0.01 (one-
way ANOVA). The data represent three independent experiments (n = 3).  
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Figure 4.4. Clk1 inhibition on CASPASE-9 alternative splicing 
A. CASPASE-9 showing the two splice variants resulting from inclusion or exclusion 
of exons 3–6 (caspase-9a and caspase-9b, respectively). Arrows indicate the 
positions of forward and reverse caspase-9 primers. B. K562 cells were treated with 
only 100 ng/mL EGF (0 μM TG003) and three concentrations of TG003 were used 
at 50, 100 and 150 μM followed by 100 ng/mL EGF. RT-PCR was performed after 
24 hours incubation and bands 742 bp (casp-9a) and 292 bp (casp-9b) were detected 
and GAPDH was used as a loading control. Each rung of the hyperLadder II 
represents 100 bp. C. Densitometric analysis of caspase-9a/9b isoforms. K562 cells 
treated with TG003 were compared with the EGF control. The graph represents the 
intensity ratio of caspase-9a against caspase-9b, where the ratio of caspase-9a/9b was 
significantly increased in the 100 μM TG003 treatment. The bars indicate standard 
error, ** P≤0.01 (one-way ANOVA). The data represent three independent 
experiments (n = 3).  
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4.4.2.3. RON splicing in K562 cells following Clk1 inhibition  
 
TG003 effects on RON splice isoforms was observed by RT-PCR and the 
quantification of Ron/ΔRon expression ratios using ImageJ software. There was a 
switch in RON expression towards the Ron splice isoform in cells treated with 150 
μM TG003 when compared to EGF control, Figure 4.5B. 
 
Both Ron and ΔRon isoforms were reduced in cells treated with 150 μM TG003 or 
TG009, Figure 4.5B. The expression ratio of Ron/ΔRon was 1.05 in cells treated 
with only 0.02% DMSO alone (DMSO control), Figure 4.5C.  There was a 
significant increased in cells treated with 150 μM TG003; 2.58 (p = 0.00) when 
compared to DMSO control, Figure 4.5C. However, this significant effect is not 
specific when compared to cells treated with the negative control inhibitor (TG009) 
(p = 0.07, one-way ANOVA).  A significant increase of 1.97 (p = 0.00) was also 
observed in cells treated with 150 μM TG009, Figure 4.5C.   
 
Ron splice variants were reduced in cells treated with higher concentration of TG003 
(150 μM) when compared to EGF control, Figure 4.6B. The expression ratio of 
Ron/ΔRon was 0.74 in cells treated with only 100 ng/mL EGF (EGF control) while 
in cells treated with 50 μM TG003 was 1.54 (p = 0.17, one-way ANOVA), Figure 
4.6C. The expression ratio of Ron/ΔRon in cells treated with 100 μM TG003 was 
1.11 (p = 0.77, one-way ANOVA), Figure 4.6C. However, these results were not 
statistically significant. There was a significantly increase in the expression ratio of 
Ron/ΔRon to 1.96 (p = 0.02) after treatment with 150 μM TG003 when compared to 
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EGF control (one-way ANOVA), Figure 4.6C. Sequences of Ron and ΔRon cDNA 
amplicons were analysed in Chapter 3 (Section 3.4.2.3.1). 
 
 
 
 
 
 
 
 
 
Figure 4.5. Clk1 inhibition on RON alternative splicing 
A. The RON gene showing the two splice variants resulting from the inclusion or 
exclusion of exon 11 (Ron and ΔRon variants, respectively). Arrows indicate the 
positions of forward and reverse Ron primers. B. K562 cells were treated with 
0.02% DMSO (DMSO control) and 150 μM TG003/9 followed by (0.02%) DMSO 
for 24 hours. RT-PCR was performed and bands at 484 bp (Ron) and 337 bp (ΔRon) 
were detected. GAPDH was used as a loading control (212 bp). Each rung of the 
hyperLadder II represents 100 bp. C. Densitometric analysis of Ron/ΔRon isoforms. 
K562 cells treated with TG003 or TG009 were compared to DMSO control. The 
ratio of Ron/ΔRon significantly increased in 150 μM TG003 and 150 μM TG009 
treatments. However, the significant increased in the expression ratio of Ron/ΔRon 
in cells treated with 150 μM is not specific when compared to 150 μM TG009. The 
bars indicate standard error, ** P≤0.01, **** P≤0.0001 (one-way ANOVA). The 
data represent three independent experiments (n = 3).  
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Figure 4.6. Clk1 inhibition on RON alternative splicing 
A. The RON gene showing the two splice variants resulting from including or 
excluding exon 11 (Ron and ΔRon variants, respectively). Arrows indicate the 
positions of forward and reverse Ron primers. B. K562 cells were treated with only 
100 ng/mL EGF (0 μM TG003) and different concentrations of TG003 were used at 
50, 100 and 150 μM followed by 100 ng/mL EGF. After 24 hours incubation, RT-
PCR was performed and bands at 484 bp (Ron) and 337 bp (ΔRon) were detected. 
GAPDH was used as a loading control (212 bp). Each rung of the hyperLadder II 
represents 100 bp. C. Densitometric analysis of Ron/ΔRon isoforms. K562 cells 
treated with TG003 were compared with EGF control. The ratio of Ron/ΔRon 
significantly increased in cells treated with 150 μM TG003. The bars indicate 
standard error, * P≤0.05 (one-way ANOVA). The data represent three independent 
experiments (n = 3).  
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4.4.2.4. RUNX1 splicing in K562 cells following Clk1 inhibition 
 
To assess whether Clk1 inhibition affected RUNX1 alternative splicing, K562 cells 
were treated with TG003 and the expression ratio of Runx1/ΔRunx1 were compared 
to cells treated with only 0.02% DMSO (DMSO control) or 100 ng/mL EGF (EGF 
control). There was a shift in splicing towards Runx1 in cells treated with 150 μM 
TG003 and 150 μM TG009, when compared to DMSO control, Figure 4.7B. The 
expression ratio of Runx1/ΔRunx1 was 1.08 in cells treated with only 0.02% DMSO 
(DMSO control) (one-way ANOVA), Figure 4.7C. The expression ratio of 
Runx1/ΔRunx1 in cells treated with 150 μM TG003 was 2.95 (p = 0.17, one-way 
ANOVA), Figure 4.7C. In addition, the expression ratio of Runx1/ΔRunx1 was 
significantly increased to 3.71 (p = 0.04) after treatment with 150 μM TG009, when 
compared to DMSO control, Figure 4.7C.. 
 
The Runx1 splice isoform was up-regulated in cells treated with a range of TG003 
concentrations (50 to 150 μM) when compared to EGF control, Figure 4.8B. The 
expression ratio of Runx1/ΔRunx1 was 1.10 in cells treated with only 100 ng/mL 
EGF (EGF control), Figure 4.8C. The expression ratio of Runx1/ΔRunx1 in cells 
treated with 50 and 150 μM TG003 were ( 1.30, p = 0.96) and (1.99, p = 0.10),  one-
way ANOVA. There was a significant increase in the expression ratio of 
Runx1/ΔRunx1 to 4.27 (p = 0.00) after treatment with 100 μM TG003 when 
compared to EGF control (one- way ANOVA), Figure 4.8C. Sequences of Runx1 
and ΔRunx1 cDNA amplicons were analysed in Chapter 3 (Section 3.4.2.4.1).  
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Figure 4.7. Clk1 inhibition on RUNX1 alternative splicing 
A. RUNX1 showing the two splice variants resulting from including or excluding 
exon 6 (Runx1 and ΔRunx1 variants, respectively). Arrows indicate the positions of 
forward and reverse Runx1 primers. B. K562 cells were treated with 0.02% DMSO 
(DMSO control) and 150 μM TG003/9 followed by (0.02%) DMSO. After 24 hours 
incubation, RT-PCR was performed and bands at 482 bp (Runx1) and 290 bp 
(ΔRunx1) were detected. Intermediate bands represent skipped exons. GAPDH was 
used as a loading control (212 bp). Each rung of the hyperLadder II represents 100 
bp. C. Densitometric analysis of Runx1/ΔRunx1 isoforms. K562 cells treated with 
TG003 or TG009 were compared with DMSO control. The ratio of Runx1/ΔRunx1 
was significantly increased in cells treated with 150 μM TG009 (negative control 
inhibitor). The bars indicate standard error (one-way ANOVA). The data represent 
three independent experiments (n = 3).  
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Figure 4.8. Clk1 inhibition on RUNX1 alternative splicing. 
A. RUNX1 showing the two splice variants resulting from including or excluding 
exon 6 (Runx1 and ΔRunx1 variants, respectively). Arrows indicate the positions of 
forward and reverse Runx1 primers. B. K562 cells were treated with only 100 
ng/mL EGF (0 μM TG003) and different concentrations of TG003 were used at 50, 
100 and 150 μM followed by 100 ng/mL EGF. After 24 hours incubation RT-PCR 
was performed and bands at 482 bp (Runx1) and 290 bp (ΔRunx1) were detected. 
GAPDH was used as a loading control (212 bp). Each rung of the hyperLadder II 
represents 100 bp. C. Densitometric analysis of Runx1/ΔRunx1 isoforms. K562 cells 
treated with TG003 were compared with EGF control (0 μM TG003). The ratio of 
Runx1/ΔRunx1 was increased in cells treated with 100 μM TG003. The bars indicate 
standard error, **** P≤0.0001 (one-way ANOVA). The data represents three 
independent experiments (n = 3). 
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4.4.2.5. Evaluation of apoptosis and necrosis in K562 cells following treatment with 
Clk1 inhibitors  
4.4.2.5.1 Detection of apoptosis using acridine orange 
K562 cells were stained with acridine orange (AO) to observe the presence of 
apoptosis after Clk1 kinase inhibition. Cell morphological characteristics were 
assessed to distinguish between cell survival and cell death (apoptosis or necrosis).  
 
K562 cells were treated with TG003 concentations of 0, 50, 100 and 150 μM, Figure 
4.9. The cell morphological features of K562 cells after treatment were compared to 
EGF control cell. Viable cells (VC) were present in K562 cells alone, Figure 4.9A. 
Apoptotic cells (Apo) were present in the EGF control, Figure 4.9B. Necrotic cells 
(NC) were present in cells treated with 50 and 100 μM TG003 when compared to 
EGF control, Figure 4.9C and D. At 150 μM TG003, little apoptosis was observed, 
Figure 4.9E. 
 
Total cell numbers after treatments were not quantified, however, at 1000 cells were 
quantified per treatment. The percentage of viable, apoptotic and necrotic cells was 
calculated and compared to EGF control, Figure 4.10. Apoptosis in cells treated with 
50 and 100 TG003 were 11.3% (p = 0.70) and 8.3% (p = 0.65), respectively, when 
compared to EGF control (one-way ANOVA). There was a siginicant increase in 
apoptosis of 44% in cin those cells treated with 150 μM TG003 (p = 0.00), Figure 
4.10. Moreover, in those cells treated with 50 and 150 μM TG003, necrosis was 
8.3% (p = 0.9) and 13.5% (p = 0.07), respectively. However, in cells treated with 
100 μM TG003, necrosis was significantly increased to 22.1% (p = 0.02) when 
compared to EGF control.    
CHAPTER 4 Clk1 in CML 
167 
 
Figure 4.9. Cell death (apoptotic and necrotic) using acridine orange  
A. Viable cells (VC) were present in untreated K562 cells. B. Apoptosis increased in 
EGF control cells; arrowheads indicate cells with condensed clear chromatin, bi-
lobed and fragmented nuclei. C–D. Treatment with 50 and 100 μM TG003 induced 
necrosis; arrowheads show swelling and rupture of the plasma membrane of necrotic 
cells releasing cytoplasmic contents into the extracellular space. E. Apoptotic cells 
(Apo) with fragmented nuclei and chromatin start to appear at 150 μM TG003. 
Approximately 1000 cells were quantified per treatment.  
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Figure 4.10. Apoptosis and necrosis percentages in inhibitor treated K562 cells  
K562 cells were stained with acridine orange following treatment with increasing 
concentrations of TG003 (50, 100, and 150 μM). At least 1,000 cells were assessed. 
The graph represents the percentages of viable cells (white bars), apoptotic cells 
(grey bars) and necrotic cells (dashed bars). Apoptosis was significantly increased in 
cells treated with 150 μM TG003, necrosis was significantly increased in cells 
treated with 100 μM TG003 treatment. The bars indicate standard error, ** P≤0.01, 
**** P≤0.0001 (one-way ANOVA). The data represent three independent 
experiments (n = 3).  
4.4.2.5.2 Annexin V-FITC apoptosis detection  
Apoptosis was identified by flow cytometry and Annexin V-FITC/PI binding. 
Viable, early apoptotic and late apoptotic (or necrotic) cells were distinguished by 
flow cytometry. Apoptotic cells were Annexin V-FITC positive and PI negative 
(Annexin V-FITC+ and PI-), while necrotic cells were Annexin V-FITC positive and 
PI positive (Annexin V-FITC+ and PI+), Figure 4.11. Apoptosis was observed in 
EGF control (0.91%) as was necrosis (3.4%), Figure 4.11A. Apoptosis in K562 cells 
treated with 50 μM TG003 was 0.29%, whereas necrosis was 8.1%, Figure 4.11B. 
Apoptosis was 0.56% while necrosis was 22.6% in K562 cells treated with 100 μM 
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TG003, Figure 4.11C. The treatment of cells with 150 μM TG003 resulted 2.3% in 
apoptosis and 17.2% in necrosis, Figure 4.11D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Apoptosis and necrosis detection by Flow Cytometry and Annexin 
V-FITC/PI  
Scatterplots of cell death (apoptosis; Annexin V-FITC and necrosis; Annexin V-
FITC with propidium iodide) in K562 cells after Clk1 inhibition. A. Control K562 
cells treated with 100 ng/mL EGF only (EGF control). B–D. Cells treated with 50, 
100 and 150 μM TG003. Apoptosis (Annexin V-FITC+ and PI-) was more than twice 
as high in cells treated with 150 μM TG003 when compared to EGF controls (values 
ranged from 0.9 to 2.3%). Necrosis (Annexin V-FITC+ and PI+) was increased in 
cells treated with 100 μM TG003 when compared to EGF control (values ranged 
from 3.4 to 22.6%). A representative of three experiments is shown.  
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4.4.3. siRNA Clk1 knockdown in K562 cells 
To investigate the effects of Clk1 kinase activity on CASPASE-9, RON or RUNX1 
alternative splicing, K562 cells were transfected with Clk1 siRNA to knockdown 
Clk1 endogenous expression. Cells were transfected with a control (si-CTRL, 75nM) 
and three different si-Clk1s (si-Clk1-1, si-Clk1-2 and si-Clk1-3, 75 nM) for 72 
hours. Following transfection, Clk1 protein expression was determined by Western 
blot and normalised to α-tubulin (75 μg whole cell lysates), Figure 4.12A-B. The 
Clk1 knockdown using si-Clk1-1, si-Clk1-2 and si-Clk1-3 produced different Clk1 
expression profiles, Figure 4.12A. A decrease in Clk1 expression was observed in 
cells transfected with si-Clk1-1 and si-Clk1-2 when compared to the si-CTRL cells, 
however si-Clk1-3 increased Clk1 expression. 
 
The same trend in Clk1 expression was observed after normalisation to α-tubulin. 
The expression ratio of normalised Clk1 following si-Clk1-1 was 0.91 (p = 0.99) 
when compared to si-CTRL cells (0.95, one-way ANOVA), Figure 4.12B. There 
was a significant decrease in the expression ratio of Clk1 in si-Clk1-2 cells to 0.18 (p 
= 0.01, one-way ANOVA). However, Clk1 expression in si-Clk1-3 was 1.21 (p = 
0.59, one-way ANOVA). These results indicate that si-Clk1-2 was the most effective 
siRNA in knocking down Clk1. 
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Figure 4.12. siRNA knockdown of Clk1 in K562 cells  
K562 cells were transfected with three siRNAs against Clk1 or scrambled control 
siRNA (si-CTRL). A. Cell lysates were extracted at 72 hours post-transfection and 
immunoblotted against anti-Clk1 and anti-tubulin antibodies, detecting Clk1 at 57 
kDa and α-tubulin at 55 kDa. B. The normalisation of Clk1 against α-tubulin (three 
replicates). Transfection of K562 cells with si-Clk1-2 significantly decreased 
endogenous Clk1 protein levels. The bars indicate standard error (one-way 
ANOVA). The data represents three independent experiments (n = 3).  
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4.4.3.1. siRNA Clk1 knockdown effects on alternative splicing in K562 cells 
4.4.3.1.1 CASPASE-9 splicing in K562 cells following Clk1 knockdown 
There were no differences in CASPASE-9 alternative splicing between si-Clk1-2 and 
si-CTRL cells, Figure 4.13B. The expression ratio of caspase-9a/9b in si-Clk1-2 
treated cells to 2.18 (p = 0.88) compared to si-CTRL cells (2.30, one-way ANOVA), 
Figure 4.13C. 
 
4.4.3.1.1 RON splicing in K562 cells following Clk1 knockdown 
There was no shift in RON splicing in cells transfected with si-Clk1-2, Figure 4.14B. 
The expression ratio of Ron/ΔRon in si-CTRL cells was 0.81 while in si-Clk1–2 
cells was 0.77 (p = 0.64, one-way ANOVA), Figure 4.14C. 
 
4.4.3.1.1 RUNX1 splicing in K562 cells following Clk1 knockdown 
There was a shift in RUNX1 splicing towards the Runx1 isoform in si-Clk1-2 cells 
compared to si-CTRL cells, Figure 4.15B. The expression ratio of Runx1/ΔRunx1 
isoforms was 1.39 in si-CTRL cells. There was significantly increased in the 
expression ratio of Runx1/ΔRunx1 in si-Clk1-2 cells (1.61, p = 0.02), one-way 
ANOVA, Figure 4.15C.  
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Figure 4.13. siRNA Clk1 knockdown on CASPASE-9 alternative splicing  
A. CASPASE-9 showing the two splice variants resulting from inclusion or exclusion 
of exons 3–6 (caspase-9a and caspase-9b, respectively). Arrows indicate the 
positions of forward and reverse CASPASE-9 primers. B. K562 cells were 
transfected with si-CTRL (75 nM) or si-Clk1-2 (75 nM) for 72 hours before caspase-
9a and caspase-9b RT-PCR. PCR bands at 742 bp (casp-9a) and 292 bp (casp-9b) 
were identified. GAPDH was used as a loading control (212 bp). Each rung of the 
hyperladder II represents 100 bp. C. Densitometric analysis of caspase-9a/9b 
isoforms. K562 cells transfected with si-Clk1-2 (75 nM) were compared with si-
CTRL (75 nM). The graph represents the intensity ratio of caspase-9a against 
caspase-9b. The bars indicate standard error (one-way ANOVA). The data represents 
three independent experiments (n = 3).   
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Figure 4.14. siRNA Clk1 knockdown on RON alternative splicing 
A. The RON gene showing the two splice variants resulting from including or 
excluding exon 11 (Ron and ΔRon variants, respectively). Arrows indicate the 
positions of forward and reverse Ron primers. B. K562 cells were transfected with 
si-CTRL (75 nM) or si-Clk1-2 (75 nM) for 72 hours before Ron and ΔRon RT-PCR. 
PCR bands at 484 bp (Ron) and 337 bp (ΔRon) were identified. GAPDH was used as 
a loading control (212 bp). Each rung of the hyperladder II represents 100 bp. C. 
Densitometric analysis of Ron/ΔRon isoforms. K562 cells transfected with si-Clk1-2 
(75 nM) were compared with si-CTRL cells (75 nM). The graph represents the 
intensity ratio of Ron against ΔRon. The bars indicate standard error, one-way 
ANOVA. The data represent three independent experiments (n = 3).  
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Figure 4.15. siRNA Clk1 knockdown on RUNX1 alternative splicing  
A. RUNX1 showing the two splice variants resulting from including or excluding 
exon 6 (Runx1 and ΔRunx1 variants, respectively). Arrows indicate the positions of 
forward and reverse Runx1 primers. B. K562 cells were transfected with si-CTRL 
(75 nM) or si-Clk1-2 (75 nM) for 72 hours before Runx1 and ΔRunx1 RT-PCR was 
performed. PCR bands at 482 bp (Runx1) and 290 bp (ΔRunx1) were identified. 
GAPDH was used as a loading control (212 bp). Each rung of the hyperladder II 
represents 100 bp. C. Densitometric analysis of Runx1/ΔRunx1 isoforms. K562 cells 
transfected with si-SRSF1 (75nM) were compared with si-CTRL (75 nM). The 
graph represents the intensity ratio of the Runx1 against ΔRunx1. The ratio of 
Runx1/ΔRunx1 increased in transfected K562 cells with si-Clk1-2 compared to si-
CTRL cells (75 nM). Transfection of K562 cells with si-Clk-2 significantly 
increased the expression ratio of Runx1/ΔRunx1. The bars indicate standard error, * 
P≤0.05 (one-way ANOVA). The data represent three independent experiments (n = 
3).  
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4.5 Discussion 
Several protein kinases regulate the phosphorylation of SRSF1, notably SRPK1 and 
Clk1 (Gosh and Adam, 2011; Liu et al., 2013). Clk1 plays an important role in 
serine, threonine and tyrosine phosphorylation, thus enhancing or repressing splicing 
activities (Jain et al., 2014). SRSF1 can effect splice site utilisation, thereby 
controlling the alternative splicing of many genes, including CASPASE-9 and Bcl-x 
(Gosh and Adam, 2011).  
 
In previous work, inhibiting Clk1 using KH-CB19 affected pre-mRNA splicing in 
Alzheimer’s disease (Jain et al., 2014). Another investigation suggested that KH-
CB20 and KH-CB19 were selective Clk1 inhibitors. Those inhibitors were effective 
in splicing two tissue factor isoforms, flTF (full-length TF) and asHTF (alternative 
spliced human TF). In addition, Clk1 inhibition by TG003 resulted in a reduction in 
phosphorylation of SRp20 in human microvascular endothelial cells (HMEC-1) 
(Fedorov et al., 2011).  
 
Since Clk1 activation by SRPK1 phosphorylates SRSF1, Clk1 plays an important 
role in regulating alternative splicing. A recent study found that HeLa, H157 and 
A549 cell proliferation was dramatically reduced after TG003 or KHCB-19 
inhibition or depletion (shRNA) of Clk1 (Dominguez et al., 2016). This Clk1 
inhibition or knockdown resulted in the increased expression of CHEK2 exon 9 
inclusion leading to defects in mitosis and cell death promotion. It has been observed 
that inhibiting Clk1 using “compound 21b” blocks EGFR, HDAC1 and p70S6 
kinase in cancer cells (ElHady et al., 2017). Another study has designed α-
benzylidene-γ-butyrolactone inhibitor targeting several kinases, such as, dual-
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specificity tyrosine-regulated kinase 1A (Dyrk1A), Clk1 and CK2. Similarly, it has 
been also proposed that co-inhibition lipid kinases PI3Kα/γ limit the proliferation of 
U87MG cells (Mariano, Hartmann and Engel, 2016). Therefore, Clk1 appears to 
control alternative splicing in malignancies (Dominguez et al., 2016). 
 
The role of Clk1 in some malignancies has been well established, however the 
literature is lacking on any possible roles in CML. This chapter hypothesises that the 
Clk1 signalling pathway is important for CASPASE-9, RON and RUNX1 splicing in 
CML cell models (K562 cells).  
 
In this study, K562 cell proliferation was reduced after treatment with increased 
concentrations of TG003, in agreement with Dominguez et al. (2016) and suggests 
that TG003 could block K562 cell proliferation. To investigate the effects of protein 
kinase inhibitors on alternative splicing, the splicing variants of CASPASE-9, RON 
and RUNX1 in K562 cells subjected to Clk1 inhibition was investigated. Due to the 
significant effect on the expression of the caspase-9a and Ron splice isoforms 
followed by negative kinase control (TG009), the effect of TG003 treatment is not 
considered as a specific effect.  
 
Additionally, TG003 treatment followed by EGF, significantly increased expression 
of the pro-apoptotic (caspase-9a), Ron and Runx1 splice isoforms. Furthermore, cells 
developed multi-nucleation following incubation with high concentrations of TG003. 
The increased appearance of multi-nucleation suggests a defect in chromosome 
segregation or cytokinesis, leading to cell death. These data are in agreement with 
TG003 evaluation and its impact on K562 apoptosis. Apoptosis increased with 
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increased concentrations of TG003. Taken together, these data demonstrate that 
TG003 increased apoptosis in K562 cells and decreased the survival rate of these 
cells. These data showing also show that blocking endogenous Clk1 activity using 
TG003, switched splicing from ΔRon to Ron and ΔRunx1 to Runx1 isoforms in 
K562 cells. 
 
The down-regulation of Clk1 using TG003 or siRNA knockdown was found to 
decrease mRNA and protein levels of Fas exon 6 exclusion in ovarian cancer cells 
(Liu et al., 2013). It was also observed that significant reduction in Clk1 protein 
levels after the transfection of ovarian cancer cells with any of three Clk1 siRNAs 
(Liu et al., 2013). However, unlike Liu et al. (2013), in our study, only si-Clk1-2 
significantly reduced Clk1 protein levels in K562 cells, suggesting Clk1 siRNAs 
exhibit greater efficiency in targeting Clk1 in ovarian cancer than leukaemic cells. 
Therefore, protein kinase (Clk1) from various types of cancer respond differently.   
 
In this study, no obvious switch in CASPASE-9 and RON splicing was observed after 
Clk1 knockdown in K562 cells. Intriguingly, Clk1 knockdown significantly shifts 
RUNX1 splicing towards Runx1 isoforms in K562 cells. Taken together, TG003 
significantly increased caspase-9a, Ron and Runx1 mRNA isoforms in K562 cells. 
In contrast, K562 cells following Clk1si-RNA knockdown, revealed a switch in 
splicing in RUNX1 towards Runx1 isoforms only, suggesting Clk1 could be the main 
protein kinase regulator of RUNX1 in K562 cells. No obvious shift in CASPASE-9 
and RON splicing in Clk1 si-RNA knockdowns would suggest the activation of other 
protein kinases for these targets.  
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4.5.1. Conclusion and future directions 
The small molecule inhibitor TG003 reduced K562 cell proliferation. Further 
analyses are required to assess the effects of TG003 on K562 cell proliferation 
compared to normal, non-cancerous cells. Treatment of K562 cells with TG003, 
switched splicing towards the caspase-9a, Ron and Runx1 isoforms. However, Clk1-
siRNA depletion caused shifts only in RUNX1 splicing towards the Runx1 splice 
isoform in K562 cells. Further experiments are required to identify the main protein 
kinase regulator for CASPASE-9 and RON and confim the main protein kinase for 
RUNX1 in K562 cells.  
 
More comprehensive analyses should address the effects of the negative control 
inhibitor (TG009) on Clk1 in K562 cells. A thorough understanding of the Clk1 
protein kinase in both normal physiological and leukaemic conditions is required as 
TG009 could prove to be a potential therapeutic target in the treatment of CML. 
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CHAPTER 5. TARGETING TYROSINE KINASE ALONE OR IN 
COMBINATION WITH OTHER PROTEIN KINASE INHIBITORS 
IN CHRONIC MYELOID LEUKAEMIA CELL LINE  
5.1 Introduction 
The activation of tyrosine kinases are regulated by receptors (RTKs) or non-receptor 
(nRTKs) tyrosine kinases. RON or recepteur d’origine Nantais is an RTK while the 
oncoprotein fusion Bcr-Abl belongs to nRTK family (Batth, Yun and Kumar, 2015b; 
Naka et al., 2016). Generally, activation of tyrosine kinases promote proliferation, 
angiogenesis and inhibits apoptosis through the phosphorylation of intracellular 
signalling pathways (Chapter 1) (Naka et al., 2016). Constitutive activation of 
tyrosine kinase initiates tumourgenesis, such as that seen in breast, gastric and 
leukaemia (CML). Therefore, it is crucial to treat different solid and haematological 
tumours through tyrosine kinase inhibition (TKIs) (Roberts and Der, 2007).  
 
5.2 Hypothesis 
To assess the co-treatment of K562 cells with imatinib and SPHINX or TG003 as 
more effective on CASPASE-9, RON, and RUNX1 alternative splicing, than either 
agent alone. 
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5.3 Objectives 
 To assess proliferation of K562 cells treated with TKI (imatinib) alone or in 
combination with other protein kinase inhibitors (Table 5.2), prior to 
epidermal growth factor (EGF) addition.   
 To assess the effects of inhibiting TK alone or in combination with other 
inhibitors on CASPASE-9, RON and RUNX1 alternative splicing in K562 
cells. 
5.4 Results 
5.4.1. The effect of TKI alone or in combination with other protein kinase inhibitors 
on K562 cells  
5.4.1.1. The proliferation of K562 cells following TKI treatment or in combination 
with other protein kinase inhibitors 
 
To investigate the proliferation of K562 cells following TK inhibition alone or in 
combination with other protein kinase inhibitors, 1 × 106 cells were used. Cells were 
treated with inhibitors followed by EGF treatment (100 ng/mL) for 24 hours. Then, 
cells were stained with trypan blue and counted using a haemocytometer. Cell 
number were compared to 1 × 106 original cells and the results represented as mean 
± SEM (n = 3). Significant reductions in cell numbers treated with IM alone or in 
combination with SPHINX or TG003 were observed, Figure 5.1. 
  
Cells, treated with the different IM ranges 1, 1.4 and 2.9 μM, were significantly 
decreased to 6.03 × 105 (p = 0.00), 3.96 × 105 (p = 0.00) and 3.80 × 105 (p = 0.00), 
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respectively when compared to 1 × 106 cells alone (one-way ANOVA). Treating 
cells with the IM ranges 1, 1.4 or 2.9 μM in combination with 30 μM Sx, 
significantly decreased cell numbers to 1.06 × 105 (p = 0.00), 5.15 × 104 (p = 0.00), 
and 1.01 × 105 (p = 0.00) respectively, when compared to the original 1 × 106 cells 
(one-way ANOVA). In addition, combining IM with TG003 cause a significant 
reduction in cell proliferation. Cell numbers treated with 1 μM IM and 100 μM 
TG003 were 6.3 × 104 (p = 0.00) while cell numbers treated with 1.4 μM IM and 100 
μM TG003 were 2.1 × 105 (p = 0.00), compared to 1 × 106 cells (one-way ANOVA). 
Similarly, cell numbers were 7.6 × 104 (p = 0.00) after combination treatments of IM 
(2.9 μM) and 100 μM TG003. 
 
Figure 5.1. K562 cell numbers after treatment with IM alone or in combination 
with SPHINX or TG003 
Quantitative analysis of K562 cell numbers treated with IM (1, 1.4 and 2.9 μg/mL) 
in combination with 30 μM SPHINX (Sx) or 100 μM TG003 for 24 hours. The y-
axis indicates cell numbers versus treatment concentrations. Approximately 1 × 106 
cells were used and compared with cells treated with inhibitors. Treatment with only 
100 ng/mL EGF (0 μM), range with IM (1, 1.4 and 2.9 μg/mL) following EGF, 
combined inhibitors of IM and Sx (30 μM) or combined inhibitors of IM and TG003 
(100 μM). The bars indicate standard error, **** P ≤ 0.0001 (one-way ANOVA). 
The data represents three independent experiments (n = 3).  
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5.4.1.2. CASPASE-9 splicing in K562 cells following TKI treatment alone or in 
combination with other protein kinase inhibitors 
 
Inhibiting TK alone or in combination with SRPK1 or Clk1, on CASPASE-9 
alternative splicing was examined in K562 cells and compared to cells treated with 
100 ng/mL EGF (EGF control) only. The expression ratio of caspase-9a/9b was 
quantified by densitometric analysis and ImageJ software.  
 
A switch in the expression of caspase-9b towards the pro-apoptotic splice isoform, 
caspase-9a was observed in K562 cells, in combination with different TKI (imatinib) 
concentrations, Figure 5.2B. The expression ratio of caspase-9a/9b was 0.75 in cells 
treated with only EGF (100 ng/mL), Figure 5.2C. The expression ratio of caspase-
9a/9b was significantly increased in cells treated with 1 μg/mL IM to 2.19 (p = 
0.001) and in cells treated with 1.4 μg/mL IM to 2.40 (p = 0.00) compared to EGF 
control cell (one-way ANOVA), Figure 5.2C. There was a significant increase in the 
expression ratio of caspase-9a/9b in cells treated with 2.9 μg/mL IM to 2.28 (p = 
0.00) compared to EGF control (one-way ANOVA). 
 
Additionally, effects on CASPASE-9 alternative splicing were analysed in K562 cells 
treated with IM and SPHINX and compared to EGF control. There was a switch in 
splicing towards the pro-apoptotic splice isoform, caspase-9a, in cells treated with 1 
μg/mL IM combined with a range of SPHINX (5–20 μM) concentrations, Figure 
5.3B. The expression ratio in cells treated with 100 ng/mL EGF alone was 1.29, 
Figure 5.3C. The expression ratio of caspase-9a/9b was significantly increased in 
cells treated with 1 μg/mL IM in combination with 5 and 10 μM SPHINX to 3.53 (p 
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= 0.01) and to 3.70 (p = 0.00) compared with the EGF control (one-way ANOVA), 
Figure 5.3C. Treatment of cells with 1 μg/mL IM and 20 μM Sx caused further 
significant increases in the expression ratio of caspase-9a/9b to 4.31 (p = 0.00) 
compared to the EGF control (one-way ANOVA). These results were statistically 
significant. 
 
The effects on CASPASE-9 alternative splicing was also analysed in K562 cells 
treated with IM and TG003 and compared to EGF control. There was a shift in 
splicing towards the caspase-9a isoform in cells treated with 1 μg/mL IM, combined 
with a range of TG003 (25–100 μM), Figure 5.4B. The expression ratio of caspase-
9a/9b was 1.32 in cells treated with EGF alone (100 ng/mL), Figure 5.4C. The 
mRNA expression ratio of caspase-9a/9b combined with 1 μg/mL IM and 25 μM 
TG003 was 1.82 (P = 0.53), Figure 5.4C. The expression ratio of caspase-9a/9b in 
cells treated with 1μg/mL IM in combination with 50 and 100 μM TG003 reached 
1.32 (p = 0.99) and 1.03 (p = 0.99), one-way ANOVA.   
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Figure 5.2. TKI effects on CASPASE-9 alternative splicing 
A. CASPASE-9 showing the two splice variants resulting from inclusion or exclusion 
of exon 3–6 (caspase-9a and caspase-9b, respectively). Arrows indicate the positions 
of forward and reverse caspase-9 primers. B. K562 cells treated with only 100 
ng/mL EGF (0 μg/mL IM) and three concentrations of IM were used at 1, 1.4 and 
2.9 μg/mL followed by 100 ng/mL EGF. RT-PCR was performed after 24 hours 
incubation and bands at 742 bp (casp-9a) and 292 bp (casp-9b) were detected and 
GAPDH was used as a loading control (212 bp). Each rung of the hyperLadder II 
represents 100 bp. C. Densitometric analysis of caspase-9a/9b isoforms. K562 cells 
treated with IM were compared to the EGF control. The graph represents the 
intensity ratio of the caspase-9a against caspase-9b. As the concentration of IM 
increased, the ratio of caspase-9a/9b significantly increased compared to the EGF 
control. The bars indicate standard error, *** P≤0.001, **** P≤0.0001 (one-way 
ANOVA). The data represents three independent experiments (n = 3). 
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Figure 5.3. TKIs in combination with SRPK1 inhibition on CASPASE-9 
alternative splicing 
A. CASPASE-9 showing the two splice variants resulting from inclusion or exclusion 
of exon 3–6 (caspase-9a and caspase-9b, respectively). Arrows indicate the positions 
of forward and reverse caspase-9 primers. B. K562 cells treated with only 100 
ng/mL EGF (0 μg/mL IM) and with 1 μg/mL IM in combination with 5–20 μM Sx 
followed by EGF (100 ng/mL). RT-PCR was performed after 24 hours incubation 
and bands at 742 bp (casp-9a) and 292 bp (casp-9b) were detected. GAPDH was 
used as a loading control (212 bp). Each rung of the hyperLadder II represents 100 
bp.  C. Densitometric analysis of caspase-9a/9b isoforms. K562 cells treated with IM 
were compared to the EGF control. The graph represents the intensity ratio of the 
caspase-9a against caspase-9b. The expression ratio of caspase-9a/9b significantly 
increased for the 1 μg/mL IM treatment with increased Sx concentration. The bars 
indicate standard error, ** P≤0.01, **** P≤0.0001 (one-way ANOVA). The data 
represents three independent experiments (n = 3).  
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Figure 5.4. TKIs in combination with Clk1 inhibitor on CASPASE-9 alternative 
splicing 
A. CASPASE-9 showing the two splice variants resulting from inclusion or exclusion 
of exon 3–6 (caspase-9a and caspase-9b, respectively). Arrows indicate the positions 
of forward and reverse caspase-9 primers. B. K562 cells treated with only 100 
ng/mL EGF (0 μg/mL IM) and with 1 μg/mL IM in combination with (25–100 μM) 
TG003 followed by EGF (100 ng/mL). RT-PCR was performed and bands at 742 bp 
(casp-9a) and 292 bp (casp-9b) were detected. Intermediate bands represent skipped 
exons. GAPDH was used as a loading control (212 bp). Each rung of the 
hyperLadder II represents 100 bp. C. Densitometric analysis of caspase-9a/9b 
isoforms. K562 cells treated with IM were compared with the EGF control. The 
graph represents the intensity ratio of caspase-9a against caspase-9b. The bars 
indicate standard error (one-way ANOVA). The data represents three independent 
experiments (n = 3). 
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5.4.1.3. RON splicing in K562 cells following TKI treatment alone or in 
combination with other protein kinase inhibitors 
 
IM alone or in combination with SPHINX or TG003 on RON splice isoforms was 
investigated by RT-PCR and quantified using ImageJ software.  
 
A range of IM concentrations reduced Ron and ΔRon splice isoforms in K562 cells 
compared to the EGF control, Figure 5.5B. The expression ratio of Ron/ΔRon was 
1.12 in cells treated with 100 ng/mL EGF alone, Figure 5.5C. The expression ratio of 
Ron/ΔRon in cells treated with 1 μg/mL IM significantly reduced to 0.46 (p = 0.00) 
while 1.4 μg/mL IM caused further significant reduction to 0.27 (p = 0.00) compared 
with EGF control (one-way ANOVA). At 2.9 μg/mL IM, the expression ratio of 
Ron/ΔRon was significantly reduced to 0.15 (p = 0.00) compared with EGF control 
(one-way ANOVA). 
 
Combining IM and Sx down-regulated both Ron and ΔRon splice isoforms in cells 
treated with 5 and 10 μM Sx, Figure 5.6B. The expression ratio of Ron/ΔRon was 
0.98 in cells treated with 100 ng/mL EGF alone, Figure 5.6C. The expression ratio of 
Ron/ΔRon in cells treated with 1 μg/mL IM in combination with 5 μM SPHINX was 
significantly reduced to 0.46 (p = 0.00) when compared to the EGF control (one-way 
ANOVA). The expression ratios of Ron/ΔRon in cells treated with 1 μg/mL IM in 
combination with 10 and 20 μM SPHINX were 0.67 (p = 0.08) and 0.83 (p = 0.71), 
one-way ANOVA. 
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Co-treatment of IM and higher doses of TG003 (100 μM) were found to down-
regulate both Ron and ΔRon splice isoforms in K562 cells, Figure 5.7B. The 
expression ratio of Ron/ΔRon was 1.01 in cells treated with 100 ng/mL EGF alone, 
Figure 5.7C. The expression ratio of Ron/ΔRon in cells treated with 1 μg/mL IM and 
25 μM TG003 revealed significant increases of 1.56 (p = 0.00) when compared with 
the EGF control (one-way ANOVA). The expression ratio of Ron/ΔRon in cells 
treated with 1 μg/mL IM and 50 μM TG003 was 1.14 (p = 0.53), one-way ANOVA. 
In contrast, treatment of cells with 1 μg/mL IM and 100 μM TG003 caused a 
significant reduction in the expression ratio of Ron/ΔRon to 0.68 (p = 0.02), one-way 
ANOVA.   
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Figure 5.5. TKI effects on RON alternative splicing 
A. The RON gene showing the two splice variants resulting from inclusion or 
exclusion of exon 11 (Ron and ΔRon variants, respectively). Arrows indicate the 
positions of forward and reverse Ron primers. B. K562 cells treated with only 100 
ng/mL EGF (0 μg/mL IM) and three concentrations of IM were used at 1, 1.4 and 
2.9 μg/mL followed by 100 ng/mL EGF.  RT-PCR was performed after 24 hours 
incubation and bands at 484 bp (Ron) and 337 bp (ΔRon) were detected. GAPDH 
was used as a loading control (212 bp). Each rung of the hyperLadder II represents 
100 bp. C. Densitometric analysis of Ron/ΔRon isoforms. K562 cells treated with 
IM were compared to the EGF control. The ratio of Ron/ΔRon decreased in cells 
treated with 1–2.9 μg/mL IM. The bars indicate standard error (one-way ANOVA). 
The data represents three independent experiments (n = 3). 
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Figure 5.6. TKIs in combination with SRPK1 inhibitors on RON alternative 
splicing 
A. The RON gene showing the two splice variants resulting from inclusion or 
exclusion of exon 11 (Ron and ΔRon variants, respectively). Arrows indicate the 
positions of forward and reverse Ron primers. B. K562 cells treated with only 100 
ng/mL EGF (0 μg/mL IM) and with 1 μg/mL IM in combination with (5–20 μM) Sx 
followed by EGF (100 ng/mL). RT-PCR was performed after 24 hours incubation 
and bands at 484 bp (Ron) and 337 bp (ΔRon) were detected. GAPDH was used as a 
loading control (212 bp). Each rung of the hyperLadder II represents 100 bp. C. 
Densitometric analysis of Ron/ΔRon isoforms. K562 cells treated with IM combined 
with Sx were compared with the EGF control. The graph represents the intensity 
ratio of Ron against ΔRon. The ratio of Ron/ΔRon significantly decreased in cells 
treated with 1 μg/mL IM and 5 μM Sx. The bars indicate standard error, *** 
P≤0.001 (one-way ANOVA). The data represents three independent experiments (n 
= 3). 
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Figure 5.7. TKIs in combination with the Clk1 inhibitor on RON alternative 
splicing  
A. The RON gene showing the two splice variants resulting from the inclusion or 
exclusion of exon 11 (Ron and ΔRon variants, respectively). Arrows indicate the 
positions of forward and reverse Ron primers. B. K562 cells treated with only 100 
ng/mL EGF (0 μg/mL IM) and with 1 μg/mL IM in combination with (25–100 μM) 
TG003 followed by EGF (100 ng/mL). RT-PCR was performed after 24 hours 
incubation and bands at 484 bp (Ron) and 337 bp (ΔRon) were detected. GAPDH 
was used as a loading control (212 bp). Each rung of the hyperLadder II represents 
100 bp. C. Densitometric analysis of Ron/ΔRon isoforms. K562 cells treated with 
IM combined with TG003 were compared with the EGF control. The ratio of 
Ron/ΔRon significantly increased in cells treated with 1 μg/mL IM and 25 μM 
TG003. The graph represents the intensity ratio of Ron against ΔRon. The bars 
indicate standard error, ** P≤0.01 (one-way ANOVA). The data represents three 
independent experiments (n = 3). 
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5.4.1.4. RUNX1 splicing in K562 cells following TKI treatment alone or in 
combination with other protein kinase inhibitors 
 
RUNX1 alternative splicing was assessed following treatment with IM alone or in 
combination with SPHINX or TG003 in K562 cells. There was no effect on ΔRunx1 
expression in cells treated with three doses of IM (1, 1.4 and 2.9 μg/mL), Figure 
5.8B. The expression ratio of Runx1/ΔRunx1 was 0.75 in cells treated with only 100 
ng/mL EGF, Figure 5.8C. The expression ratio of Runx1/ΔRunx1 in cells treated 
with 1 μg/mL IM was 0.60 (p = 0.98), one-way ANOVA. Additionally, treatment 
with 1.4 and 2.9 μg/mL IM resulted in expression ratios of 0.93 (p = 0.96) and 0.94 
(p = 0.95) for Runx1/ΔRunx1, Figure 5.8C. 
 
Additionally, RUNX1 splice isoforms were assessed in K562 cells treated with IM 
alone or in combination with Sx. There were no effects on RUNX1 splice variants, 
Figure 5.9B. The expression ratio of Runx1/ΔRunx1 was 0.87 in cells treated with 
100 ng/mL EGF alone, Figure 5.9C. The expression ratio of Runx1/ΔRunx1 in cells 
treated with 1 μg/mL IM and 5 μM Sx (ratio = 0.96, p = 0.99) compared with EGF 
control (one-way ANOVA), Figure 5.9C. The expression ratio of Runx1/ΔRunx1 in 
cells treated with 1 μg/mL IM and 10 μM Sx was almost identical to the EGF control 
(ratio = 0.88, p = 1.00, one-way ANOVA). At a higher concentration of Sx (20 μM), 
in combination with 1 μg/mL IM, an increase in the expression ratio of 
Runx1/ΔRunx1 to 1.12 (p = 0.78) was observed when compared with the EGF 
control (one-way ANOVA). 
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Furthermore, there was no change in RUNX1 alternative splicing in cells treated with 
IM and TG003, Figure 5.10B. The expression ratio of Runx1/ΔRunx1 was 0.86 in 
cells treated with only 100 ng/mL, Figure 5.10C. The expression ratio of 
Runx1/ΔRunx1 in cells treated with 1μg/mL IM and TG003 (25 and 50 μM) were 
0.99 (p = 0.95) and 0.99 (p = 0.96), one-way ANOVA. In addition, the expression 
ratio of Runx1/ΔRunx1 in cells treated with 1 μg/mL IM and TG003 (100 μM). to 
1.04 (p = 0.96) and 1.06 (p = 0.87) compared with EGF control (one-way ANOVA).   
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Figure 5.8. TKI effects on RUNX1 alternative splicing  
A. RUNX1 showing the two splice variants resulting from including or excluding 
exon 6 (Runx1 and ΔRunx1 variants, respectively). Arrows indicate the positions of 
forward and reverse Runx1 primers. B. K562 cells treated with only 100 ng/mL EGF 
(0 μg/mL IM) and three concentrations of IM were used at 1, 1.4 and 2.9 μg/mL 
followed by 100 ng/mL EGF. RT-PCR was performed after 24 hours incubation and 
bands at 482 bp (Runx1) and 290 bp (ΔRunx1) were detected. GAPDH was used as 
a loading control (212 bp). Each rung of the hyperLadder II represents 100 bp. C. 
Densitometric analysis of Runx1/ΔRunx1 isoforms. K562 cells treated with IM were 
compared with the EGF control. The bars indicate standard error (one-way 
ANOVA). The data represents three independent experiments (n = 3). 
  
B
A
C
8
Runx1
ΔRunx1
65 7
99 bp 192 bp 162 bp
105 bp 162 bp
F R
5 7
8
29 bp
29 bp
H
y
p
er
L
ad
d
er
II
R
T
-V
E
GAPDH (212 bp)
Runx1 (482 bp)
ΔRunx1 (290 bp)300 bp
500 bp
IM (μg/mL) 1                  1.4                 2.9 
EGF (100 ng/mL) +                    +                    + +
200 bp
CHAPTER 5 TK, SRPK1 & Clk1 in CML  
196 
 
  
 
 
 
 
 
 
 
Figure 5.9. TKI in combination with SRPK1 inhibition on RUNX1 alternative 
splicing  
A. RUNX1 showing the two splice variants resulting from including or excluding of 
exon 6 (Runx1 and ΔRunx1 variants, respectively). Arrows indicate the positions of 
forward and reverse Runx1 primers. B. K562 cells treated with only 100 ng/mL EGF 
(0 μg/mL IM) and with 1 μg/mL IM in combination with (5–20 μM) Sx followed by 
EGF (100 ng/mL). RT-PCR was performed after 24 hours incubation and bands at 
482 bp (Runx1) and 290 bp (ΔRunx1) were detected. GAPDH was used (212 bp). 
Each rung of the hyperLadder II represents 100 bp. C. Densitometric analysis of 
Runx1/ΔRunx1 isoforms. K562 cells treated with IM combined with SPHINX were 
compared with the EGF control. The graph represents the intensity ratio of Runx1 
against ΔRunx1. The bars indicate standard error (one-way ANOVA). The data 
represents three independent experiments (n = 3). 
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Figure 5.10. TKIs in combination with CLK1 inhibition on RUNX1 alternative 
splicing 
A. RUNX1 showing the two splice variants resulting from including or excluding 
exon 6 (Runx1 and ΔRunx1 variants, respectively). Arrows indicate the positions of 
forward and reverse Runx1 primers. B. K562 cells treated with only 100 ng/mL EGF 
(0 μg/mL IM) and with 1 μg/mL IM in combination with (25–100 μM) TG003 
followed by EGF (100 ng/mL). RT-PCR was performed after 24 hours incubation 
and bands at 484 bp (Ron) and 337 bp (ΔRon) were detected. GAPDH was used as a 
loading control (212 bp). Each rung of the hyperLadder II represents 100 bp.  C. 
Densitometric analysis of Runx1/ΔRunx1 isoforms. K562 cells treated with IM 
combined with TG003 were compared with the EGF control. The graph represents 
the intensity ratio of Runx1 against ΔRunx1. The bars indicate standard error (one-
way ANOVA). The data represents three independent experiments (n = 3). 
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5.5 Discussion 
Reducing IM binding site affinity in CML enhances disease treatment through the 
co-targeting of protein kinases (Change et al., 2011; Henkes et al., 2008). A recent 
study has shown that multi-targeting of spleen tyrosine kinase (SYK) and oncogenic 
FLT3 kinase has a potential effect in acute myeloid leukaemia (AML) (Weisberg et 
al., 2017). In contrast, it has been suggested that suppressing Ax1 using a single 
agent (TP-0903) would overcome the AML resistance (Park et al., 2015). Other 
studies found that targeting STAT3/5 alone or in a combination with Janus kinase 
1/2 (JAK1/2) has a potential effect on adenoviral transgene expression (Akinfenwa 
et al., 2017).   
 
To develop these observations, this study investigated the effects of IM alone or in 
combination with SPHINX (SRPK1 inhibitor) or TG003 (Clk1 inhibitor) on 
CASPASE-9, RON, and RUNX1 alternative splicing in K562 cells. To achieve this, it 
was important to evaluate K562 cell proliferation upon treatment with IM alone or in 
combination with other protein kinase inhibitors. In previous work, rapid reductions 
in K562 and BaF3/Bcr-AblT315I proliferation was observed in cells treated with 
amiloride in combination and IM (Change et al., 2011). In addition, cell proliferation 
was reduced by co-treatment with rapamycin and everolimus (mTOR inhibitors) in 
CML cell lines. It has been suggested that rapamycin, combined with IM, acts 
synergistically and improves CML therapy (Henkes, van der Kuip and Aulitzky, 
2008). This suggests that Bcr-Abl kinase activity plays an important role in CML 
cell lines. In accordance with previous studies, this study showed that K562 cell 
proliferation was significantly reduced following IM treatment alone, similar to co-
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treatment with Sx or TG003. This demonstrates that co-inhibitors affect K562 cell 
survival.  
 
It has been recently reported that cells treated with Hedgehog (Hh) inhibitor 
(Vismodegib) and autophagic inhibitor chloroquine (CQ), stimulated apoptosis of 
both IM sensitive or resistant Bcr-Abl+ CML cells (Zeng et al., 2015). It has been 
shown that increasing apoptosis may re-sensitise CML cells to cancer therapy. Renne 
et al., (2005) investigated six RTKs in Hodgkin/Reed-Sternberg (HRS) cell lines, 
one of which RON, was aberrantly expressed. Therefore, IM could be a promising 
therapeutic for HL patients (Renne et al., 2005). It was also shown that combining 
IM with arsenic trioxide exerted effects on mice with myeloproliferative neoplasms 
(MPNs) (Philips et al., 2014).  
 
Expanding on previous published data, this study observed CASPASE-9, RON and 
RUNX1 alternative splicing, following TK inhibition alone or in combination with 
SRPK1 or TG003 inhibition in K562 cells. There was a clear switch in splicing form 
towards the pro-apoptotic splice isoform, caspase-9a in K562 cells treated with IM 
alone or in combination with Sx. This could be due to the inhibition of TK pathways 
via IM-mediated apoptosis. However, co-treatment of IM and TG003 caused non-
specific effects on the expression of caspase-9 in K562 cells.  
 
In addition, the treatment of cells with IM alone inhibited expression of all Ron 
isoforms. As RON is an RTK, inhibiting TKs would exert strong effects on the 
expression of Ron isoforms in K562 cells. A switch from Ron expression towards 
the ΔRon splice isoform was seen in cells co-treated with IM and Sx and suggests 
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that SRPK1 is overexpressed in K562 cells, or inhibiting SRPK1 may trigger other 
protein kinase activation leading to increased cell motility and migration for RON in 
K562 cells. In contrast, K562 cells treated with IM and low TG003 doses increased 
Ron isoform levels, suggesting that Clk1 could be the primary protein kinase 
regulator for RON splicing in K562 cells.  
 
It is noteworthy to observe the resistance of RUNX1 splicing to IM alone or in 
combination with Sx or TG003 in K562 cells. This observation suggests that TKs are 
not directly involved in RUNX1 splicing/regulation in K562 cells. Similarly, it may 
be that inhibiting SRPK1 or Clk1 in combination with TKIs, activated unknown 
protein kinases which compensate for the loss of SRPK1 or Clk1 activity.   
5.5.1. Conclusion and future directions 
The data has indicated that co-targeting the tyrosine kinases, SRPK1 or Clk1 induced 
the expression of caspase-9a isoform in K562 cells. Further assays will confirm 
elevated levels of apoptosis in K562 cells treated with IM and Sx or TG003. This 
research strategy could enhance the development of a therapy against resistant or 
persistent CML progenitors. Another important finding is the enhancement of cell 
migration and invasion for RON after treatment with IM and Sx in K562 cells. In 
contrast, the combination of IM and TG003 limited K562 cell migration and 
invasion.  
 
Additionally, the expression of Runx1 and ΔRunx1 splice isoforms were resistant 
following IM alone or in combination with SPHINX or TG003. It is therefore 
important to identify the main regulator protein kinase for RUNX1 in K562 cells. 
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CHAPTER 6.  CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Although IM has become a successful and powerful therapy for CML, patients 
develop resistance over time (Salizzato et al., 2016). Allogenic bone marrow 
transplantation is the only curative therapy, however survival rates are low due to 
infection, bleeding, GvHD and difficulties in finding suitable donors (Jain et al., 
2013; Fausel, 2007). This study has provided important insight on CASPASE-9, RON 
and RUNX1 alternative splicing in K562 cells, upon targeting protein kinases and 
splice factors.   
6.1 K562 cell proliferation following protein kinase inhibiton 
A number of studies have suggested that small molecule inhibitors of SRPK1 or 
Clk1 reduce cell proliferation rates in tumour cell lines (Dominguez et al., 2016; 
Siqueira et al., 2015). Other studies have demonstrated that co-treatment with 
inhibitors, decrease cell proliferation rates in CML cells (Henkes, van der Kuip and 
Aulitzky, 2008; Change et al., 2011). In this study, the inhibitors, SRPIN340 or 
SPHINX did not suppress K562 cell proliferation, suggesting that inhibiting SRPK1 
may trigger the activation of other compensatory protein kinases in K562 cells. It 
also suggests that K562 cells express high levels of SRPK1 or that there is a high 
level of resistance to SRPK1 in K562 cells.  
 
TG003 or IM treatments reduced cell proliferation in K562 cells. Co-treatment of IM 
with Sx or TG003 strongly reduced K562 proliferation, suggesting that Clk1 or TKs 
play important roles in K562 cell proliferation. It also suggests that TKI treatment in 
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combination with SRPK1 or Clk1 inhibitors, induced significant reduction in 
proliferation of K562 cells.  
6.2 CASPASE-9 splicing in K562 cells following protein kinase inhibiton 
Inhibiting phosphorylation of Akt by sulforaphene induces apoptosis in lung cancer  
(Yang et al., 2016). In this study, the inhibitors, SRPIN340 or SPHINX were shown 
no effect in the CASPASE-9 splice isoform in K562 cells. This confirms high SRPK1 
levels or stimulation of other protein kinase after inhibiting SRPK1 in K562 cells. 
However, TG003 induced apoptosis through increasing pro-apoptotic isoforms in 
K562 cells, suggesting CASPASE-9 may be regulated by Clk1.  
 
It was also shown that IM treatment alone or in combination with Sx increased pro-
apoptotic isoform in K562 cells. However, cells treated with IM in a combination 
with TG003, resulted in non-specific effect on apoptosis in K562 cells. This would 
indicate that TKs contribute to regulation of apoptosis and that a combination of 
kinase inhibitors can trigger apoptosis in K562 cells, thus potentially inhibiting 
transformation to a malignant state. According to cell morphological characteristics, 
apoptosis was decreased during SRPIN340 or SPHINX treatment. Annexin V 
staining confirmed that SRPIN340 or Sx reduced apoptosis in K562 cells, as shown 
in Figure 6.1.  
 
6.3 RON splicing in K562 cells following protein kinase inhibition 
Smith et al. (2013) observed that SRSF1 regulates the expression of ΔRon in breast 
and gastric carcinoma (Smith et al., 2013), while the RON/c-Met dual kinase 
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inhibitor suppressed ΔRon expression in colon cancer cell lines (Zhang et al., 
2008b). Since constitutive activation of the ΔRon isoform is regulated through 
SRSF1 phosphorylation, it was therefore relevant to target SRPK1 or Clk1 signalling 
to down regulate SRSF1 proto-oncogenic activity in K562 cells. No switch in RON 
splicing was observe in K562 cells treated with SRPIN340 or SPHINX followed by 
EGF addition.  
 
In contrast, treatment with TG003 increased Ron expression when compared to the 
EGF control. As Ron is an RTK, TK inhibition through IM alone has a strong effect 
on the production of Ron isoforms through inhibiting both Ron and ΔRon isoforms 
in K562 cells. K562 cells treated with combinations of IM and Sx increased ΔRon 
splice isoform expression. SRPK1 inhibition did not switch RON splicing, while 
combinations of SRPK1 and TK inhibitors increased ΔRon splice isoform 
expression. This therefore confirms high levels of SRPK1 in K562 cells. In contrast, 
combinations of IM and TG003 increased Ron isoform expression in K562 cells. 
Combinations of kinase inhibitors such as IM and TG003 exhibited a more effective 
shift in RON splicing towards Ron isoforms, than either agent alone, as shown in 
Figure 6.1.   
 
6.4 RUNX1 splicing in K562 cells following protein kinase inhibition 
It was reported that ΔRunx1 splice isoforms control heamatopoietic progenitor 
clonogenicity (Wang et al., 2009). Evidence shows that ERK1/2 serine/threonine 
kinases play important roles in the regulation and splicing of RUNX1 (Wang et al., 
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2009), while others reported that arginine methyltransferase 1 (PRMT1) was the 
main RUNX1 regulator (Mizutani et al., 2015). 
 
In this study, SRPIN340 or Sx did not cause a shift in RUNX1 splicing in K562 cells. 
Treatment with TG003 increased expression of the Runx1 isoform in K562 cells, 
suggesting Clk1 directly affects RUNX1 splicing. In addition, IM alone or in 
combination with the kinase inhibitors IM with SPHINX or TG003 had no clear 
effect on RUNX1 splicing. Taken together, inhibiting SRPK1 or TKs, either alone or 
in combination wih IM generated weak splicing effects, suggesting these protein 
kinases may not be directly involved in RUNX1 splicing in K562 cells, as shown in 
Figure 6.1.   
6.5 The knockdown of SRPK1 and Clk1 in K562 cells  
The splice site selection of VEGF is regulated by SRSF1, which is phosphorylated 
by SRPK1 (Nowak et al., 2010). According to a recent report, a significant switch 
was observed in VEGF splicing towards the VEGF165b splice isoform following 
SRPK1 knockdown, resulting in decreased tumour growth in orthotopic mouse 
models of prostate cancer (Mavrou et al., 2015).  
 
In this study, no SRPK1 expression reduction was observed, while SRSF1 was 
reduced in K562 cells, generated from a stable knockdown of SRPK1. There was no 
significant reduction in SRPK1 in K562 cells, generated from an siRNA knockdown 
of SRPK1. However, in PC-3 cells, an si-SRPK1 knockdown strongly reduced 
SRPK1. In our hands, it would appear that SRPK1 knockdown in K562 cells elicited 
very little phenotypic, molecular and protein expression alterations, whereas in PC-3 
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cells, profound effects on SRPK1 protein expression were observed, suggesting high 
SRPK1 expression levels in K562 cells.  
 
In addition, there were significant reductions in SRSF1 in K562 cells, in 
combination with siRNA SRSF1 knockdown. Equally, there were no switches in 
CASPASE-9, RUNX1 or RON splicing in K562 cells, in combination with SRSF1 
knockdown. These observations suggest that SRSF1 may not be the main splice 
factor for CASPASE-9, RUNX1 or RON splice isoforms in K562 cells.  
 
As Clk1 distributes phosphorylated SRSF1to splice sites, this study has determined 
that Clk1 plays a role in CASPASE-9, RON and RUNX1 alternative splicing in 
siRNA knockdown of Clk1 in K562 cells. Three different siRNA successfully 
reduced Clk1 levels in ovarian cancer cell lines (Liu et al., 2013).  
 
In comparison to these findings, one siRNA significantly reduced Clk1 levels in 
K562 cells, predicting that cell-signalling pathways in ovarian cancer cells are 
different to CML. At the mRNA level, no shifts in CASPASE-9 and RON splicing 
were seen in K562 cells, in combination with Clk1 knockdown. This suggests that 
Clk1 knockdown could stimulate other protein kinases. In contrast, Clk1 knockdown 
caused a significant switch in RUNX1 splicing towards the Runx1 isoform, 
suggesting that Clk1 exerts direct effects on RUNX1 alternative splicing in K562 
cells, as shown in Figure 6.1.   
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Figure 6.1. Schematic diagram of the kinase inhibitors inducing alternative 
splicing in K562 cells alone or in a combination with imatinib (IM). 
Targeting SRPK1 or SRSF1 through inhibition (SRPIN340 or Sx) or knockdown 
(siRNA or shRNA) had no significant effects on the alternative splicing of 
CASPASE-9, RON and RUNX1 in K562 cells. Inhibiting Clk1 with selective 
inhibitor (TG003) resulted in increased expression of caspase-9a, Ron and Runx1 
splice isoforms, while, knockdown of Clk1 only increased the levels of Runx1 
splicing isoform in K562 cells. Inhibiting tyrosine kinase with imatinib (IM) 
increased apoptosis and decreased both Ron and ΔRon splice isoforms. Co-treatment 
of cells with IM and Sx increased the production of caspase-9a and ΔRon splice 
isoforms. K562 cells treated with IM and TG003 leads to increased levels of Ron 
only. Abbreviations: Casp: caspase, Sx: SPHINX, IM: imatinib. 
 
6.6 Conclusions and future perspectives 
SRPK1 and Clk1 are protein kinases that regulate SRSF1 phosphorylation in 
mammalian cells (Zhou and Fu, 2013). While SRPK1 plays a direct role in importing 
phosphorylated SRSF1 into the nucleus, Clk1 has an indirect role whereby it controls 
SRSF1 nuclear distribution to splice sites (Zhou and Fu, 2013).  
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The work presented here proposed the following hypothesis; the targeting of SRPK1 
or Clk1 along with the splice factor (SRSF1) through inhibition or knockdown, could 
affect CASPASE-9, RON and RUNX1 alternative splicing in K562 cells. These 
observations may provide the basis for useful therapeutic options for leukaemic 
patients.  
 
Future research directions may focus on comparing SRPK1 levels in K562 cells to 
other haematological malignancies and solid cancers. Research could investigate 
CASPASE-9, RON and RUNX1 alternative splicing following SRPK1 knockdown in 
K562 cells.  
 
In terms of therapy, it will be important to ascertain if combining inhibitors is a more 
efficient therapy than single inhibitor use. Evaluating these strategies would provide 
useful alternative therapeutic options in overcoming IM resistance in leukaemic 
patients. 
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